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The cell wall biosynthesis pathway is made up of a number of steps which can be 
targeted by a number of antimicrobial natural product inhibitors. These can be utilised 
in medicine for the treatment of bacterial infection. One of these steps is catalysed by 
the membrane protein, Phoshpo-MurNAc-pentapeptide translocase, also known as 
MraY. Although MraY is the target of a number of known natural products there has 
been little success in developing inhibitors to be used clinically. 
MraY is the site of action of bacteriophage ФX174 which produces lysis protein E. 
The RWxxW sequence of E protein is thought to be responsible an interaction between 
it and the ninth transmembrane helix (TM9) of MraY. Previous work showed that 
MraY could be inhibited by pentapeptides containing this motif. A dipeptide, NH2-
Arg-Trp-octyl ester which was also based on this motif showed antimicrobial activity, 
but no inhibition of MraY.  
This project aimed to synthesise molecules which were able to exhibit antimicrobial 
activity and inhibit MraY. A series of dipeptides were synthesised based on RWoct. 
The side chains of the amino acids were changed for other cationic and aromatic 
residues. The length of the octyl chain was altered. The series of dipeptides was then 
tested using a MIC50 determination assay and the inhibition by the dipeptides was 
assessed. All of the peptides showed antimicrobial activity, but none showed inhibition 
of MraY. Four of the most promising dipeptides were selected to be tested against the 
ESKAPE pathogens, and this showed some promising activity against these clinically 
relevant strains. 
In order to see inhibition and improve the MIC50 a series of peptidomimetics were 
synthesised. The first series were based on a benzamide backbone. These would allow 
the installation of a second tryptophan residue, incorporating the entire RWxxW motif. 
The antimicrobial activity was maintained but still no inhibition of MraY was seen. 
The second series of peptidomimetics utilised a cyclic triazinedione backbone. This 
provided a more rigid framework and again antimicrobial activity was seen. The 
ESKAPE pathogen data from this second series of peptidomimetics was an 
improvement on that seen for the previous groups of compounds.The data obtained 
indicated that the compounds synthesised are working via several undetermined 
mechanisms which differ between compounds in the same series.
1 
 
CHAPTER 1: INTRODUCTION 
1.1 PEPTIDOGLYCAN BIOSYNTHESIS 
The bacterial cell wall provides structural integrity which allows the bacteria to 
maintain their shape at different osmotic pressures. 1 If the cell wall is compromised 
the bacteria cannot maintain normal function and the cell wall lyses due to osmotic 
stress. As the cell wall is so pivotal to the function of the bacteria, it is a major target 
for antibiotic design. The biosynthesis of peptidoglycan has many steps which can be 
targeted to affect the cell wall stability.  
Both Gram positive and Gram negative bacteria have a cell wall which is composed 
of peptidoglycan. The structural cell wall differences between Gram negative and 
Gram positive are shown in Figure 1. Despite having a thinner cell wall, Gram negative 
bacteria have a membrane on the outside of the cell wall which makes them more 





Figure 1: The differences in structure of Gram positive and Gram negative bacteria.  
 
Peptidoglycan is a cross linked polymer of carbohydrates and amino acids. It is a β-
1,4-linked polysaccharide consisting of alternating N-acetylglucosamine (GlcNAc) 
and N-acetylmuramic acid (MurNAc) units.2 The MurNAc unit’s lactyl sidechain is 
attached to a pentapeptide chain which has the general structure L-Ala-γ-D-Glu-X-D-
Ala-D-Ala. The residue X is either L-Lys (found in most Gram positive) or meso-
diaminopimelic acid (DAP, found mainly in Gram-negative bacteria). The 






Figure 2: Schematic of peptidoglycan biosynthesis pathway 
 
1.1.1 Synthesis of the peptidoglycan precursors 
The synthesis of the components which make up the bacterial cell wall starts in the 
cytosol. A series of enzymes catalyse the production of the lipid carrier (undecaprenyl 
phosphate) and the cell wall precursor UDP-MurNAc-pentapeptide.  
Undecaprenyl phosphate (C55-P) once synthesised is able to translocate hydrophilic 
cell wall intermediates across the hydrophobic cellular bilayer.3 Initially undecaprenyl 
pyrophosphate (C55-PP), a 55 carbon isoprenoid that is synthesised by undecaprenyl 
pyrophosphate synthase (UppS), is dephosphorylated at the membrane by 
undecaprenyl pyrophophatase (UppU), producing C55-P.
4 The synthesis of 





Figure 3: The synthesis of undecaprenyl phosphate (UP). Enzymes are shown in blue. 
 
The second substrate synthesised in the cytoplasm is UDP-Mur-NAc-pentapeptide. Its 
synthesis is catalysed by the enzymes MurA-MurF from the starting material 
UDPGlcNAc. This cascade of enzymes is highly conserved across all bacteria. The 
biosynthetic pathway for UDP-Mur-NAc-pentapeptide is shown in Figure 2, and 
summarised in Figure 4. 
 
 
Figure 4: UDPMurNAc-pentapeptide biosynthesis 5 
 
1.1.2 Biosynthesis of the peptidoglycan monomers 
The second stage of cell wall biosynthesis is catalysed by phosphor-MurNAc-
pentapeptide translocase, commonly referred to as MraY or translocase 1. MraY is an 
integral membrane protein which catalyses the reversible transfer of phospho-
MurNAc-pentapeptide to the lipid carrier undecaprenyl phosphate (C55-P) to give 
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Lipid I (undecaprenyl-pyrophosphoryl-MurNAc-pentapeptide).1,6 The by-product of 
this reaction is uridine 5’-monophosphate (UMP). This enzymatic reaction is shown 
in Figure 5.  
In the following step, N-acetylglucosamine (GlcNAc) is incorporated into the lipid I 
intermediate. This is catalysed by the final Mur enzyme, glycotransferase MurG. This 
transfer gives GlcNAc-β-(1,4)-undecaprenyl-pyrophosphoryl-MurNAc-pentapeptide, 
also known as lipid II. The by-product is uridine diphosphate (UDP). 
Lipid II is transferred across the membrane, by what is thought to be a flippase enzyme. 
Lipid II is the monomeric building block of peptidoglycan.2 
 
 
Figure 5: The formation of lipid 1 a reaction catalysed by MraY.  
 
1.1.3 Polymerisation to form peptidoglycan 
Lipid II is polymerised to form peptidoglycan by penicillin binding proteins (PBPs).7 
The polymerisation process is catalysed by glycosyltransferases which form glycan 
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chains and transpeptidases which form peptide cross links. (Shown in Figure 6). The 
polymerisation continues as further monomers are flipped across the membrane.  
The transpeptidation step is the last to occur.8 These reactions catalysed by 
transpeptidases cross-link the neighbouring monomers by the pentapeptide chains. The 
ε-amino group of the residue at the third position of the pentapeptides chain 
(Lys/DAP), and the D-Ala residues at the fourth position of a neighboring 
pentapeptides are subjected to transpeptidation catalysed by penicillin binding proteins 
(PBP). 
This stage of the peptidoglycan biosynthesis is the step which varies the most between 
species, particularly between Gram negative and Gram positive bacteria. The 
differences in this step are responsible for differences in the rigidity and strength of 
the cell wall between species. 
 
Figure 6: Transpeptidation and transglycosylation in the formation of peptidoglycan.2 
 
1.1.4 Antimicrobials targeting cell wall biosynthesis 
Several steps of the cell wall biosynthesis pathway are known to be inhibited by natural 
products, and some examples of these are discussed in this section. This inhibition 
ultimately leads to cell death. Studying these natural product inhibitors provides a great 
platform for drug discovery. 
 
Fosfomycin, discovered in 1969, inhibits the synthesis of the cell wall precursor 
UDPMurNAc.9 The target of fosfomycin is MurA and its structure is shown in Figure 
7. MurA ligates phosphopenol pyruvate (PEP) to the 3’hydroxyl group of 
7 
 
UDPGlcNAc. Fosfomycin is a PEP analog which is able to inhibit MurA by the 
alkylation of a cysteine residue found within the active site. Sold under the brand name 
monurol, fosfomycin is commonly used in the treatment of bladder infections. 
 
 
Figure 7: The structure of fosfomycin and phosphoenol pyruvate. 
 
Bacitracin, which was first isolated from Bacillus licheniformis in 1945, disrupts the 
cell wall of Gram positive bacteria by inhibiting UppU, preventing the 
dephosphorylation  of C55-isoprenyl pyrophosphate.
10 Bacitracin is made up of several 
related cyclic peptides with bacitracin A being the most prevalent. Bacitracin A is 
shown in Figure 8. It is commonly used in topical medication to prevent skin and eye 
infections. Resistance to bacitracin is seen in MRSA, likely caused by the drugs 
overuse in the farming industry.11 
 
 




The class of uridyl natural products inhibitors of MraY, such as tunicamycin, will be 
discussed in section 1.2.3. These inhibitors prevent the formation of lipid I. 
Ramoplanin is a glycolipodepsipeptide antibiotic which inhibits MurG by 
complexation of lipid I, and so prevents the formation of lipid II.12 It is used for the 
treatment of antibiotic-resistant Clostridium difficile infection of the gastrointestinal 
tract after its development was fast-tracked by the US FDA. The structure of 
ramoplanin A2 is shown in Figure 9. 
 
 
Figure 9: The structure of a glycolipodepsipeptide antibiotic ramoplanin A2. 
 
Penicillins are a well-known class of β-lactam containing antibiotics which inhibit the 
formation of cross links within the peptidoglycan (Figure 10). Penicillin does this 
through the inhibition of the penicillin binding protein DD-transpeptidase.13 Many 








Moenomycins are a group of phosphoglycolipid antibiotics which are able to bind to 
bacterial transglycosylases, preventing the extension of the cell wall glycan chain and 
therefore destabilizing the peptidoglycan.14 These are the only known compounds 
which are able to inhibit transglycosylases and no known resistance to them has 
emerged, making them promising antibiotics. Moenomycins are not currently used in 
human medicine but are commonly added to cattle feed.15,16 The general structure of 
this family of antibiotics is shown in Figure 11. 
 
 
Figure 11: The core structure of the moemycin antibiotic group. 
 
Vancomycin is an antibiotic used to treat many complicated infections caused by 
MRSA.17 Vancomycin forms hydrogen bonds with the D-Ala-D-Ala portion of the cell 
wall pentapeptide. This results in the inhibition of transpeptidases and cell wall cross 
links cannot be formed.18,19 Bacteria which have developed resistance against 
vancomycin have a D-lactate in place of the last D-Ala and this prevents the binding 









1.2 TRANSLOCASE MraY 
1.2.1 Catalytic mechanism of MraY 
Translocase MraY is an integral membrane protein of very low natural abundance, 
which catalyses the reaction between UDP-MurNAc-pentapeptide and the 
undecaprenyl phosphate lipid carrier in the presence of Mg2+.1 
The catalytic mechanism could either be a one step or two step reaction.  
One proposal is a single-step phosphotransfer at the β-phosphate of the UDPMurNAc-
pentapeptide, via a complex of MraY, UDPMurNAc-pentapeptide and undecaprenyl 
phosphate.20  
Alternatively, a two-step mechanism has also been proposed, including an attack by 
an active site nucleophile. The two-step mechanism suggests UMP is lost to yield a 
covalently bound phosphate-UDPMurNAc-pentapeptide intermediate, which is then 
attacked by undecaprenyl phosphate to yield lipid intermediate I.21 
There are three aspartic acid residues found in the active site which are highly 
conserved (Asp115, Asp116, Asp267 in E. coli MraY).1 These three residues are the 
only completely conserved nucleophilic residues in the MraY sequence. Mutation 
studies showed the importance of these nucleophilic residues which when replaced 
render the enzyme inactive.1 One of the proposed roles for the aspartic acids suggested 
that two of them may form a binding site for the Mg2+ cofactor of MraY. The third 
could then act as a catalytic nucleophile at the active site. Other residues at the active 
site have also been found to be important for activity, but there is more variation 
between species.  
 
1.2.2 Crystal structure of MraY 
In 2013 it was reported that A. aeolicus MraY (MraYAA) had been expressed, purified 
and crystallised by Chung et al. and the final model refined.1 (Figure 13). It was shown 
that MraY crystallises as a dimer which has an oval shaped tunnel at the interface. The 
protomers contain ten transmembrane helices (TM1-TM10) linked by four periplasmic 
loops and five cytoplasmic loops. Both the C- and the N- terminus of MraY are found 
on the periplasmic face of the membrane. TM9 has a substantial kink in it breaking the 





Figure 13: TOP: The MraY dimer showing TM9b circled in yellow. BOTTOM: The surface 
representation of the MraY dimer, showing the channel formed at the centre. (PDB: 4J72) 
 
Lloyd et al. reported the presence of the three conserved nucleophilic aspartate 
residues (Asp115, Asp116, and Asp267), found on the cytoplasmic face of the 
membrane that are essential for the catalytic activity of MraY.22 It was then found by 
Chung et al. that there is also a catalytically active histidine residue (His324) in the 
active site.1 There is a triad of histidine residues (His324, His325, and His326; HHH 
motif) conserved in the bacterial sequences of the polyprenylphosphate N-
acetylhexosamine 1-phosphate transferase (PNPT) superfamily, which are positioned 
on loop E. They also challenged the previously proposed roles of the aspartate residues, 
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and it is now suggested Asp265 interacts with Mg2+ rather than acting as nucleophile. 
Bouhss proposed that Asp117 could in fact deprotonate the phosphate moiety of the 
lipid carrier.6 The relevant active site residues are shown in Figure 14.  
 
Figure 14: The active site of MraY with the residues consider to be important shown in orange 
and the Mg2+ ion shown in green.23(PDB: 4J72) 
 
The surface representation of MraY shows a groove that extends from TM9b to the 
active site where Asp117 is located, which could accommodate the lipid chain which is 





Figure 15: The groove formed by TM9b shown on with a black arrow on the surface 
representation of the MraY monomer. The catalytic aspartate residues are shown in pink and the 
Mg2+ ion is shown in dark blue. (PDB: 4J72) 
 
1.2.3 Natural product inhibitors 
It is well known that natural product inhibitors provide a great resource for the 
development of new antibiotics. A sub group of natural product inhibitors of MraY are 
called the uridylpeptide natural product family (or uridyl peptide antibiotics-UPAs). 
UPAs have shown in vivo efficacy against a number of pathogenic bacteria, which 
include vancomycin-resistant Enterococcus (VRE) and methicillin resistant 
Staphylococcus aureus (MRSA).24–26  
There are several known groups of UPAs, which have the potential to form new groups 
of antimicrobial agents.27 The groups of UPAs can be split into pacidamycins (also 
containing the mureidomycins, napsamycins and sansanmycins), muraymycins, 
caprazamycins (also containing lipidomycins), capuramycins, and tunicamycins. Their 
exact mechanism of action is unknown and because of their large size it is unclear how 
they reach the active site of MraY. This said mureidomycin A and lipidomycin B were 
shown to be slow binding inhibitors and tunicamycin a reversible inhibitor of 
MraY.28,29 Figure 16 shows some examples of UPAs. It is possible that the pore which 
is seen at the center of the MraY dimer could provide an entry route to the cytoplasmic 





Figure 16: Examples of UPAs 
 
The rapid action of UPAs and their broad spectrum of activity, coupled with 
microorganisms’ low development of resistance against them is promising. Despite 
this, there are still issues with synthesis, bioavailability, metabolic stability, the route 
of administration and the cost of production. Recently synthetic analogues of 
sansanmycin UPAs have been synthesised and show promise for the treatment of TB.30 
In 2016 and 2017 new co-crystal structures of MraY complexed with tunicamycin and 
muraymycin D2 were published.31,32 MraY from the pathogenic Gram-positive 
bacterium Clostridium bolteae (MraYCB) was crystallised in complex with 
tunicamycin and MraY from Aquifex aeolicus (MraYAA) in complex with muraymycin 
D2 (MD2). The structures of these uridyl inhibitors are shown in Figure 17. The two 





Figure 17: The structures of tunicamycin and muraymycin D2 (MD2). The uridine moiety is 




Figure 18: The structures of MraY-Ligand complexes, which show the location of the active site 





Both crystal structures show that a significant change in active site geometry occurs 
compared to the previous crystallised apo MraYAA, caused by a notable 
conformational change which occurs on binding. TM9b rotates away from the active 
site and this can be seen in Figure 19. This leads to a widening of the active site and 
the HHH motif. The conformational plasticity which the enzyme is able to exhibit may 
explain how the active site is able to accommodate such a diverse range of inhibitors. 
The two inhibitors occupy a similar space with the uracil moiety found wedged in a 
small pocket participating in π-π stacking interactions. In a uridine adjacent pocket the 
aminoribose moiety participates in hydrogen bonding via its amino group. In the 
bonding of tunicamycin the conserved HHH motif interacts with the 4’- and 6’- 
hydroxyl groups of the GlcNAc. The tunicamine hydroxyl group was found to interact 
with one of the catalytic Asp residues (Asp231). MD2 differs in its binding motif as it 
does not bind with several of the catalytic residues which were considered to be 
important, including the three aspartic acid residues. The acyl chain of tunicamycin 
cannot be seen in the crystal structure due to its flexibility, however the structure 





Figure 19: Blue is the Apo MraY and orange shows the complex between MraY and MD2. The 
two structures are overlaid to show the movement of TM9b when an inhibitor is bound to the 





In 2019 Mashalidis et al. published three further crystal structures of MraY-inhibitor 
complexes.33 This time the inhibitors were the uridyl containing carbacaprazamycin, 
capuramycin and 3’hydroxymureidomycin. These are potent inhibitors of MraY and 




Figure 20: The structures of the three natural product inhibitors co-crystalised with MraY. 
Uridine shown in blue. 
 
The binding of carbacaprazamycin uridyl moiety and the aminoribose is similar to 
those of tunicamycin and MD2. The carboxylate group is shown to form a hydrogen 
bond with H325 of the HHH motif.  As with tunicamycin the alkyl chain is presumed 
to compete with the lipid carrier (C55-P) lying in the groove shown in Figure 15, and 
is therefore critical for activity.34 The tunicamycin-MraY complex did not demonstrate 





Figure 21: The alkyl chain of caprazamycin shown in TM9 groove. Both images shown the same 






Capuramycin binds in the uridine and uridine adjacent pockets. The caprolactam group 
binds at a site which is not seen with the other inhibitors. It is on the cytoplasmic face 
of the enzyme where the caprolactam sits in a shallow hydrophobic pocket. Replacing 
the caprolactam group with a smaller group such as a hydroxyl leads to a dramatic 
reduction in inhibitory activity.35 This binding pocket is shown in Figure 22. 
 
 
Figure 22: The active site capuramycin complex showing the caprolactam binding site in pink. 
K121, L122 and K125 are the residues (highlighted in pink) which participate in the binding 





The mureidomycin features a tetrapeptide containing a meta-tyrosine which is shown 
to bind in the uridine adjacent pocket via a hydrogen bond with the hydroxyl group. 
The urea group in the tetrapeptide binds in the TM9b/loopE pocket, similarly to the 
urea group seen in MD2. This is shown in Figure 23. 
 
 





1.3 BACTERIOPHAGE ФX174 - E PROTEIN  
Bacteriophage means “bacteria eater” as they destroy the host cell. They are viruses 
which infect bacteria. Double stranded DNA bacteriophages are generally composed 
of two genes which enable them to cause host cell lysis. These two genes code for 
endolysin and holin. Holin allows endolysin to cross the cytoplasmic membrane and 
gain access to the cell wall.36 Endolysin is an enzyme which is able to degrade the cell 
wall. Once the cell wall has been degraded the cell cannot maintain osmotic pressure 
and lyses. Small single stranded DNA phage such as ΦX174 in contrast have one 
single lysis gene E.37 Expression of E causes the lysis of E. coli.38,39 Protein E is made 
up of a hydrophobic transmembrane domain in the N- terminal region and a positively 
charged soluble domain found near to the C- terminal.40 The N-terminal 35 residues 
making up the transmembrane domain are thought to be responsible for causing lysis.41 
The C terminal can be replaced with LacZ without effecting cell lysis, demonstrating 
that the transmembrane region is of key importance for cell lysis.42  
There is no evidence to suggest that the E protein is able to degrade the cell wall, and 
so its mechanism of facilitating cell lysis must be distinct from direct degradation of 
the cell wall. Due to its simple structure it is unlikely to have enzymatic activity and 
E-mediated lysis requires cell growth. The exact mechanism by which lysis occurs is 
unknown and many models have been proposed. Lubitz and co-workers proposed the 
E protein is able to form “transmembrane tunnels” which then release cytoplasmic 
contents, which include the progeny virions, but there is little genetic evidence to 
support this model. 43 
 
1.3.1 Target of E protein 
In order to identify the host genes required in E-mediated lysis, Young and coworkers 
isolated recessive mutations in the host gene slyD which are able to block the effects 
of E.44 The gene slyD encodes an FK506 binding protein-type peptidyl-prolyl cis-trans 
isomerase (PPIase).45 It is thought that the slyD mutant is able to block accumulation 
of protein E in the membrane, and based on this it is proposed that SlyD is involved in 
membrane folding and/or membrane insertion. This proposal fits with the role of 
PPIase which are associated with protein folding.46,47 Despite playing a role in the lysis 
mechanism of protein E, slyD is not a target of the bacteriophage. 
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Bernhardt et al. established in 2000 that E. coli MraY is the site of action of lysis E 
protein from bacteriophage ΦX174.46 Lysis resistant mutations (F288L and ∆L172) 
were found in MraY genetic mutants. This resistance strongly suggests that E protein 
is able to induce lysis by inhibiting cell wall biosynthesis. There are two proposals for 
the role of slyD. Firstly it is thought it could allow the accumulation of E, possibility 
by assisting with folding and stability during membrane insertion. Secondly it is 
possible that slyD is able to promote the interaction between E and MraY. This is 




Figure 24: Proposed model for the mechanism of E-mediated cell lysis. 
 
From this it was concluded that the inhibition of MraY by protein E is through a 
protein-protein interaction distant from the active site. Cell lysis requires a peptidyl-
prolyl isomerase SlyD, however the exact role of SlyD is unknown. SlyD was shown 
by Mendel et al. to have a strong interaction with E protein.42 Later Bernhardt et al. 
proposed that SlyD was able to protect E protein from proteolysis which was consistent 
with the data collected by Mendel et al. From this it was proposed that this protection 
allowed E protein to disrupt protein-protein interactions with MraY which are essential 





Figure 25: The proposed function of slyD in the E-MraY interaction site.42 
 
1.3.2 Protein interaction site with MraY 
The 37-residue transmembrane domain was synthesised (Epep) by Mendel et al. It was 
concluded that Epep could inhibit particulate MraY but not detergent solubilized MraY. 
The mutation F288L in MraY causes resistance to protein E. Phe288 is found in TM9a, 
close to the exterior face of the membrane, this gives some indication of the interaction 
site. The fluorescence assay alone is insufficient to conclude that Epep interacts with 
MraY. Assays such as a pull down assay could be used to definitively conclude this 
claim. 
Based on the fluorescence assay data, Rodolis et al. proposed an interaction site 
between E protein and TM9 of MraY (Figure 26).48  An alpha-helical wheel based 
model of TM9 was aligned with the known alpha-helix transmembrane domain of 
protein E. The proposed model revealed that it was possible for π-stacking interactions 
to occur between Phe288 and two tryptophan residues (Trp4 and Trp7) found in 
protein E. It is possible that the guanidinium side chain of Arg3 of E protein could also 
form favourable hydrogen bonding interactions with Glu287 found in the TM8-TM9 
turn of MraY. Glu287 is conserved in all MraY sequences. It is also conceivable that 
π-cation interactions are occurring between Arg3 and Phe288. From this model the 
motif Arg-Trp-x-x-Trp (where x is any amino acid) is proposed as an interaction site 





Figure 26: The proposed interaction site between MraY TM9 and E protein.48 
 
1.3.3 RWxxW containing antimicrobials 
The Arg-Trp-x-x-Trp motif can been seen in other microvirdae bacteriophages related 
to ΦX174 as well as in several cationic antimicrobial peptides.48  The RWxxW motif 
is seen close to the N- or C- terminus of several naturally occurring cationic 
antimicrobial peptides which are shown in Table 1. Arginine and tryptophan rich 
peptides are known to have antimicrobial effects and this will be discussed in the next 
section.27 Hancock and co-workers have also observed high activity in peptides where 







Table 1: The sequence similarities between E protein and known antimicrobial peptides.  
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1.4 ANTIMICROBIAL PEPTIDES 
Due to the increasing issue caused by the emergence of antimicrobial resistance there 
has been an increase in research effort dedicated towards the development of 
antimicrobial peptides (AMPs).50 AMPs are produced in the mammalian immune 
system and in a wide range of plants and insects. This is partly due to their low toxicity 
and broad spectrum of activity attributed to their bacteriolytic abilities.51,52 In addition 
to this, a significant advantage of AMPs over conventional antibiotics is their 
imperviousness to resistance. Despite this there has been limited success in the 
development of AMPs that are suitable for clinical use. This is due to a number of 
reasons including: the high manufacturing costs associated with AMPs, as well as low 
activities and cytotoxicity toward mammalian cells.53 
AMPs have multiple target, in contrast to conventional antibiotics which have a single 
target, and hence for resistance to occur it would be necessary for modifications to 
arise at all the sites of action.54 Features of naturally occurring AMPs are often 
incorporated into the design of new synthetic AMPs and antimicrobial agents. AMPs 
are known to have intracellular targets such as enzymes, causing the inhibition of cell 
wall synthesis and protein synthesis, and some are able to interact with RNA and 
DNA.55  
 
1.4.1 Arg-Trp containing antimicrobial peptides 
Antimicrobial peptides can be split into several categories. One of these categories are 
cationic peptides which are rich in arginine and tryptophan residues.27,56–59 Several 
subsections of the AMP family are made up of groups of peptides which are rich in 
particular amino acids.60 The success of the Arg and Trp containing peptides stems 
from the physical properties of these two amino acid residues. Examples of peptides 
found in this group include tritrpticin and indolicidin.61,62 The arginine residues, which 
in physiological conditions are always cationic, are able to interact in π-cation 
interactions and electrostatic interactions with the anionic constituents of the lipid 
bilayer. This creates specificity, as the peptides can act preferentially with bacteria 
over the neutral mammalian cell membrane. The sidechain of arginine is also able to 
participate in hydrogen bonding interactions. Tryptophan is a hydrophobic residue 
which has a preference to exist in the interfacial region of the lipid bilayer, and is able 
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to participate in π-cation and π- π- stacking interactions.63 In combination with one 
another these two residues are able to participate in stacking interactions which 
facilitate peptide-membrane interactions and aid with peptide secondary structure 
formation and stability. Even at short lengths, Arg-Trp AMPs can be highly potent.61 
Various biophysical studies suggest that AMPs mode of action may be through pore 
formation which causes the permeabilisation of the lipid membrane of bacteria.59,64,65 
This often leads to cell death. There are a number of mechanisms by which bacteria 
can make holes in the membrane, and these are described below. 
 
1. The carpet model 
The carpet model mechanism involves the AMPs forming a “carpet” of peptide by 
laying parallel to the membrane. The peptides are able to exhibit detergent like effects 
which lead to the formation of pores in the membrane. Shown in Figure 27. 
 
 
Figure 27: Carpet model mechanism 56 [Red= hydrophilic, Blue= hydrophobic] 
 
2. The toroidal pore 
These pores are formed from both AMPs and lipids and curve inwards towards the 
pore. The longevity of these pores is thought to vary, but is thought to be a mechanism 
of shuttling AMPs from one side of the membrane to the other. Shown in Figure 28. 
 
 




3. The barrel-stave mechanism   
AMPs span the membrane forming barrel-stave pores. These pores are lined with 
peptides. Shown in Figure 29. 
 
 
Figure 29: barrel-stave mechanism 56 [Red= hydrophilic, Blue= hydrophobic] 
 
AMPs are also known to have intracellular targets such as enzymes, causing the 
inhibition of cell wall synthesis and protein synthesis, and some are able to interact 
with RNA and DNA.  
A recent example of Arg- and Trp- rich antimicrobial peptides was shown by 
Castelletto et al. (2020) who synthesised three tripeptides with the sequence RXR, 
where X is an aromatic residue (e.g tryptophan).66 Their aim was to target 
Pseudomonas aeruginosa through membrane lysis. This was tested using biofilms and 
theactivity was related to the binding of the second messenger molecule (nucleotide c-
di-GMP). There was strong selective activity against P. aeruginosa biofilms observed 
for RFR and RWR. It was observed that all three peptides were able to self assemble 
into cluster nanostructures. The antimicrobial activity however was attributed to 
membrane disruption caused by the cationic arginine residues. This membrane 
disruption likely occurs by one of the mechanisms discussed in this section.  
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1.5 RWXXW PEPTIDE ANALOGUES 
Rodolis et al. synthesised a series of Arg-Trp containing dipeptides and pentapeptides 
to investigate the hypothesis of the RWxxW motif experimentally.48 Once synthesised, 
the in vitro inhibition of the peptides and the antimicrobial activity were tested. The 
results of these tests are shown in Table 2.  
 
 
Table 2. The inhibition and antimicrobial data that were obtained for a series of pentapeptides 
and dipeptides by Rodolis et al.48  
 
The series of pentapeptides served to identify if any of the residues of the RWxxW 
motif were solely responsible for the inhibition. The arginine and two tryptophan 
residues were separately varied for glycine and then the inhibition was tested. This 
showed that no one residue was responsible for the inhibition of MraY. Inhibition was 
however seen for all of the pentapeptides suggesting the motif derived for the 
hypothesised binding region to be correct. The pentapeptides however did not show 
any antimicrobial activity. It is possible that these pentapeptides did not adequately 
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mimic the secondary structure of the α-helical E protein. The zwitterionic nature of the 
pentapeptides may have affected the activity they were able to exhibit.  
Looking at the series of dipeptides, the dipeptide Gly-Trp-octyl ester (GWoct) 
inhibited E. coli MraY but not the F288L and E287A varients confirming the 
importance of the residues Phe288 and Glu287 at the interaction site. Despite this 
MraY inhibition, no antimicrobial activity was seen. The dipeptide Arg-Trp-octyl ester 
(RWoct) showed antimicrobial activity against E. coli but no measurable inhibition of 
MraY. It is possible that the arginine and tryptophan residues of the RWxxW motif are 
responsible for the Epep antimicrobial activity and the final tryptophan of the motif 
responsible for the inhibition. It is also possible that full inhibition of the enzyme and 
antimicrobial activity is not possible for the pentapeptides as they may not be able to 
localise in the membrane. The dipeptides have lipophilic tails which may aid this. 
Further testing of RWoct was carried out to determine its target. MraY was over 
expressed in E. coli which was then treated with RWoct.48 Rodolis states that the MIC 
for RWoct is increased when MraY is being overexpressed and concluded that this 




Table 3: MIC of RWoct against E. coli cells overexpressed with MraY 
 
This project aims to build on this observation by synthesising related dipeptides to 
explore the structure function relationship between MraY and RWoct. Ideally these 
RWoct peptide analogues will show antimicrobial activity and MraY inhibition. The 






Since the discovery of the first bioactive peptide, insulin, in 1922 there has been an 
interest in the discovery and use of bioactive peptides in medicine. In 1955 Sanger 
resolved the amino acid sequence of insulin, which opened the door for the exploration 
of peptides as therapeutic agents. Both insulin and vasopressin (Figure 30) are peptide 
drugs which are used in there intact state and are administered into the bloodstream.67  
 
 
Figure 30: The structure and amino acid sequence of vasopressin  
 
To date the majority of discovered bioactive peptides are not suitable drug candidates 
as they are not pharmacokinetically favourable, as discussed in section 1.4. Peptide 
drugs are susceptible to rapid excretion. They have low metabolic stability and lack 
oral activity. These drawbacks coupled with their low membrane permeability make 
them unsuitable drug candidates. Despite the drawbacks associated with bioactive 
peptides, the beneficial properties which they can display cannot be ignored. For this 
reason functional mimicry of bioactive peptides has become a methodology to 
overcome many of the issues mentioned. This has given rise to a class of molecules 
which can be described by the broad term: peptidomimetics.68 With the emergence of 
3-dimensional structural information of the discovered peptides, and the proteins 
which they target, the discovery of peptidomimetic drugs has been accelerated. 
Peptidomimetics can be classified into three groups. The first of these are structures 
which mimic the local topography of and surrounding the amide bond (type I 
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peptidomimetics).69 Amide bond isosteres are examples of this. Examples of the use 
of isosteres are shown in Figure 31.70 This class can also include the use of unnatural 
amino acids (β and γ) and peptoids (poly-N-substituted glycines). The second type are 
functional mimetics which are small non-peptide molecules that bind to a peptide 
receptor (type II peptidomimetics). The molecules are often able to produce similar 
effects to the parent peptide but bind at a different subunit of the receptor, as they do 
not necessarily mimic its structure. The third type are often referred to as “ideal 
peptidomimetics” (type III peptidomimetics) and are topographical mimics. These 
compounds are novel templates which contain the most important groups from the 




Figure 31: The aminoethylene isotere in an inhibitor of β-amyloid precursor protein, designed by 
Sunesis-Merck and a trifluoroethylamine isostere developed by Zanda et al. which is selective a 
cathepsin K inhibitor.70 
 
The changes made in the classes described improve the bioavailability and stability of 
the compounds by minimising the breakdown of the compounds in biological 
conditions (i.e proteolysis), and so increasing the rate of excretion. Coupled with these 
benefits, peptidomimetics allow us to introduce conformational restriction to a 
molecule. Conformational restriction can improve the binding ability and the target 
selectivity, and so increasing the overall activity of a compound. It is possible the 
lowest energy conformer of the parent compound is not the most active, meaning the 
active conformer could be unstable, and consequently restricting the conformation to 
the active one can be beneficial. Additionally conformational restriction can enhance 
membrane permeability, one of the main disadvantages of peptide drugs. This has been 
demonstrated thought the incorporation of a cyclopropane scaffold which replaces the 





Figure 32: peptidomimetic scaffold designed by Wipf et al. which incorporated a cyclopropane in 
place of the amide bond.70 
 
1.6.1 Secondary structure mimetics 
The secondary structure of bioactive peptides are an important consideration when 
designing peptidomimetics, as many biological targets recognise secondary structure. 
Examples of this are seen in GPCRs which recognise turn motifs and proteolytic 
enzymes often recognise beta-sheet structures.69 The inhibition of protein-protein 
interaction (PPI) sites relies on both the primary and secondary structure of the proteins 
involved. The secondary structure influences the binding affinity and so when 
designing peptidomimetics for these interactions it is important to find ways of 
replicating the orientation of the important side chain groups.71  
The α-helical secondary structure is the most abundant of the secondary structures and 
is commonly seen in PPI interactions.72 Apoptosis regulators are a predominant target 
for α-helical mimetics, p53/MDm2 and Bcl-2 family interactions which are targets in 
the treatment of cancer.73 
An α-helix is a right handed coil which has a turn every 3.6 residues which creates a 
binding surface. The residues which occupy the binding surface are denoted i, i+4, i+7, 
and so on. The development of structural backbone mimics which present the amino 
acid side chains correctly has been of interest. This usually involves reproducing the 
characteristics of the i, i + 3 or i + 4, and i + 7 residues, located along one face of the 
helix (Figure 33).  
There a several backbone mimics which have been designed which include 
terphenyls74 and terpyridines, benzoylureas75,76 and oligobenzamides77,78. The 
structures of these backbones are shown in Figure 33. A number of these backbones 





Figure 33: A. shows the alpha helix and the residues which are presented down the same face. B. 
previously reported a-helix backbone mimetics which present the side chain residues in a similar 
manner (as shown by the red dots)79. 
 
The terphenyl74 (Figure 33) and terpyridine80 (Figure 34) backbones were designed 
and synthesised by the Hamilton group who were the first researchers to investigate 
their use as α-helical PPI inhibitors. Terphenyl backbones have the important residues 
situated at the ortho-positions of the aromatic rings, which take on a staggered 
conformation. This conformation is a result of the conjugation between the rings and 
the steric interactions of the side chain groups. Figure 35 shows the comparison of the 
parent α-helix compared to the terphenyl mimetic.  Their use as drug molecules is 
limited by their poor water solubility. This terphenyl-based backbone was used to 






Figure 34: terpyridine α-helix mimetic. 
 
 
Figure 35: A. The schematic representation of the parent alpha-helix. The i, i+3 and i+7 residues 
are shown in red. (side view) B. The top view of the parent peptide, residues shown in red. C. The 
top view of the terphenyl mimetic. D. Side view of the mimetic. E. The crystal structure of the 
mimetic74. 
 
The terphenyl backbones are able to rotate freely which is not consistent with an α-
helix. In order to prevent this from occuring, both the benzoylureas and 
oligobenzamides were designed with the ability to form internal hydrogen bonds 
which would constrain the molecules somewhat, preventing rotation (Figure 36).74 
Hydrogen bonds between amide –NHs and alkoxy groups promote extended 
conformation in O-alkylated benzamides and restrict the rotation about the aryl amide 
axes.82. Boger et al. saw high-affinity against HIV-1 gp41 from a benzamide α-helix 




Figure 36: benzoylurea and benzamide backbones constrained by hydrogen bonding. The 
hydrogen bonds are shown in blue. 
 
A structural mimetic has been shown to inhibit the trans-activator of transcription 
(TAT) protein interaction with viral TAR-RNA (transactivation response element 
RNA) which is crucial to HIV proliferation. The formation of the TAR-RNA and TAT 
complex accelerates the transcription of HIV. An oligopyridylamide-based α-helix 
mimetic was designed, with the aim of improving upon previous peptide based 
inhibitors acting at this site.84 The compound shown in Figure 37 was the most of the 
effective of the compounds tested against the TAR-RNA-TAT complex (IC50 = 1.5 






Figure 37: Oligopyridylamide α-helix mimetic designed to inhibit TAR-RNA/TAT PRI.84 
 
Our aim is to synthesise peptidomimetics following the synthesis and testing of the 
dipeptide series. The RWxxW motif is taken from an alpha-helix (E protein) and so 
aspects of the Hamilton and Boger backbone structures will be utilised in the design 





1.6.2 Cyclic mimetics 
These backbone mimetics are designed to mimic peptides which are greater than 10 
residues in length. This is mostly because in order for an alpha helix to form there must 
be enough hydrogen bonds to hold the structure, and therefore there must be enough 
residues to form at least two turns.85 So along with these backbone structures we turned 
our attention to backbone structures designed to mimic shorter peptide sequences. The 
peptide bond isoteres have already been discussed but will not feature in the design of 
our mimetics. A cyclic backbone was identified that had been designed and 
synthesised by Houghten et al. which was one of a number of backbones which 
focused on mimicking di- and tripeptides.83 These were originally designed to allow 
the conversion of pre-existing active peptides into cyclic structures which would, as a 
result of the cyclisation, be more resistance to proteolysis. A diazepine derivative 
which could be synthesised on a resin bead was chosen as a starting point for the cyclic 
peptidomimetic design. This is shown in Figure 38. This compound and an alternate 
cyclic structure will be discussed in more detail in chapter 5. 
 
 





1.7 AIMS AND OBJECTIVES 
1.7.1 Structure activity studies on Arg-Trp-octyl ester 
During this project we aimed to synthesise a series of dipeptides which are based on 
Arg-Trp-octyl ester, the dipeptide synthesized by Rodolis which showed antimicrobial 
activity.87 It is hoped that one of these dipeptides may have both antimicrobial activity 
and is also able to show in vitro inhibition of MraY. 
The structure of dipeptide RWoct was split into four areas where changes could be 
applied and these are shown in Figure 39. These areas are the N-terminal, the aromatic 




Figure 39: RWoct split into the four regions of interest for the synthesis of new RWxxW based 
peptides. Purple: cationic side chain, yellow: N-terminal, orange: aromatic tryptophan side chain, 
green: ester linker and blue: octyl chain 
 
Firstly the length of the ester alkyl chain (blue) was altered to a 6 and a 10 carbon 
chain. It is thought that this chain aids the insertion of the dipeptide into the membrane. 
The ester linker (green) was be changed for an amide to prevent break-down by 
esterases. The N-terminus (yellow) of the dipeptide was protected with a Boc and 
acetyl group. It has been shown that Boc protection can improve antimicrobial activity 
of short cationic peptides.27 The arginine residue was exchanged for a lysine and a 
histidine residue as well as a non-natural heterocyclic arginine residue. The tryptophan 
reside was swapped for the other aromatic residues phenylalanine and tyrosine, to 
determine the importance of the indole. To determine if the aromatic residue is 
necessary at all, a glycine residue was also be used to replace the tryptophan. 
43 
 
Once the series of dipeptides had been synthesised a series of biological tests were 
carried out on them. Antimicrobial tests was carried out using a microtitre broth 
dilution technique. The ability of the dipeptides to inhibit MraY will be determined 
using a continuous fluorescence assay and a radiochemical assay. This utilizes a 
fluorescent or radio labelled MraY substrate which when converted to lipid 1 gives an 
increase in fluorescence. The overexpression of MraY in E.coli was also used to 
demonstrate an interaction. Finally an assay using the dye resazurin was used to help 
assess how the dipeptides exhibit antimicrobial activity.  
 
1.7.2 Peptidomimetics based on RWxxW motif 
Using the data obtained from the biological testing of the dipeptide series, two groups 
of peptidomimetics will be designed and synthesised. These will be tested using the 
same biological methods. The aim is to reproduce and/or improve upon the dipeptide’s 
activities.  
One group of mimetics will focus on introducing functional groups onto a benzamide 
backbone and the other group will be peptidomimetics which replace the peptide 
backbone with a cyclic structure which limits the flexibility of the compound. 
Examples of these structures are discussed in section 1.7 
The basic frameworks which we have chosen are shown below in Figure 40. 
 
 





We will also consider the possibility of using a cyclic structure which was not 
originally designed as a peptide mimetic but does allow the incorporation of three 





CHAPTER 2: DIPEPTIDE DESIGN AND SYNTHESIS 
The first part of the project was to carry out structure-activity studies on the dipeptide 
RWoct which was synthesised and tested by Rodolis.48,87 The alterations described 
will probe the proposed interaction site of RWoct and the enzyme MraY. Liquid phase 
peptide synthesis was used to couple appropriately protected amino acids. Purification 
and deprotections were the carried out to give the final dipeptides. 
All of the peptides synthesised contain a residue with an alkyl chain attached by an 
amide or an ester. The residues used were mostly tryptophan but this was swapped for 
phenylalanine and a tyrosine. This chain is installed first by an esterification or amide 
coupling reaction. The length of the chain was also varied with a hexyl and decyl chain 
linked by an ester to tryptophan. Once this chain had been installed the coupling 
reaction to the cationic residue could be carried out. The general scheme for this 
reaction is shown in Figure 41. 
 
 
Figure 41: Solution phase peptide synthesis scheme for the general synthesis of the dipeptide 
series. Show in this scheme is protected RWoct which is not isolated before deprotection. 
[PG=protecting group) 
 
The coupling reactions mainly used an uronium based coupling reagent as the 
activator. The cationic residues coupled to the tryptophan ester were arginine, lysine, 
histidine and a heterocyclic arginine analogue. These residues were protected and 
following the coupling reaction the protecting groups could be removed.  
In some cases the α-amine protecting group was not removed or an alternate protecting 
group was installed (Boc and Ac).  





Table 4: Table of dipeptides synthesised to probe the interaction site between RWoct and MraY. 





2.1 Synthesis of tryptophan alkyl esters 
The majority of the dipeptides that we wanted to synthesise contain a C-terminal ester 
which is thought to aid insertion into the cytoplasmic membrane. In contrast to the E 
protein which the dipeptides are modelled, on the dipeptides will approach MraY 
extracellularly and so the alkyl chain is important. Rodolis showed that a methyl ester 
at the C terminus showed no inhibition of MraY or antimicrobial activity.87 In order to 
optimise the membrane localisation and insertion of the dipeptides, the octyl chain was 
replaced with a hexyl and decyl chain. The ester chain will also serve as a carboxylic 
acid protecting group during liquid phase peptide synthesis (LPPS). A Fischer 
esterification was carried out on L-tryptophan using an excess of the corresponding 
alcohol (hexanol, octanol or decanol) and a catalytic amount of H2SO4.
48,88 (Scheme 
1). The long chain alcohols were used as the solvent and were removed by silica 
chromatography due to their high boiling points. The silica was first deactivated using 
5% TEA in petrol to prevent the tryptophan amine sticking.  
The nitrogen of the tryptophan side chain, was not protected as it was unlikely to be 
reactive enough to effect the esterification or coupling reaction which would follow. 
 
 
Scheme 1: Fischer esterification of L-tryptophan using 1-hexanol, 1-octanol and 1-decanol as the 





2.1.1 Tyrosine and Phenylalanine alkyl esters 
The tryptophan was then replaced by phenylalanine and tyrosine (Scheme 2). We 
wondered whether there was potential for the tyrosine hydroxyl group to be involved 
in hydrogen bonding at the E-MraY interaction site. 
The octyl esters of L-tyrosine and L-phenylalanine were synthesised by the same 
method as the tryptophan octyl ester. The hydroxyl group of the tyrosine was also not 









2.2 Peptide coupling methods 
Liquid phase peptide synthesis was used for the synthesis of the series of dipeptides 
designed in this project. The general method is shown in Figure 42. An alternative 
method would have been to use solid phase peptide synthesis (SPPS) which is usually 
the more popular choice in the synthesis of peptides.89 We decided against this method 
mainly because we only need to carry out one coupling reaction per peptide and 
carrying out SPPS would require a coupling first to the resin which would increase the 
number of steps. The coupling to the resin would occur at the C terminus which is 
where our alkyl esters have already been installed. 
LPPS like solid phase peptide synthesis (SPPS) requires an activator and an activator 
base to be present. In the presence of these reactants an active ester is formed in situ 
which can then be attacked by an amine of a second amino acid, forming an amide 
bond. (Figure 42). If there is no activation of the carboxylic acid the formation of an 
amide bond is not energetically favourable.90 The activated ester has a good leaving 
group which is electron withdrawing, thus enhancing the electrophilicity of the 
carbonyl, making it susceptible to nucleophilic attack by the amine.90 
 
 
Figure 42: The general peptide coupling reaction between amino acid 1 (blue) and amino acid 2 
(orange). A= activator, R1 and R2= side chain, R3= ester chain, PG= protecting group. 
 
The activator initially used for the couplings was HATU (a commonly use coupling 
agent). The activator base used is Hünigs base (DIPEA). The structures of these 





Figure 43: The structures of the uronium coupling agents HATU (left) and HBTU (middle). The 
difference between the two coupling agents are highlighted in blue and pink respectively. DIPEA 
(right) is the accompanying base. 
 
HATU is in a class of uronium based coupling agents which prevent racemization 
occurring, something which is sometimes seen when alternate groups of coupling 
agents are used such as carbodiimides (DCC or DIC). HBTU is a cheaper alternative 
to HATU. HATU is used as an amine acylation agent where it reacts with a carboxylic 
acid to form an active ester which can then react with the amine nucleophile to produce 
the acylated product (amide bond formation). It was first reported by Carpino in 
1993.91 The initial activation step proceeds by the carboxylic anion attacking HATU 
to form the O-acyl(tetramethyl)isouronium salt (which is highly unstable). The anion 
attacks the isouronium salt forming the active ester. The step leads to the formation of 
the tetramethylurea by-product. The active ester is then subject to a nucleophilic attack 
from the amine. It is possible that the pyridine nitrogen atom is able to stabilise the 
amine through a hydrogen bond, and it thought that this neighbouring group effect is 
responsible for the quick reaction times and high coupling efficiency of HATU. The 





Figure 44: The reaction mechanism of a peptide coupling activated by HATU. The predicted 
hydrogen bond formed between the pyridine nitrogen and amine hydrogen is circled in green. 
Amino acid 1 is shown in blue and amino acid 2 is shown in orange. 
 
HBTU is considered to be less effective when synthesising longer peptides.92 HBTU 
lacks the pyridine nitrogen that HATU possesses and this may be the reason for a 
decrease in efficiency. This difference and the structure of HBTU is shown in Figure 
43. As our peptide is only two residues in length and ultimately we need milligram 
quantities of final product, this did not matter. Levels of racemisation are higher when 
using HBTU, likely due to the lack of the stabilising pyridine nitrogen and this is 
prevented with the use of DIPEA.93 DIPEA is a tertiary amine and its approach to the 
chiral centre of the reacting amino acid intermediate is hindered, and this impedes 
racemisation. The coupling reactions were monitored using LRMS.  
The side product of both coupling agents is tetramethylurea (TMU) which is toxic to 
cells.94 It is easily removed by RP-HPLC, but where peptides were purified by other 
methods its removal was more difficult. It was most effectively removed under 
vacuum using freeze drying and could take a number of days because of the high 
boiling point (177 °C). Its complete removal could be verified using 1H-NMR. The 12 
protons of TMU are seen as a large singlet at ≈ 2.8 ppm. 
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2.2.1 Arginine protecting groups. 
In order to prevent the side chains of amino acids interfering with the coupling 
reaction, a variety of protecting groups can be used. These protecting groups are 
usually labile either in acid or base which allows selective deprotection. This is useful, 
as the amine of the residue is also protected, and this protecting group is usually 
removed in different conditions to the side chain to allow further amino acid residues 
to be coupled. 
Fmoc-Arg(Pbf/Pmc)-OH is one of the most commonly used protecting strategies for 
arginine residues in peptide synthesis.95,96 The Fmoc protecting group is removed with 
piperidine and the Pbf/Pmc groups are removed with TFA. 
Using this protecting strategy the deprotection of the arginine side chain was 
unsuccessful. A variety of conditions were used, but LRMS showed that the Pbf or 
Pmc group had not been removed to form the deprotected dipeptide. The LRMS trace 
showed a peak at m/z 826.4 (Pbf protected compound) but no peak was seen at m/z 
473.2 (deprotected). The concentration of TFA was increased (from 20%-100%), a 
scavenger (TIPS) was included and the solution was heated up to 80ºC, but no 
deprotection was seen. (Alternative methods of deprotection include HF where the 
risks outweigh the gains.) 
Initially it was thought that the Pbf group had not been removed from the arginine. 
This had previously been seen by Stierandova et al. who were able to conclude that an 
unprotected tryptophan side chain could accept Pmc or Pbf protecting groups from an 





Figure 45: The migration of the Pbf arginine side chain protecting group from the arginine 
residue to the neighbouring tryptophan residue side chain, and the removal of the N-terminal Boc 
protecting group.  
 
With the most common protecting strategy being unsuccessful we next used an 
arginine residue with an unprotected side chain. The guanidinium group was 
considered to be sufficiently unreactive to not interfere with the coupling reaction. 
Initially the Boc-Arg-OH was purchased and coupled to the tryptophan octyl ester (1) 
(Scheme 3). This coupling reaction was a success as was the deprotection on the crude 
coupling product to give Arg-Trp-octyl ester (6), which was then purified (section 2.5). 
The coupling procedure was carried out with the hexyl and decyl tryptophan esters (2 
and 3 respectively) to give RWhex (7) and RWdec (8). 
 
 
Scheme 3: The coupling reaction between Boc-Arg-OH and Trp-octyl ester following by the acid 





2.2.2 Boc deprotection 
The mechanism for the removal of Boc protecting groups under acidic (TFA) 
conditions is shown in Figure 46. The most common deprotection agent for acid labile 
groups in peptide synthesis is TFA. The tert-butyl carbamate is initially protonated by 
the acid. A carbamic acid is formed due to the loss of the tert-butyl cation. The 
carbamic acid is decarboxylated and this gives a free amine. A TFA salt forms due to 
the protonation of the amine in the acidic conditions. Dipeptides which were TFA salts 
were problematic for the biological testing. Erratic cell death has been frequently seen 
where cells have been treated with compounds which contain the TFA counter ion.98 
The TFA salt can therefore produce variable biological results and false positives. 
 
 
Figure 46: The mechanism of Boc deprotection using TFA and the formation of the toxic TFA 
salt. 
 
It is possible to remove the TFA salt using Amberlyst A21 (a free base) resin. The 
dipeptide was stirred with the resin in DCM overnight. All peptides which were treated 
with TFA were then treated with Amberlyst A21 resin to remove the TFA salt. All 
dipeptides were analysed by 19F-NMR to confirm the complete removal of the TFA 
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salt. For a TFA related group the range of 19F chemical shifts is between −85 ppm and 
−67 ppm (relative to CFCl3).
99,100 
It is possible to avoid using TFA by using 4M HCl in dioxane, as this gives the 
hydrochloride salt instead. The chloride anion has been shown to have no effect on 
cells in cell based assays.98 Towards the end of synthesising the dipeptide series this 
was used as an alternative to TFA deprotection.  
2.2.3 2,5-diketopiperazine formation 
Rodolis had previously seen spontaneous cyclisation of dipeptides which contained a 
less bulky side chain (i.e glycine) in basic conditions.87 Specifically during a work-up 
using Na2CO3 which we decided not to carry out. The 2,5-diketopiperazine formation 
is shown in Figure 47. Some of the dipeptides were synthesised using Fmoc-Arg-OH 
which was deprotected using piperidine and so it was possible that the diketopiperizine 
formation would occur. There was no evidence for this formation by LRMS analysis 
and this is likely due to the bulky side chains, and so the cheaper Fmoc protected 
arginine residues were used in most cases. 
 
 
Figure 47: Base catalysed cyclisation of a dipeptide ester to for 2,5-diketopiperazine. X=ester 
chain, R=amino acid side chain. 
 
2.2.4 Fmoc deprotection 
As the Fmoc protected amino acids were cheaper and no diketopiperazine formation 
was seen during the deprotection, most of the couplings were carried out with Fmoc-
Arg-OH. The deprotection mechanism is shown in Figure 48, and this shows the Fmoc 
adduct which is formed as a by-product. The Fmoc adduct is insoluble in water but is 
soluble in diethyl ether, in which the dipeptides had limited solubility. The majority of 
the Fmoc adduct needed to be removed as the purification method (RP-HPLC, 
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discussed in section 2.5) used water, and any precipitation would be damaging to the 
HPLC machine. The dipeptides where precipitated into diethyl ether and then removed 
by filtration leaving the by-product in the filtrate. The Fmoc adduct can be seen by 




Figure 48: The mechanism of Fmoc removal using piperidine and the formation of the Fmoc 
adduct byproduct. 
 
The coupling procedure was carried out with the hexyl and decyl tryptophan esters (2 
and 3 respectively) which were coupled to either Boc-Arg-OH or Fmoc-Arg-OH to 
give RWhex (7) and RWdec (8). Phe-oct (4) and Tyr-oct (5) were also coupled to 
either Boc-Arg-OH or Fmoc-Arg-OH to give and RFoct (9) and RYoct (10) after 
deprotection.  
 
2.2.5 Protected RWoct analogues 
In the literature it has been shown that Arg/Trp containing peptides showed greater 
antimicrobial activity with an N-terminal protecting group, particularly Boc or one or 
more amino acids before the cationic residue.27,101 The exact reason for this is 
unknown, but it is speculated that the protecting group can help anchor/position the 
dipeptide correctly. Both the Boc protected and acetylated RWoct analogues were 
synthesised. For the Boc protected analogue the dipeptide was simply left with the 
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protecting group attached having been synthesised from Boc-Arg-OH to give Boc-
RWoct (11). The acetylated analogue was synthesised by combining the crude RWoct 
(an oil) with acetic anhydride to give Ac-RWoct (12) which was then purified. (Shown 
in Scheme 4).  
 
 





2.3 Dipeptides containing arginine analogues  
The arginine was replaced with other basic residues and a modified arginine residue 
with the aim to enhance the π-cation and π stacking interactions of the MraY 
interaction site. The structures of the four residues are shown in Figure 49. The 
literature shows examples of cationic peptides containing Lys-Arg and some E protein 
sequences contain His-Arg.27,101 
 
 
Figure 49: Showing arginine and the analogues of it which were incorporated into the dipeptide. 
 
2.3.1 Dipeptide containing histidine in place of arginine  
The imidazole side chain of histidine is protonated and partially cationic at pH 7. For 
this reason it was chosen to enhance π-π stacking, and potentially π-cation interactions, 
although this is less likely. Histidine residues are also present next to tryptophan 
residues in some bacteriophage sequences.48 For the coupling reaction with the 
tryptophan ester, a doubly protected histidine residue (Boc-His(trt)-OH) was used. By 
protecting the amines the protecting groups reduced the basicity of the dipeptide, and 
this meant that the dipeptide could then easily be purified by column chromatography 
using deactivated silica gel. The acid labile protecting groups were then removed with 
TFA and the dipeptide His-Trp-octyl ester (13) was precipitated from diethyl ether. 
The dipeptide was then stirred in DCM with Amberlyst A21 (a free base) resin to 




2.3.2 Dipeptide containing lysine in the place of arginine 
Lysine is a basic residue which is positively charged at physiological pH. Intially 
Fmoc-Lys(Boc)-OH was coupled to the tryptophan ester. The dipeptide was 
deprotected first with piperidine to remove the Fmoc group followed by TFA or HCl  
to remove the Boc protecting group. To reduce the number of deprotection steps Boc-
Lys(Boc)-OH (14) was synthesised from L-lysine and Boc2O in the presence of base 
(Scheme 5). This meant that following the coupling the protected dipeptide 15, could 
be purified by silica chromatography and then deprotected using 4N HCl in dioxane 
to afford a pure deprotected dipeptide, Lys-Trp-oct. (16) (72%)  
 
 
Scheme 5: The simultaneous Boc protection of the α-amine and the side change amine of L-
lysine, using Boc2O and NaOH. 14 is then coupled to 1 and the resulting peptide (15) is 
deprotected using HCl in dioxane 
 
2.3.3 Dipeptide containing heterocyclic arginine analogues 
The heterocyclic arginine residue was synthesised from 2-chloropyrimidine and Boc-
ornithine under basic conditions to give 17 (Scheme 6). 17 was then coupled to 1 by 
the procedure previously discussed and deprotected using HCl to give R1Woct (18). 
This residue had previously been synthesised by Ulhaq et al. by a similar method.102 
The α-amino group of the ornithine was protected with a Boc group. This protecting 
group was used to prevent the SNAr reaction occurring at the α-amino group as well 
as the side chain amine. The electron deficient ortho carbon is subject to a nucleophilic 
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attack by the amine side chain, causing the ejection of a chloride ion. This reaction 
would ideally be carried out at high temperatures (80-100°C), however because the 
ornithine residue needed to remain protected by  the Boc group the temperature used 
was much lower (40°C) to prevent its removal.102 This meant the reaction time was 
approximately 3 days.  
 
 
Scheme 6:  Synthesis of heterocyclic arginine from 2-chloropyrimidine and Boc-Orn-OH. 
 
Once synthesised it was purified by column chromatography using deactivated silica 
and coupling to 1 using the same methods described in this chapter and then 




2.4 Dipeptides containing n-octyl amide 
All of the peptides synthesised up until this point contain an ester bond to the alkyl 
chain. Ester bonds in drug molecules can be problematic due to the presence of 
esterases in the body. At the active site of esterases ester bonds can be hydrolysed. 
During drug design in many cases this is undesirable, as the original compound is no 
longer intact. Increasingly there are exceptions to this rule. Some drug molecules are 
designed with an ester bond and until this is hydrolysed the drug is inactive. These are 
known as prodrugs with esterase triggered release.103 The purpose of these drugs is to 
improve stability, solubility and oral bioavailability by masking the polar moieties 
during administration.104 
 
2.4.1 Functional group exchange: ester to amide 
To decide whether the ester is susceptible to being broken down by esterases the ester 
bond must be replaced and the biological data of the two molecules compared. A 
simple and logical replacement is to change the ester bond to an amide bond. Amide 
bonds can be broken down by proteases but these are often more specific than 
esterases, and for this reason the breakdown of this bond should be slower, if not 
completely stopped.105 The breakdown of the peptide bond between the two amino 
acid residues is more likely to breakdown first as proteases breakdown amide bonds 
between amino acids. Comparing the dipeptides which contain an ester and an amide 
bond will elucidate whether the ester bond is broken down. This said, it is possible that 
the removal of the alkyl chain may render the dipeptide more active and this is 
something that will need to be considered when analysing the biological data obtained. 
 
2.4.2 Synthesis of N-octyl amide dipeptides 
The addition of an octyl chain bound by an amide to L-tryptophan can be carried out 
in 3 steps. To couple 1-octylamine to the acid of L-tryptophan its α-amine must first 
be protected. (This protection prevents the polymerisation of tryptophan). Boc 
anhydride was reacted with L-tryptophan under basic conditions. Once Boc-L-
tryptophan (19) had been synthesised, the acid was activated using DCC and 1-
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octylamine was added under basic conditions to give 20. The reaction scheme is shown 
in Scheme 7. 
 
 
Scheme 7: The synthesis of the tryptophan octyl amide. L-Tryptophan is protected at its α-
amine using a Boc group. This is followed by the coupling of 1-octylamine to the free acid. The 
Boc group can then be removed in acidic conditions.  
 
DCC is one of several carbodiimide condensation reagents. The mechanism for DCC 
mediated peptide coupling is given in Figure 50. This is the general mechanism for all 
carbodiimide couplings, but the groups on the nitrogen atoms differ between 
reagents.106 (The difference in groups between the carbodiimides alters the urea by-
product that is formed). In the case of DCC the by-product N,N’-dicyclohexylurea is 
insoluble and precipitates as the reaction advances.107 Most of this by-product can be 
filtered off with any remaining by-product being removed using a silica column. The 
urea by-product of EDC (another carbodiimide) is water soluble and is easily removed 
in an aqueous work-up. 
 
 
Figure 50: General mechanism of a DCC coupling between and acid and an amine. The insoluble 




A problem associated with the use of carbodiimides for peptide coupling is 
racemisation.106 The mechanism of racemisation caused by carbodiimides is shown in 
Figure 51. Racemisation proceeds via an oxazolone intermediate.90 The α-amine 
protecting group (Boc) is electron withdrawing, and this promotes the abstraction of a 
hydrogen atom from the α-carbon by a base. The ion which is formed is resonance 
stabilised. On opening of the oxazolone intermediate, the conversion between the two 
enantiomers, at the α-carbon, can occur. 
 
Figure 51: The mechanism by which racemisation occurs when using carbodiimide coupling 
agents. [Pink=Boc group, Blue=carbodiimide coupling agent, Orange=amino acid] 
 
To reduce the amount of racemisation that occurs, an auxiliary nucleophile can be 
added. 1-Hydroxybenzotriazole (HOBt) is often used in peptide coupling reactions for 
this reason. HOBt binds to the carbonyl group which shortens the lifetime of the O-
acyl-isourea.108 The amine can now react with the acyl group without racemisation 






Figure 52: The mechanism by which HOBt prevents racemisation.  
 
The final step of the tryptophan octyl amide synthesis is removing the amine protecting 
group from 20 which was removed under acidic conditions. The octyl amide 
tryptophan residue (21) was then coupled to protected arginine and purified by RP-
HPLC to give RW-Noct (22). Fmoc-Lys(Boc)-OH was coupled to 21 to give the 
protected dipeptide 23 with a yield of 53%. A basic (piperidine) and an acidic (HCl) 
deprotection afforded KW-Noct (24). As not all of the crude was purified and a known 
concentration was not used at the beginning of the HPLC purification, there are no 
yields. 
From the previous work carried out it is clear that the cationic residue is important for 
antimicrobial activity.48 The beginnings of the investigation into the importance of the 
tryptophan (or an aromatic) residue was described in section 2.1.1. 
The replacement of the aromatic residue with a glycine, RGoct, had previously been 
done and had shown no activity. The ester bond was replaced with an amide in case 
the ester bond was being broken down by esterases. This was done using the same 






Scheme 8: The synthesis route used for the synthesis of KG-Noct (28) 
 
First Boc-Gly-N-oct (25) was synthesised by coupling 1-octylamine to Boc-glycine 
using EDC before being deprotected with HCl to give 26. For ease of purification we 
coupled Boc-Lys(Boc)-OH (14) to a glycine octyl amide (26) using the method 
previously described. The protected dipeptide 27 was purified by silica 






2.5 Purification of dipeptides 
Initial attempts to purify the dipeptides using RP-HPLC were problematic for a number 
of reasons. The available HPLC machine was intended for analytical separation. Small 
amounts can be injected into this machine, and the flow rate used and the pressure 
reached are not suitable for the large scale purification we needed to carry out. The 
peptide solubility was generally poor, and this could pose issues with precipitation in 
the machine. Each peak would have to be collected manually and analysed by LRMS 
in order to determine where the dipeptide eluted. Following the determination of which 
peak contains the desired product, it would then have to be collected manually which 
would be time consuming. Finally, each crude material had several side products due 
to the steps of each reactions carried out without purification prior to the final step. 
This was the case due to the problems encountered when purifying arginine containing 
compounds. 
In order to avoid this several purification methods were attempted: 
1. Recrystallization. Recrystallization from diethyl ether did not leave the 
dipeptides suitably pure to continue. Attempts to recrystalise from other 
solvents were also unsuccessful. Liquid-Liquid separations, using Na2CO3 
(sat) and EtOAc were likewise unsuccessful as the arginine side chain remains 
charged even in the most basic of conditions. An emulsion formed and the 
layers did not separate. 
2. Purification of protected dipeptides. The dipeptides were left protected and 
then purified using silica chromatography. Boc-Arg(Pbf)-Trp-oct could be 
purified in this way albeit with a low yield of 2%. As the side chain protecting 
group could not be removed (Section 2.2.1) the final compound could not be 
reached. Due to the unprotected arginine side chain being strongly basic and 
the silica gel being strongly acidic the interaction between the two is strong 
and irreversible so it was not possible to purify the deprotected dipeptides in 
this way. Unprotected arginine could not be eluted even when the silica had 
been deactivated and methanolic ammonia was used as the eluent. 
3. Cation exchange chromatography. The arginine side chain was proving to be a 
hindrance to successful purification so the next purification method was chosen 
to try and take advantage of the cationic nature of the guanidium group. FPLC 
using a Mono S cation exchange resin column and a gradient of 0.1M 
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ammonium acetate to 1M ammonium acetate was used to purify RWhex. A 
detection wavelength of 280 nm was used for monitoring the elution from the 
column. All of the peaks were collected but none of the peaks corresponded to 
the RWhex (determined by LRMS). The dipeptide did not elute. It is likely that 
on unbinding from the column the poorly soluble dipeptide precipitated in the 
aqueous conditions and therefore could not elute.  
4. Amberlyst 15 cation exchange resin. It is likely that FPLC was unsuccessful 
because of precipitation. The Amberlyst cation exchange resin uses the same 
principle but the dipeptide would be more tolerant to the solvent. This is a 
strongly acidic cation exchange resin which when mixed with the peptide 
causes the deprotection of the Boc protecting group and binding of the peptide 
(arginine side chain and amine terminus) to the resin. The resin is washed with 
a series of solvents and then stirred with ammonia solution (4M in methanol) 
which exchanges with the peptide. The peptide is now isolated. The concerns 
with this method were that the ammonia may cause hydrolysis of the ester 
leading to increased side products and an increased chance of diketopiperazine 
formation. There is no evidence for this happening from the analysis carried 
out on the peptides. The method only worked on a small scale (20-50 mg of 
crude material) and the Boc deprotection was often incomplete. Some peptides 
were protected with Fmoc and so these could not be successfully purified by 
this method. Whilst some of the dipeptides were purified in low yield (<8%) 
using this method the majority of attempts did not yield pure compound 
therefore this method was not continued. 
5. C18-reverse phase silica. This silica resembles that found in RP-HPLC 
columns. Using this reverse phase silica in a similar manner to a normal silica 
would mean a larger quantity of material could be loaded onto the column. A 
gradient of water to acetonitrile was used as eluent. Initially this was carried 
out in a similar way to normal silica column chromatography however the 
nature of C18 silica packed very tightly, and this meant the pressure build up 
from using the bellows was very high and elution was very slow. Changing the 
apparatus to a Buchner funnel and vacuum pump was more successful. A step 
wise gradient from of 0% - 100% MeCN + 0.01% TFA was used. This method 
successfully purified both the Boc protected and acetylated RWoct dipeptides 
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as small amounts of these dipeptides eluted after the impurities. The 
unprotected dipeptides eluted at a similar point to the impurities and separation 
was not possible as the gradient was carried out manually.  
6. RP-HPLC. As none of the previously mentioned methods of purification had 
been suitably successful, RP-HPLC (Synergi™ 4 µm Polar-RP 80 Å) was 
employed. The peptides were dissolved in MeOH but at the beginning of the 
gradient (0% MeCN + 0.01% TFA to 100% MeCN + 0.01% TFA (with water 
+ 0.01% TFA) there was precipitation which blocked the machine. The method 
was optimised so that the run started with a higher concentration of acetonitrile 
(20%). At this concentration there was not precipitation and the compound had 
not begun eluting. Some impurities could be washed out at this concentration 
before the gradient increased to 100% acetonitrile over the next 35 minutes. 
All the dipeptides from this point were purified by HPLC. TFA is normally 
used to improve the resolution of the peaks but it was found in our case that 
there was no need for the addition of TFA and so this was stopped due to 
toxicity concerns.  
Yields are not stated in the experimental section as only the amount of product required 
for analysis and biological testing was purified (typically 5-10 mg). Some compound 
is lost during HPLC purification on column and it is possible that there is 
decomposition under the purification conditions.109 (As the fractions were collected 
manually it is hard to account for the delay between the chromatogram on the screen 
and the collection pipe, and so it is likely that further material is lost here). 
 
2.5.1 Analysis of peptide purity  
Following purification using the semi-preparative column (Synergi™ 4 µm Polar-RP 
80 Å) the dipeptides were run through the analytic column (Kinetex 5u EVO C18 
100A) to ensure they were pure. This is shown in Figure 53. This was used as a method 





Figure 53. A shows the RP-HPLC trace from the purification of RWoct (blue) with a gradient 
(orange) of water and MeCN. B. shows the HPLC trace of purified RWoct (blue) and the gradient 
(orange) of water and MeCN. Both were monitored at 250 nm. The desired compound (RWoct) 






The series of dipeptides were synthesised using LPPS which was considered to be an 
advantage in the circumstances over SPPS. A variety of protecting and deprotecting 
strategies were tested and utilised over the series of dipeptides. Following this the 
purification by RP-HPLC was carried out. Of the many purification techniques carried 
out this was the only one which was widely successful. With this series of dipeptides 
synthesised and purified, the next step was to carry biological tests to determine the 
antimicrobial activity and the inhibition of MraY. A summary of the synthesis and 









CHAPTER 3: BIOLOGICAL EVALUATION OF 
DIPEPTIDE ANALOGUES 
In order to determine the antimicrobial activity and inhibition of MraY, a number of 
biological assays were carried out, which are described in this chapter. Antimicrobial 
testing was carried out using a microtitre broth serial dilution method. A continuous 
fluorescence assay and a radiochemical assay were utilised to determine the inhibition 
of the MraY by the dipeptides, and an assay involving the overexpression of MraY in 
E.coli was also be carried out to determine the same thing. Finally an assay which uses 
a resazurin based dye to determine the viability of cells was used to determine if pores 
are being formed in the membranes when treated with the dipeptides. 
The results of these assays will determine the functional groups which will be included 
in the peptidomimetics which was designed and synthesised in chapters 4 and 5. The 
antimicrobial testing, inhibition assay and cell pore test (described in this chapter) was 





3.1 Antimicrobial testing 
Previous work by Rodolis et al. showed that the dipeptide RWoct (6) had antimicrobial 
activity against E. coli, P. putida and B. subtilis.48,87 Based on this activity a set of 
cationic dipeptides with alkyl chains were designed and synthesised (see chapter 2). 
We will test these compounds to see if the changes we have made will increase the 
antimicrobial activity. 
 
3.1.1 Microtitre Broth Dilution Method 
A microtitre broth dilution method was used to quantify the antibacterial properties of 
the dipeptides. This method is used commonly for its high throughput screening of 
potential antimicrobial agents.110 From the results, it is possible to calculate the 
minimum inhibitory concentration (MIC) and the concentration at which the growth 
of the bacteria is reduced by 50% MIC50. Figure 54 shows how these values are 
calculated. 
 
Figure 54: The graph shows how the MIC, MIC50 and MIC90 are calculated from the results of 
the antimicrobial testing by microtiter broth dilution. The graph showed the growth inhibition of 




The number of colony forming units (CFU) of bacteria in the starting culture must be 
known and maintained for all experiments.  To do this the Miles and Misra method 
was used to calculate the correct dilution factor of the bacterial culture which would 
give us 1000 colony forming units per mL of culture (CFU/mL) in each well.111 Each 
strain of bacteria is inoculated and incubated overnight (at either 30 or 37˚C). The 
cultures are then diluted. A dilution series carried out (10-1, 10-2, 10-3, 10-4, 10-5, 10-6, 
10-7 and 10-8 fold dilution). From each dilution 20 μL is taken and dropped onto an 
agar plate and incubated. Some dilutions will not have distinct single colonies but for 
the dilutions where there are the colonies are counted. The number of colonies is 
multiplied by 50 to give the CFU/mL. The dilution for which CFU/mL=1000 is 
chosen. 
Once the CFU/mL was found, the overnight bacterial cultures could be diluted to the 
correct concentration. To a sterile 96-well plate, 190 µL of seeded broth 
(CFU/mL=103) was added to each well. To this, 10 µL of dipeptide solution was added 
to give a total volume of 200 µL. The inhibitors were prepared by first making a 2.5 
mg/mL solution in methanol or DMSO and a twofold dilution series carried out using 
water. The final inhibitor concentration in the wells was 125, 62.5, 31.25, 15.63, 7.82, 
3.90, 1.95 and 0.97 μg/mL. The plates were covered with a sterile lid or film and 
incubated for 14 hours.  
Each compound was tested in triplicate for each bacteria. A number of controls were 
run which included a media blank, media blank and MeOH/DMSO and media and 






Figure 55: An example of the contents of each well of the 96-well plates used to calculate the MIC50 
values for each dipeptide. 
 
For each compound three plates were prepared with the compound tested in triplicate 
on each plate. On each plate the average OD595 for each concentration of inhibitor was 
calculated. The average OD595 values were plotted against concentration of inhibitor 
as shown in Figure 54 and the MIC50 was calculated for each plate. An average of 
these MIC50 values was taken for each compound and the standard error calculated. 
This would allow us to determine whether the differences in MIC50 we saw were 
significant.  
 
3.1.2 Assay optimisation 
The original protocol used deep well 96-well plates which can hold up to 1.1 mL of 
media. These plates needed to be sterilised before each use. From the autoclave 
process, water often got trapped in the wells. When the assay was run on these plates, 
the concentration of the bacteria and inhibitor was decreased, and so the results were 
not reliable. These plates also required a sterile film to be stuck over the top, and this 
occasionally introduced contamination. To overcome this, normal depth plates with 
lids which had been pre-sterilised were purchased, and these can hold 300 μL of media.  
When checking the growth of the bacteria in the deep well plate, it was found that 
Rhodococcus. jostii did not grow in the time that the plate was incubated. This is likely 
because the incubation time wasn’t long enough, due to the lag phase in the growth of 
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this organism coupled with the insufficient aeration in the wells. The use of R. jostii 
was withdrawn. The growth of the remaining chosen bacteria was retested in the 
normal plates. E. coli and P. putida grew normally in these plates, however B. subtilis 
did not. When testing against B. subtilis, the deep well plates were used, and extra care 
was taken to ensure they were dry after sterilisation.  
Initially the bacteria were grown in LB. The results were inconsistent with large 
variation within each plate. LB media provided a limited amount of carbon sources 
which can but utilised by bacteria and around a third of the amount of Mg2+ (~30 mM) 
that E. coli requires.112 E. coli is thought to need 100 mM Mg2+ to bridge the highly 
negatively charged lipopolysaccharide molecules in its outer membrane.112,113 It is 
likely that the integrity of the membrane is compromised and could be causing the 
variability in the data. Mueller-Hinton broth was designed to be used for MIC 
determination, containing around 500 µmol per litre of Mg2+. Where the test 
compounds are cationic Mueller-Hinton 2 (cation adjusted) can be used. The use of 
this media prevents the inhibitors interacting with the media and affecting the 
results.114  All of the tests carried out using LB were repeated using the cation adjusted 
Mueller-Hinton broth and this method gave consistent MIC values, and so was used 
for all the testing from this point.  
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3.1.3 Antimicrobial MIC50 testing 
After optimising the assay, all of the inhibitors was tested against P. fluorescens, E.coli 
and B. subtilis. From this data the MIC50 values were calculated and shown in Table 6. 
 
 
Table 6: The results of the antimicrobial testing carried out on the series of dipeptides. The three 
organisms tested against were E. coli, B. Subtilis and P. fluorescens. *R1=heterocyclic arginine. 
**Noct= amide linked octyl chain. 
 
The MIC50 values for each of the compounds against E. coli (TOP10) can be compared 
with the positive control (ampicillin). KWoct is able to match that level of 
antimicrobial activity and shows the best activity against both B. subtilis and P. 
fluorescens. With RW-Noct and RWdec having a comparable activity to amipicillin 
against E. coli. 
These values cannot be compared to those obtained by Rodolis (Table 2) due to 
different strains of bacteria being used. 
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3.1.4 ESKAPE pathogen MIC data 
The six bacterial pathogens which are commonly associated with bacterial disease are 
combined to give the acronym ESKAPE.115,116 The ESKAPE pathogens are 
Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumonia, Acinetobacter 
baumannii, Pseudomonas aeruginosa and Enterobacter. The acronym is also a 
reference to their ability to escape the effects of commonly used antibiotics. These 
pathogens have an increased resistance to antibiotics which are commonly used 
clinicaly, including penicillin and vancomycin. Mechanisms of resistance displayed 
by these pathogens include β-lactamases deactivating β-lactams, biofilm production 
and modification of the target site. Efflux pumps are also able to pump antibiotics out 
of some of the Gram-negative pathogens.117 
A selection of dipeptides were submitted to the Warwick University antimicrobial 
screening facility and the MIC and MBC values against the ESKAPE pathogens were 
determined by John Moat and Julie Todd. The results are shown in Table 8. The 
positive controls which were carried out are shown in Table 7. The positive controls 
are ciprofloxacin, penicillin G and colistin. Ciproflaxin is a fluoroquinolone which 
works by inhibiting DNA gyrase. Penicillin G inhibits peptidoglycan biosynthesis. 
Colistin is polymyxin E which is a last resort drug which behaves as a detergent.  
The MBC is the minimum bactericidal concentration. This is the lowest concentration 
of compound which is require to kill a given pathogen. Antimicrobial agents are 










Table 8: The MIC and MBC values in μg/mL of the four selected dipeptides against the ESKAPE 
pathogens 
 
The dipeptide RWoct showed no observable activity against the ESKAPE pathogens. 
The activity of RWNoct and KWNoct was very similar, with both showing the best 
activity against S. aureus. However when comparing the dipeptide data to the positive 
controls none reach that level of antimicrobial activity The data for both implies that 
they are bactericidal agents, based on the relationship between the MIC and the MBC 
values. KWoct has the best activity overall against the ESKAPE pathogens out of the 
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 After optimising the protocol, antimicrobial data was obtained for all of the 
dipeptides. All of the dipeptides synthesised had activity against the 3 strains of 
bacteria.  
Based on this data (Table 6) we can conclude that the tryptophan residue is important 
for antimicrobial activity, more so than the other aromatic residues tested. The 
dipeptide containing phenylalanine shows better activity than the tyrosine containing 
peptide. (Order of activity Trp>Phe>Tyr). This shows that there is not a favourable 
hydrogen bonding occurring at the hydroxyl group of the tyrosine side chain. Rodolis 
et al. showed the importance of the tryptophan residue by replacing it with a glycine 
residue. RGoct showed no antimicrobial activity. However the dipeptide KG-Noct 
showed activity which was comparable to RWoct. This may be because of the amide 
bond linker (which replaced the ester linker), or that KG-Noct has a different 
mechanism of action to RGoct.  
Of the dipeptides with the varied chain length the decyl ester gave the lowest MIC50 
value, this could be because its longer alkyl chain allows it to insert into the membrane 
more readily.  
The protected dipeptides showed no improvement of MIC50, although they were still 
active, and so protecting groups will not be used when designing the peptidomimetics.  
Several cationic residues were used and both arginine and lysine showed the good 
activity over all the bacterial strains, but the KWoct showed the best activity. Both the 
HWoct and R1Woct were incorporated in the hope they would be involved in π-cation 
stacking, but showed no improvement on the MIC50 of RWoct. 
When comparing the amides and the esters to each other it has not been possible to 
conclude which is a better choice. In the arginine series, RW-Noct has a lower MIC50 
than RWoct, whereas in the lysine series, KWoct has a lower MIC50 than KW-Noct. 
This suggests that the arginine dipeptides may be working via a different mechanism 
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to the lysine dipeptides. It is also possible that alkyl chains (mainly the ester linked) 
could be removed in vivo by esterase and peptidase activity.  
Through these observations it is likely that there are a number of mechanisms of action 
occurring within this series of dipeptides. Further tests will be needed to help elucidate 
these. 
Based on the data obtained against the ESKAPE pathogens it is likely that KWoct, 
RWNoct and KWNoct are acting in a bactericidal manner. The data also supports the 
conclusion already made that the ester and amide linkers may have different 





3.2 Continuous Fluorescence Assay for MraY Activity 
One of the main aims of this project was to synthesise a compound which showed 
antimicrobial activity and inhibited MraY. Previously Maria Rodolis showed that 
RWoct did not inhibit MraY, whereas GWoct did show inhibition.87 However GWoct 
showed no antimicrobial activity, whereas RWoct did. The series of dipeptides which 
we have synthesised was tested using a continuous fluorescence assay, to determine 
whether the compounds inhibit MraY as well as having antimicrobial activity. 
The continuous fluorescence assay was developed by Brandish (1995) and was then 
further optimised by Mihalyi (2013). This assay can quantitatively measure the in vitro 
inhibition of MraY.28,119 The substrate of MraY (UDPMurNAc-pentapeptide) is 
isolated and then a dansyl fluorescent group is attached, which exhibits polarity 
dependent fluorescence. (Figure 56) When lipid 1 is formed by MraY using the 
dansylated substrate, this polarity dependent change in fluorescence gives a two fold 
increase in fluorescence intensity. 
 
 
Figure 56: The reaction of UDPMurNAc-pp and dansyl chloride to give the dansylated MraY 
substrate UDPMurNAc-pp(Dans). This is followed by the dansylated substrates reaction with the 




3.2.1 Preparation of UDPMurNAc-pentapeptide from Bacillus subtillis 
A dansyl group can be attached to DAP residue of the UDPMurNAc-pentapeptide 
(Figure 56). This was previously prepared by a summer student (Namrita Modgill), 
using UDPMurNAc-pentapeptide purchased from BaCWAN. The preparation of cell 
wall intermediates was not continued after 2015 by BaCWAN and no other providers 
are available.  
The substrate for MraY (UDPMurNAc-pentapeptide) was previously isolated from 
antibiotic treated cells of B. subtilis by Brandish et al.28 As B. subtilis is a Gram 
positive bacteria it is more suitable for producing cell wall intermediates, but differs 
from other Gram positive bacteria as it uses diamiopimelic acid (DAP) at the third 
position of the pentapeptide instead of lysine. This DAP containing pentapeptide is the 
natural substrate for E. coli MraY. The preparation of UDP-MurNAc-pentapeptide 
involved growing B. subtilis W23 in a rich medium (PYP) to mid-logarithmic phase, 
when the rate of cell wall synthesis is at its highest. The cell pellets were then collected 
and resuspended in cell wall synthesis medium (CWSM). This medium contains 12.5 
mg/mL vancomycin, 50 mg/mL chloroamphenicol and 50 mg/mL ampicillin. 
Vancomycin is a glycopeptide which inhibits the second stage of cell wall biosynthesis 
but inhibiting the polymerization of the phosphodisaccharide-pentapeptide lipid 
complex.120 It binds to D-Ala-D-Ala of the pentapeptide unit of lipid 2, leading to the 
accumulation of UDPMurNAc-pentapeptide. The use of ampicillin (transpeptidase 
inhibitor) gave Brandish et al. greater yields, whereas Chloroamphenicol has a 
damaging effect on bacterial protein synthesis.121 This medium also contains uracil, 
and the amino acids found in the pentapeptide unit, to increase the yield. The cells 
were grown in CWSM for 45 minutes at 37°C and the cells were then collected by 
centrifugation. The pellets were initially resuspended in 5% (w/v) TCA (5 mL/g cells). 
to precipitate the macromolecules as done by Brandish. After several attempts with 
little success, the cells were lysed using the cell disruptor. This prevented the cell wall 
intermediates being treated with strong acid which may lead to their breakdown.  The 
sample was initially purified by gel filtration (Sephadex G25, 3 x 80 cm), eluting with 
water. The fractions were analysed using UV spectroscopy. Any fractions containing 
an absorbance at 262 nm were collected and analysed.  Mass spectrometry was needed 
to identify which peak contained the desired product. UDPMurNAc-pp was not seen 
in any of the fractions collected. Attempts to purify UDPMurNAc-pentapeptide were 
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then carried out using C18 reverse phase HPLC, using a gradient of 0:100 to 30:70 
Acetonitrile/ 0.05M aqueous NH4HCO3 as previously carried out by Siricilla et al.
122  
The peaks were collected and de-salted before submitting to Lijiang Song for LC-MS 
analysis. One peak did showed 1194.3464 [M+H]+ corresponding to UDPMurNAcpp, 
and this peak was collected. After many runs the amount of material collected was less 
than 2 mg, which was not sufficient for analysis by NMR. A small scale dansylation 
was carried out on the product. The reaction is shown in Figure 57. LC-MS analysis 
provided no evidence that the dansylated substrate had been formed.  
 
 
Figure 57: The reactions which occurs between the DAP side chain amide and dansyl chloride 
under basic conditions (pH ≅ 9.5) in water. This reaction was carried out on the DAP containing 
UDPMurNAc-pentapeptide. 
 
The substrate preparation was attempted more than ten times with a variety of 
techniques (including changes to the cell lysis technique, alterations to the antibiotics 
used and purification techniques and eluents) used to try and improve the success of 
the substrate synthesis and isolation. None were successful and the stocks made by 
Namrita Modgill were used on the inhibition assay for the duration of this project. 
 
3.2.2 Continuous fluorescence assay protocol 
For this assay the preparation of E. coli membranes overexpressing MraY must be 
done in advance. This was previously carried out by Mihalyi (2013) using the C43 
strain of E. coli containing plasmid pET52b-MraY, overexpressing E. coli MraY. 




The dansyl group is able to exhibit polarity dependent fluorescence. The polarity 
dependent change in fluorescence is seen when the transfer of phosphor-MurNAc-
pentapeptide to the lipid carrier (undecaprenyl phosphate) has occurred, forming lipid 
1. When UDPMurNAc-pentapeptide is added to the membranes with MraY 
overexpressed and undecaprenyl phosphate a blue shift in fluorescence is seen 
indicating the formation of Lipid 1. When tunicamycin a natural inhibitor of MraY is 
added no increase in fluorescence is observed as lipid 1 is not formed.  
The entire dipeptide series was subjected to the assay in triplicate. The inhibitors were 
added to the well of the 96-well plate to give a final concentration of 125 µg/mL. The 
excitation wavelength was 340 nm and the emission was measured at 530 nm.  The 
results of the assay of the dipeptides which were considered to have the best 
antimicrobial activity based on the previous assay are shown in Figure 58. Also in 
Figure 58 are shown the two controls, a methanol blank and tunicamycin. None of the 
dipeptides show inhibition of MraY under these conditions. 
 
 
Figure 58: The fluorescence reading of the MraY inhibition assay over 700 seconds of four of the 
dipeptides which are considered to have the best antimicrobial activity. The final concentrations 





3.2.2 Conclusion  
No inhibition was seen by RWoct or related dipeptides, which is consistent with the 
observations made by Rodolis. Rodolis then examined the effect of MraY 
overexpression on the MIC of RWoct. Their data from this assay indicated an 
interaction between MraY and RWoct. This assay will be discussed in section 3.4.   
This assay alone is insufficient in the determination of an interaction between MraY 
and the dipeptides. There is no observable evidence that the protein complex which is 
predicted to form is actually forming. In order to confirm an interaction at MraY 
further biological data would need to be obtained. One method of doing this would 
have been to carry out a pull down assay. Pull down assays allow the isolation of 
protein complexes by adsorbing the complex onto beads. Firstly however it would be 
important to determine if there is truly an interaction between Epep and MraY as this 




3.3 Radiochemical assay for the determination of MraY inhibition 
Due to the limited amount of dansylated UDPMurNAc-pentapeptide not all of the 
compounds synthesised in this project could be tested using the fluorescence based 
inhibition assay (section 3.2).  
An alternate method to determine the inhibition of MraY uses [14C]-UDPMurNAc-
pentapeptide (phosphor-MurNAc-L-Ala-γ-D-Glu-m-DAP-[14C]-D-Ala-[14C]-D-Ala). 
The preparation of the substrate was carried out by Agnes Mihalyi using a procedure 
based on the method used by P. Brandish at Smith Kline Beecham Pharmaceuticals in 
1991. 
The radiolabelled substrate is mixed with C55-P, inhibitor and over expressed E. coli 
membranes (prepared by Maria Rodolis) and then left for 30 minutes to allow the 
formation of radiolabelled lipid I.22 The reaction is quenched with pyridinium acetate 
and butanol is added. Separation occurs between the organic butanol and aqueous 
reaction mixture. The unconverted radiolabelled substrate remains in the aqueous layer 
whilst the radiolabelled lipid I is extracted into the organic butanol layer. This butanol 
layer is carefully removed and added to scintillation fluid. The ionizing radiation of 
these samples can be detected and measured using a liquid scintillation counter. By 
comparing the counts of the samples containing inhibitor to those of the controls it is 
possible to determine the percentage inhibition of the inhibitors. 
The controls used are as follows: scintillation fluid on its own, substrate with no 
enzyme, tunicamycin and no inhibitor. The scintillation fluid control allows the 
deduction of the background radiation from all of the samples. The substrate with no 
enzyme serves as an extraction control. Tunicamycin is an inhibitor of MraY and 
serves as a negative control. The sample with no inhibitor gives a value which 
represents 100 % activity of MraY. 
The assay was carried out with the help of Prof. Tim Bugg, and the samples were 




3.3.1 Radiochemical inhibition assay results dipeptides 
Two of the dipeptides were tested with this assay to allow comparison with the 
peptidomimetics which will be described in chapters 4 and 5. The results are shown in 
the bar chart below (Figure 59). 
 
 
Figure 59: A bar chart showing the % activity of MraY with no inhibitors and when treated with 
200 μM RWoct (6) and KWoct (16) with the controls which use no inhibitor (100% activity) and 
tunicamycin (100 μg/mL) 
 
The large error bars seen on the tunicamycin value are due to a reading which is 
thought to be higher because of static interference, which is occasionally seen in assays 
of this type. In an assay previously run by Prof. Tim Bugg the tunicamycin inhibition 
of MraY was 96%.  
The percentage activity calculated for MraY when treated with both RWoct (6) and 
KWoct (16) is higher than the no inhibitor sample which gives the 100% MraY activity 
value. Prior to commencing the assay the error was estimated to be around 5% however 
based on this assay it is higher this. Whilst the error between duplicates is low (see 
error bars on bar chart), the RWoct (6) and KWoct (16) samples compared to the no 
inhibitor sample show some disagreement. Possible causes of this error could be from 
pipetting errors. For future assays it may be advisable to remove a smaller portion of 
butanol to insure no aqueous layer is removed. Due to time restraints no further assays 
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were carried out and so this data is preliminary. From this data however there is no 





3.4 Effect of overexpression of MraY on antimicrobial MIC 
Zheng et al. (2008) showed that when MraY was overexpressed on a pBAD30 plasmid 
it was able to protect against infection by the ΦX174 E gene, which was expressed on 
a λ prophage. This can be explained by a 1:1 complex being formed formed between 
the enzyme and inhibitor, therefore increasing the amount of MraY can protect against 
inhitibitors. As RWoct had shown antimicrobial activity against E. coli this method 
could be used to investigate the interaction with MraY in vivo. An increase in IC50 
would be seen if a complex than led to inhibition formed between MraY and RWoct. 
This is shown pictorially in 
 
 
Figure 60: schematic of the overexpression of MraY protecting against RWoct. [Yellow rectangle 
represents bacteria and green shape represents MraY] 
  
This result was seen by Rodolis and is shown in Table 9.87 This time a pET52b plasmid 
was used instead of pBAD30. 
 
 
Table 9: The MIC results seen by Rodolis when MraY (and the two mutants F288L and E287A) 




3.4.1 Testing of dipeptides 
The four most promising compounds (based on the antimicrobial testing) from the 
series of dipeptides: RWoct (6), RW-Noct (22), KWoct (16) and KW-Noct (24) were 
chosen to initially test via this method. None of these compounds showed inhibition 
of MraY based on the data obtained from the in vitro fluorescence assay (section 3.2.2) 
but had all shown antimicrobial activity (section 3.1.3).  
The overexpression experiment was carried out using a similar protocol to Rodolis.87 
A pET52b vector which contained WT MraY, E287A MraY or F288L MraY was used. 
This vector contains a T7 RNA polymerase promoter and terminator which allowed 
the transcription of the mraY genes when induced with IPTG. The target gene which 
is downstream from the T7 promoter is transcribed from the vector by the 
bacteriophage T7 polymerase.123 The overexpression of integral membrane proteins 
has been shown to be toxic to E.coli in some instances and had been observed earlier 
by Lloyd et al. (2004).22 Rodolis conducted a growth experiment to ensure the 
concentration of IPTG did not cause toxic levels of overexpression and normal cell 
growth occurred.87 It was found that 0.5 mM IPTG did not affect the growth of the 
bacteria.  
Usually BL21 E. coli is used as the host strain in T7 promoter systems, however Lloyd 
et al. (2004) previously showed that higher levels of MraY expression can be achieved 
using E.coli C43. C43 is a mutant strain of BL21, which has been shown to tolerate 
the overexpression of integral membrane proteins without the toxic effects.22,124  
The overexpression assay was carried out on 96-well plates in a similar way to the 
antimicrobial testing with the controls previously mentioned. The addition of 
ampicillin (100 μg/mL) to the media of E.coli was included where the plasmids were 
present to ensure plasmid maintenance. 




Table 10: an explanation of the controls used to determine the results of the overexpression assay. 
The expected results are explained and the nomenclature used in table 10. 
 
The plates were incubated for 8 hours at 37˚C and then absorbance measurements 




Table 11: The table shows the calculated IC50 values for the four selected peptides against the 5 
C43 E. coli which contain no plasmid, an empty plasmid, WT MraY or one of the two mutant 
MraY (E287A or F288L) which are under control of the T7 promotor. This data is displayed in 




Figure 61: The graph shows the calculated MIC50 values for the four selected peptides against the 
5 C43 E. coli which contain no plasmid, an empty plasmid, WT MraY or one of the two mutant 
MraY (E287A or F288L) which are under control of the T7 promotor. This data is shown in Table 
11. (* shows where the MIC50 exceeds 250 μg/mL) 
 
The MIC50 values for all of the inhibitors were higher in C43 E. coli than in TOP10 E. 
coli. The C43 strain is more resistant to toxic proteins and this might indicate why the 
MIC50 is higher that the TOP10 strain.  
The MIC50 values for the empty plasmid are higher than the MIC50 values for the C43 
strain. Therefore, although the MIC50 values are higher than C43 when MraY is 
overexpressed, this is primarily due to some effect of the pET52b plasmid, so the 
increase in MIC observed by Rodolis may not be due to MraY overexpression. 
Also the data obtained for KWoct (16) shows a different pattern, so it is possible that 
its mechanism of action differs from the other dipeptides. Based on the results the 
initial conclusion is that there is a gene on the pET52b plasmid which is leading to an 





3.4.2 Troubleshooting of the overexpression assay 
In order to be able to interpret this data it is first necessary to determine why the empty 
plasmid increases the MIC50 against the four inhibitors. The three differences between 
the conditions was the addition of 0.5 mM IPTG, the addition of 0.29 mM ampicillin 
and the pET52b plasmid. Ampicillin, an antibiotic, would cause a decrease in growth 
rather than protecting the bacteria. Ampicillin does cause the plasmid to be retained 
but this was accounted for in the controls used. As IPTG has been used in this sort of 
assay many times it was unlikely to be the reason for the increased IC50. However an 
increase in MraY expression could make the bacteria more vulnerable to lysis. This 
said where pET52b was present (with and without mraY over expression) an increase 
in MIC50 was seen, and the growth of the bacteria was not stunted by the addition of 
IPTG when compared to C43. TOP10 and C43 were tested against RWoct (6) in the 
presence of 0.5 mM IPTG to establish whether IPTG was effecting the growth. This is 
shown in Figure 62. 
 
 
Figure 62: This graph shows the effect that the concentration of RWoct (6) has on the 




A notable change which had been caused by the introduction of the pET52b plasmid 
is the resistance to ampicillin which is caused by the β-lactamase gene.  
With the aim of determining whether the β-lactamase gene caused the protection 
against the inhibitors an IC50 determination experiment was carried out with RWoct. 
This time 3 “empty” plasmids containing different resistance genes were transformed 
into TOP10 E. coli. For the ampicillin resistance pET52b was used again and pET28a 
(kanamycin resistance) and pBR322 (tetracycline resistance) were used. Colonies 
were picked and grown overnight in LB with the associated antibiotic. The cultures 
were diluted 100-fold in the morning with MH2 plus the working concentration of 
antibiotic. The seeded broth was added to 96-well plates with RWoct and KWoct as 
previously described. The plates were incubated at 37˚C for 8 hours. The data from 
this experiment is shown below in Table 12 and Figure 63. 
 
 
Table 12: The IC50 values calculated when E. coli TOP10 with and without plasmids conferring 
resistance to ampicillin, kanamycin and tetracycline were treated with the respective antibiotic 






Figure 63: Graphs showing The IC50 values calculated when E. coli TOP10 with and without 
plasmids conferring resistance to ampicillin, kanamycin and tetracycline were treated with the 
respective antibiotic and RWoct (Left) and KWoct (Right). Amp=ampicillin resistance gene, 
Kan=kanamycin resistance gene and Tet=tetracycline resistance gene.  
 
The data obtained from this experiment clearly shows that the plasmid containing the 
β-lactamase gene (ampicillin resistance) increases MIC50 RWoct and KWoct. Both the 
kanamycin and tetracycline resistant E. coli showed a similar IC50 to TOP10 (without 
a resistance gene). The protection which seems to be caused by the ampicillin 
resistance gene rather than the kanamycin or tetracycline resistance genes could be due 
to the differing mechanisms of action of these antibiotics.  
Ampicillin is a β-lactam containing antibiotic which inhibits cell wall biosynthesis. 
Ampicillin is able to penetrate the cell wall where it then binds irreversibly to 
transpeptidases,125 which catalyse the last step of peptidoglycan biosynthesis. The β-
lactamase gene found in the pET52b vectors, leads to the production of the β-lactamase 







Figure 64: The chemical change that ampicillin undergoes at the active site of a β-lactamase. The 
β-lactamase gene on the pET52b plasmid allows the bacteria to be resistant to ampicillin. 
 
Kanamycin is an aminoglycoside antibiotic which inhibits protein synthesis. 
Kanamycin irreversibly binds to the 30S subunit of prokaryote ribosomes.127 This 
causes the incorrect alignment of mRNA triggering mistranslation and the incorrect 
amino acid being inserted. As a result a non-functional peptide is produced. The gene 
which encodes kanamycin resistance (found is pET28a) is the neomycin 
phosphotransferase (npt) gene.128 The gene encodes for aminoglycoside 3’-
phosphotransferase enzyme. Kanamycin is inactivated by this enzyme by the addition 
of a phosphate group (from ATP) to the 3’-hydroxyl group (Figure 65). 
 
 
Figure 65: The addition of a phosphate group to kanamycin by aminoglycoside 3’-
phosphotransferase enzyme causing its inactivation. This is the reaction which occurs allowing 
bacteria with which possess the pET28a plasmid to be resistant to kanamycin. 
 
The two antibiotics have very different mechanisms of action and the resistance genes 
have very different effects on the drug molecules. Ampicillin has a site of action in the 
cell wall which we expect our dipeptides also do. A possible cause for the β-lactamase 
gene causing resistance against our compounds could be hydrolysis of the peptides 
causing them to become inactive. However this is unlikely as two of the peptides tested 
did not contain ester bonds, and there is no literature evidence to support this. As our 
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compounds do not have a 3’-hydroxyl group or a phosphate group, phosphorylation 
will not occur and the compound’s activity will not be effected by this gene. So we 
decided to use a kanamycin resistance cassette for this assay instead of the ampicillin 
resistance gene. 
A further consideration is that ampicillin interacts with the peptides in some way and 
deactivating them. To determine if this is the case an MIC50 was carried out as 
described in section 3.1 with RWoct. The cells were also treated with a sub MIC50 
amount of ampicillin (0.8 μg/mL). If ampicillin was inactivating the peptide the MIC50 
would increase. The results of this assay are shown in Table 13. 
 
 
Table 13: The MIC50 values calculated for the treatment of E. coli C43 treated with RWoct (6) 
with and without ampicillin (0.8 μg/mL). 
 
The MIC50 of RWoct (6) is decreased upon the addition of ampicillin. This shows that 
ampicillin is not deactivating RWoct (6). E. coli C43 was did not grow when treated 
with 0.8 μg/mL of ampicillin and so whilst it is unlikely that ampicillin interacts with 
RWoct in C43 it is not possible to definitively conclude that. 
 
3.4.3 Antibiotic Cassette Replacement - Transferring the MraY gene from pET52b to 
pET28a 
We wanted to create a plasmid which contained the mraY gene under control of the T7 
promotor and the kanamycin resistance cassette. It was important that the plasmid did 
not contain an active β-lactamase gene.  
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Our first attempt would remove the mraY gene from the pET52b vector (Figure 66) 




Figure 66: Plasmid map showing the pET52b plasmid containing the mraY gene under the control 





Figure 67: Plasmid map of pET28a 
 
To do this, appropriate restriction sites on both plasmids needed to be found. SacI and 
XbaI were the enzymes used to digest the two plasmids (restriction sites shown on both 
plasmid maps in Figure 66 and Figure 67). This released the mraY insert from pET52b 
and opened the pET28a vector in the appropriate place. The insert and vector were 
combined with T4 DNA ligase overnight at 16˚C. The ligation mix was transformed 
into E. coli TOP10, and then spread onto LB+Kan (50 μg/mL) agar plates, which were 
incubated at 37˚C overnight. A ligation mix which contained no insert was also 
prepared in the same way, and this would show whether self-ligation was occurring. 
This plate showed that self-ligation was occurring. The number of self-ligating 
colonies was similar to the number of colonies on the pET28a-MraY ligation plate. 
This indicated that it was likely these colonies had self-ligated and did not contain the 
MraY gene. Both of the enzymes cut the DNA and left sticky ends (Figure 68), which 




Figure 68: The restriction sites for SacI and XbaI which give sticky ends. 
 
To further confirm that self-ligation had occurred 30 colonies were picked and the 
plasmid DNA extracted. To confirm if the mraY gene had been inserted, a restriction 
site within the gene and in the vector were chosen. PstI and SmaI are shown on the 
plasmid maps in Figure 66 and Figure 67. Then the cut DNA was run on an agarose 
electrophoresis gel only two bands were seen. (Figure 69). We would expect to see 
three bands if the desired plasmid had been successfully cut with these two enzymes. 
This coupled with the evidence of self ligation showed that the insertion of the mraY 
gene under the control of a T7 promoter had been unsuccessful. 
 
 
Figure 69: A. The agarose electrophoresis gel of plasmids created from the ligation of the MraY 
insert and a cut pET28a plasmid using PstI and SmaI (1-3 show the same reaction but 3 separate 
attempts). The presence of only two bands showed that the ligation was not successful. B. the 1kb 







3.4.4 Antibiotic Cassette Replacement - Transferring the kanamycin cassette to 
pET52b 
As we could not insert the mraY gene into pET28a, we then attempted to place the 
kanamycin resistance gene into the pET52b plasmid which already contains the mraY 
gene. This method would require us to remove or disrupt the ampicillin resistance 
gene. Within this gene there is a ScaI restriction site (Figure 70). This enzyme was 
used to digest pET52b and the enzyme was then denatured by heating the mixture to 
80˚C for 20 minutes.  
Figure 70: The restriction site of ScaI which creates blunt ends. 
 
To the now open pET52b plasmid we needed to ligate the kanamycin resistance 
cassette. The kanamycin cassette from the plasmid pALM-kan was amplified using 
PCR. (Figure 71). The kanamycin cassette which was 1.4 kbp was isolated on an 
agarose electrophoresis gel and then extracted. 
 
 
Figure 71: This agarose electrophoresis gel shows the kanamycin resistance cassette 
(approximately 1.4 kbp) which had been amplified by PCR from the plasmid pALM-kan. The 
DNA from this band was extracted. (Lanes 1-3 shows three successful attempts of the same 
reaction). 
 
The cassette was added to the open pET52b vector and ligase was added. The ligation 




agar plates, which were incubated at 37˚C overnight. Any colonies which grew on 
these plates had to contain the kanamycin resistance gene and 10 colonies were 
obtained. It was therefore very likely these were the desired plasmid, however because 
the cut plasmid and insert had blunt ends it was possible other products had formed. 
This plasmid is shown in Figure 72. 
 
 
Figure 72: Plasmid map the pET52b-MraY plasmid with the kanamycin resistance gene inserted 
and the β-lactamase gene disrupted (shown in two parts “bla” and “beta-lactamase”. 
 
To confirm that the product was correct, the plasmid DNA was extracted from the 10 
colonies which had grown, and then digested with PstI and XbaI. From this digest we 
would expect to see bands at around 1.0 and 6.6 kbp on an agarose electrophoresis gel. 





Figure 73: The agarose electrophoresis gel which shows the plasmid DNA extracted from the 10 
colonies which grew after the ligation between pET52b (cut with SacI) and the kanamycin 
resistance cassette. This DNA had been digested with PstI and XbaI. The expected bands of 1 
(orange box) and 6.6 kbp (blue box) can be seen in samples 3-10. (lanes 1-10 show the 10 different 
colonies which were obtained) 
 
As the cut sites were both blunt ended it meant the kanamycin resistance gene (kan) 
could be inserted into the plasmid running forwards and backwards. Whilst it was 
thought it wouldn’t affect the function of the gene, this still needed to be checked. If 
both the forward and backward gene behaved the same one direction would be selected 
and this choice would be maintained for all of the plasmids.  
To determine the direction of the cassette SacI was employed to digest the extracted 
plasmid. The digestion was run on an agarose electrophoresis gel and gave two 
different patterns depending on the direction of the cassette. This result is seen as the 
SacI cut site is at one end of the kanamycin cassette. The forward direct was considered 
to be the same direction as the β-lactamase gene. (Forward: 5 and 2.6 kbp. Backward: 
6.2 and 1.2 kbp). The results of the gel are shown in Figure 74. Both directions of the 
kan cassette had the same activity when tested against kanamycin.  
The creation of the new plasmid and determination of the kanamycin cassette direction 





Figure 74: The agarose electrophoresis gel which shows the pET52b-MraY-Kan plasmid when 
cut with SacI. This digest was used to determine the direction of the kanamycin resistance cassette 
which had been inserted into the pET52b plasmid which contained the MraY gene under the 
control of a T7 promoter. This plasmid had been cut in the β-lactamase gene to disrupt the 
ampicillin resistance. The orange box shows the band pattern from the cassette being inserted 
forwards and the blue box backwards. (lanes 3-10 show the 7 of the 10 different colonies which 
were obtained) 
 
After successfully cloning the kanamycin resistance gene into the pET52b vectors by 
cutting the β-lactamase gene it was important to confirm that that gene was no longer 
functional. The forwards and backwards pET52b-MraYKan were transformed into E. 
coli TOP10 and a single colony was inoculated in LB+Kan and incubated at 37 ˚C 
overnight. E. coli TOP10 was also inoculated in LB and incubated overnight. The 
cultures were diluted to 1000 CFU/mL and 190 μL of seeded broth was added to the 
wells of a sterile 96-well plate. To this 10 μL of ampicillin (final concentrations 125, 
62.5, 31.25, 15.63, 7.82, 3.90, 1.95 and 0.98 μg/mL) was added. The plates were 
incubated for 16 hours at 37˚C and then absorbance measurements taken at 595 nm 
(OD595).  
The results are shown in Figure 75. The data shows that β-lactamase gene is no longer 
active as the MIC for the two pET52b-MraYKan plasmids is the same as E. coli 
TOP10. The graph also shows pET52b which has the intact β-lactamase gene and so 
the growth of the bacteria is not affected by ampicillin. Based on this we deemed the 
forward pET52b-MraYKan plasmids suitable to be transformed in E. coli C43 and to 
be used in the overexpression protection assay. The results obtained should now reflect 





Figure 75: The graph shows the concentration of four bacteria containing different plasmids 
which had been treated with increasing concentrations of ampicillin and incubated for 16 hours. 
The four bacteria were E. coli TOP10 containing no plasmid, pET52b-MraYKan with the 
kanamycin cassette forwards and backwards and pET52b (ampicillin resistant). 
 
3.4.5 Testing the overexpression of MraY using a kanamycin resistance cassette 
The overexpression assay could now be repeated as before (using kanamycin 
resistance instead of ampicillin). This time the assay was run using only RWoct. 
The MIC50 values calculated from this data are shown in Table 14. 
 
 
Table 14: The table showing the MIC50 results of the protection assay with the new kanamycin 
resistant plasmids which were made in section 3.4.4 
 
The MIC50 values with the exception of the empty plasmid do not differ greatly. 
However, Figure 76 clearly shows that when MraY is overexpressed the growth of the 
bacteria inhibited compared to both the empty and C43 (no plasmid). This indicates 
that the overexpression of MraY is having toxic effects which were not seen when the 
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assay was previously carried out. The empty plasmid which was treated with IPTG 
shows no stunted growth further indicating that the MraY overexpression is 
responsible for the effect seen. Therefore, it is not possible to determine if there is a 
relationship between RWoct and MraY from this data.  
 
 
Figure 76: The graph generated from the determination of the IC50 values of the protection assay 
with RWoct. This shows that the growth of the bacteria in the samples where MraY is 
overexpressed (WT, E287A and F288L) and no RWoct was added is inhibited when compared to 
C43 (no plasmid) and empty (no overexpression of MraY). 
 
The growth of the E. coli was not effected when overexpressing MraY using the 
original pET52b plasmids. This might indicate that MraY was not being 
overexpressed, and this could be a result of the plasmids not being maintained. During 
the course of the assay the concentration of ampicillin will decrease as it is inactivated 
by the β-lactamase. These enzymes will continue to deactivate ampicillin in the media 
even after the host cell has lysed. As the concentration of the ampicillin drops there is 
no advantage maintain the plasmids, particularly because of the overexpression of a 
toxic protein (MraY). Therefore the population of bacteria seen at the end of the assay 























C43 empty WT E287A F288L
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3.4.6 Conclusion  
Evidence to determine whether inhibition of MraY was occurring in vivo could not be 




3.5 Membrane permeabilisation assay 
It is known that many cationic antimicrobial peptides have multiple mechanisms of 
action, and so it is possible that this is the case for the series of dipeptide synthesised 
in this project.56 
An alternate or additional mechanism of action would be that the peptides could 
permeabilise the membrane. The dipeptides have a lipophilic alkyl chain and polar 
charged head group which are the two properties which make up surfactants. An 
example of a cationic surfactant is shown in Figure 77. Surfactants can act as 
detergents and disrupt membranes, and this characteristic would make the dipeptides 
toxic to both bacteria and human cells. Cationic antimicrobial peptides (notably ones 
containing arginine and tryptophan) are known to create pores in cell membranes 
because of their detergent-like abilities.56,59  
 
 
Figure 77: The comparison of RWoct to cationic surfactant cetltrimethyl ammonium bromide. 
The cationic head groups of the two compounds are shown in blue and the lipophilic tales are 
shown in orange. 
 
Previously Rodolis carried out an assay using a fluorescent dye, NPN, to determine 
whether membrane permeabilisation was occurring.87 NPN is a fluorescent dye which 
is non-polar and exhibits an increase in fluorescence when in phospholipid 
environments compared to aqueous environments (Figure 78).129 There was no 
evidence of membrane permeabilisation by RWoct. Attempts to repeat this assay were 
unsuccessful, and this was likely due to the insolubility of the dye. As this assay was 
time consuming and not suitable for screening many compounds an alternate protocol 





Figure 78: The fluorescent dye N-phenylnaphthalen-1-amine (NPN) 
 
3.5.1 Resazurin Based Assay 
In order to test the new series of dipeptides which may differ in their mechanism of 
action compared to RWoct an alternate dye was sourced. 
Resazurin is a blue dye that is weakly fluorescent but can be reduced irreversibly to 
resorufin which is red and highly fluorescent.130 (Figure 79). Resazurin was first used 
to quantify bacterial content in milk by Pesch and Simmert in 1929.131 It is commonly 
used in cell viability assays as an indicator of oxidation/reduction.132,133 Resazurin is 
able to cross the cell membrane and there the irreversible reaction is proportional to 
aerobic respiration. Resazurin is the active ingredient in the cell viability reagent 
alamarBlue™. There are other reagents which can be used in a similar manner 
(MTT/XTT) but alamarBlue™ has a much lower toxicity and therefore can be used 
over longer periods of time.134  
 
 
Figure 79: A. The irreversible reduction of blue dye resazurin that takes place inside the cell, 




This dye can be used to analyse a number of cell assays but for the purpose of this 
project it will be used to determine whether the dipeptides are bacteriostatic or 
bactericidal. If bacteriostatic the growth of the bacteria will be slowed or completely 
halted but the cell will remain intact and will not necessarily die. If bactericidal the 
compounds will kill the bacteria, and this will likely be due to them acting as in a 
detergent like manner. Where the dye is added to cultures which have been treated 
with a bacteriostatic agent a colour change from blue to red will be seen and there will 
be a large increase in fluorescence. The colour change can be seen because respiration 
is still occurring and the dye is being reduced. Where the dye is added to a culture 
which has been treated with bactericidal agent the dye will remain blue as there is no 
respiration occurring. 
An assay protocol was developed and carried out. An overnight culture of LB was 
diluted 100 fold with MH2 media and then grown to exponential phase at 37 °C. It was 
then added to a 96-well plate with 90 µL per well. The antimicrobial compounds were 
added (10 µL per well giving a final concentration 250 μg/mL) and the plate was 
incubated at 37 °C for one hour. An hour was considered long enough for the 
compound to have an effect on the bacteria. The alamarBlue™ reagent was added (10 
µL per well) and incubated for a further 3 hours at 37 °C. The plate was then read on 
the Hidex microplate reader with an excitation of 540 nm and emission of 590 nm. 
A number of controls were used, and it is the comparison of the dipeptide readings to 
these controls which determine the results of this assay. 
In order to show that it was not the antimicrobial agents causing the reduction of the 
dye, media blanks with the antimicrobial agents were used. In these wells the dye 
remained blue, showing that the compounds do not reduce the dye. Further controls 
containing media only, boiled E.coli or bacterial culture with no inhibitor were also 
tested. These wells gave the minimum and maximum fluorescence readings.  
Ampicillin was used as a control to demonstrate the effects of a bacteriostatic agent. 
Ampicillin inhibits transpeptidases, preventing the third stage of bacterial cell wall 
synthesis.125 As cell wall synthesis cannot proceed the bacteria cannot multiply. In the 
wells treated with 250 μg/mL ampicillin the dye turned pink. 
The final control used was polymyxin B (Figure 80). This antimicrobial agent alters 
the membrane permeability by binding to the lipopolysaccharide layer via an 
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electrostatic interaction.53,135 The positively charged cyclic amino group of the 
polymyxin B interacts with the negatively charged lipopolysaccharide layer. The 
lipophilic tail of polymyxin B is then able to disrupt the cytoplasmic membrane. It is 
non-specific and disrupts all membranes making the drug highly toxic and a last resort 
in treatment of resistant bacteria. Despite this it is on the World Health Organization's 
List of Essential Medicines, which details the most effective and safest medicines 
needed in the healthcare system.136 In the wells treated with 250 μg/mL polymyxin the 
dye remained blue, showing no respiration was occurring, due to the polymyxin 
induced lysis of the cells. 
 
 
Figure 80: The structure of polymyxin B. The lipophilic portion is coloured in orange and the 





3.5.2 AlamarBlue™ Assay results 
The assay was carried out as described in the previous section with the dipeptides 
RWoct (6), KWoct (16), RW-Noct (22), KG-Noct (28) and KW-Noct (24). The results 
of this are presented in a bar chart in Figure 81. 
 
 
Figure 81: A graph to show the fluorescence readings from the AlamarBlue™ assay. [NB= no 
bacteria, NI= no inhibitor, Poly= polymyxin, Amp= ampicillin]. The pink box shows the 
fluorescence readings considered to be bacteriostatic agents and the blue box the bactericidal 
agents.  All compounds were tested at 250 μg/mL. 
 
The results from wells with no inhibitor and ampicillin were considered to be the 
maximum fluorescence that could be obtained from this assay and represent bacteria 
which were respiring. These wells were pink in colour showing that the conversion of 
resazurin to resorufin had occurred. The results from the wells with no bacteria and 
polymyxin were considered to be the lowest range of fluorescence. These wells were 
blue in colour indicating there had been no reduction of resazurin. The colours of the 
wells under all of the conditions described are shown in Table 15. These controls 
provided two ranges of fluorescence shown on Figure 81 by a pink and a blue box. 
The pink box represents the range in which the fluorescence reading of a sample 




Table 15: A table showing the colours of the alamarBlue™ dye after 2 hours in the different 
conditions used in the assay.  
 
3.5.3 Conclusion  
The dipeptides RWoct and KWoct were tested as the results from the protection assay 
suggested that there was a difference in mode of action. RWoct shown in Figure 81 
and Table 15 is clearly comparable to the resorufin controls and could be considered 
bacteriostatic and not creating pores in the membrane. KWoct on the other hand falls 
in the blue box and is comparable to polymyxin. This indicates that it acts differently 
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to RWoct and is bactericidal, likely because it exhibits detergent like properties leading 
to the formation of pores in the membrane. The amide containing dipeptides RWnoct 
and KWnoct were tested and showed similar effects to KWoct. This suggests that the 
incorporation of an amide linked octyl chain alters the mechanism of action.   
Finally KGnoct was tested as is does not have the aromatic group and so it is a cationic 
group and a lipophilic chain. The results from this peptide are inconclusive. The FU 
value falls between the two regions with the error bars extending into both the blue 
and pink region. The colour of this well was purple (as shown in Table 15) and this is 
consistent with the fluorescent results.   
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3.6 Conclusion  
The conclusions drawn from this chapter will influence functionality which will be 
installed onto the peptidomimetics in the next part of the project. 
As no inhibition was seen, in the fluorescence assay and the overexpression assay 
could not be carried out due to the toxicity of MraY. The radiochemical inhibition 
assay carried out also showed no evidence of MraY inhibition. The majority of the 
conclusions must be drawn from the antimicrobial testing. 
The antimicrobial testing results were discussed in section 3.1. Based on this the 
groups which were carried forward to the peptidomimetic design are the guandinium 
group, the indole group and an alkyl chain. Initially an octyl chain will be used which 
can later be optimised. The ester linkages will not be include due to the known break 
down of the bonds by esterase enzymes.105 
The results obtained from the resazurin based assay indicate that the dipeptides differ 
in mechanism of action. It is not however possible to determine what these mechanism 
might be. The most promising peptide based on this assay is RWoct. It may be that the 
octyl chain is being removed by esterases to give NH2-RW-OH. 
As no inhibition of MraY was seen development of the peptidomimetics will focus 




CHAPTER 4: Peptidomimetics based on α-helical mimetics 
– design, synthesis and testing 
The use of peptides as therapeutic agents is limited by poor membrane permeability, 
rapid excretion and bad stability.137 To overcome the downfalls which peptides as drug 
molecules have, peptidomimetics can be designed and synthesised to produce 
molecules which mimic the parent peptide but are more “drug-like”. This often 
involves altering the peptide backbone structure to make the compound less 





4.1 Dipeptide Peptidomimetic Design 
The series of dipeptides are proposed to interact at a PPI site rather than at the active 
site of MraY. The interaction site of E and MraY is shown in Figure 82. (section 1.3.2). 
 
 
Figure 82: A. The crystal structure of the MraY monomer with the proposed E protein-MraY 
protein-protein interaction site shown in orange. The orange residues are E287 and F288. B. 
shows the surface representation and the channels (yellow arrows) lead to the interaction site. 
(PDB: 4J72) 
 
PPI sites are large, solvent exposed and do not have contiguous binding sites, and this 
complicates the design process.138 For this reason small-molecules drugs which 
directly disrupt PPIs are relatively rare, with many sites unable to support binding 
interactions with such molecules and are considered “undruggable” targets.139 Recent 
developments in the area have seen some success disrupting interactions between 
globular proteins and single chain peptides, particularly where there are binding 
pockets on the surface of the globular proteins. A recent review by Scott et al. (2016) 
lists examples of drugs which are currently in clinical trials which target PPI sites.139  
The design of PPI disrupters is usually aided by X-ray crystallography and protein 
based NMR spectroscopy. Crystal structures with inhibitors bound at the active site 
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are available, but none exist for the site which we are trying to target. MraY is a 
membrane protein and obtaining this sort of structural data is difficult.  
It is important to consider the secondary structures involved in the interaction, such as 
α-helices and β-sheets. The E protein is α-helical but our dipeptides contain too few 
residues to adopt this structure, and this could have caused the side chain groups to be 
orientated incorrectly, and is therefore the reason no inhibition of MraY was seen. 
Each turn of an α-helix is 3.6 residues with 2-3 turns (minimum) needed to actually 
maintain the structure through hydrogen bonding.140 It is also important to consider 
the flexibility of the dipeptides. The peptide backbones are not constrained structures 
and the arginine side chain and the alkyl chain are both very flexible. 
 
 
Figure 83: A. Examples showing the 3.5 residues in one turn of a section of α-helix (TM10 of 
MraY. The side chain groups are presented outwards. B. The corresponding wheel diagram 
showing a representation of the α-helix from above. 
 
In order to synthesise peptidomimetics which would inhibit MraY, two α-helical 
backbone structures were chosen to install an arginine or a lysine residue, an indole 
ring and an octyl chain. The side chain groups would now more closely mimic the 
orientation and spatial arraignment which is seen in the RWxxW motif. Onto these 
backbones it would also be possible to install a second indole group and so completing 




    
   
Figure 84: Proposed structures of the peptidomimetics designed based on the antibacterial data 
obtained for the series of dipeptides (PM 2 is based on a Hamilton model.140 PM 1 is based on a 
Boger model.83)  
 
Peptidomimetic 1 and 2 are based on α-helical backbone mimetic models designed by 




4.2 Dipeptide peptidomimetic: Peptidomimetic 1  




Figure 85: The synthetic route proposed for the synthesis of peptidomimetic 1. [PG= protecting 
group] 
 
The first step of the synthesis is the alkylation of the hydroxyl group of 3-hydroxy-4-
nitrobenzoic acid to give the benzoic acid alkyl ether. Hydroxyl groups can be reacted 
with organohalides under basic conditions, by a Williamson reaction to form ethers.141 
The alkoxide ion which forms, reacts with a primary halide via an SN2 reaction. To 
attach an indole by the ether linker the primary halide, 3-(2-Bromoethyl)indole, was 
used.  
The success of this synthesis required the chemoselective alkylation of the hydroxyl 
group over the carboxylic acid. The difference in pKa of the hydroxyl group should 
allow this to be achieved. Tetrabutylammonium bromide (TBAB) can be used as a 
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phase transfer catalyst and enhances nucleophilicity.142 Pandey et al. showed that the 
use of (tetrabutylammonium hydroxide) TBAH instead of TBAB lead to the alkylation 
of a benzoic acid group as well as a hydroxyl group during a similar syntheis.143 
However the alkylation did not proceed when the benzoic acid was not protected. The 
carboxylic acid group of 3-hydroxy-4-nitrobenzoic acid was protected using thionyl 
chloride and methanol to form the methyl ester 29. Initally H2SO4 was used, this gave 
a yield of 49% compared to a 78% yield using thionyl chloride. After the installation 
of the methyl ester the alkylation was successful to give 30 (Scheme 9). 
 
 
Scheme 9: Protection of the carboxylic acid using thionyl chloride and MeOH to give a methyl 
ester followed by alkylating the hydroxyl group using K2CO3 and TBAB. The nitro group is 
then reduced in the presence of Pd/C under H2(g). 
 
Following the alkylation, the nitro group was reduced by hydrogenation using Pd/C 
under hydrogen to give aniline 31. Some literature states that indoles can be reduced 
under these conditions96. There was no evidence of this occurring based on the HRMS 
and NMR data obtained for 31. 
Anilines (pKa≈ 4.6) are less basic than amines which are bonded to an aliphatic group 
(i.e amino acids, pKa≈ 9.5). The weak basicity is attributed to a resonance effect and 
the inductive effect of the neighbouring more electronegative sp2 carbon. The weak 
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bascicity of the aniline made coupling the arginine residue more difficult as the 
nitrogen lone pair in its sp2 orbital is delocalised into the π system of the ring.  
 
Figure 86 shows the reagents used initially to couple the arginine residue to the aniline.  
Both uronium based and carbodiimide activating agents were used with the appropriate 
organic bases and solvent. None of these conditions gave the desired product by LRMS 




Figure 86: The conditions tested to couple an arginine residue to an aniline 31.  
 
N-hydroxysuccinimide was coupled to Fmoc-Arg-OH to form the active ester and then 
was added to the aniline again using the conditions described in Error! Reference 
source not found..144 This coupling was also unsuccessful, despite the formation of 
the succinimide active ester, which was identified by LRMS. 
Coupled with the lack of reactivity from the aniline it is possible that the arginine 
residue was undergoing δ-lactam ring formation once activated with the coupling agent 
(see Figure 87).145 This was not a side reaction which had been identified when 
synthesising the dipeptides.  
 




Protecting the side chain of arginine can prevent the δ-lactam ring formation (as well 
as the loss of the guanidine side chain).145 Traditionally Pmc and Pbf groups are used 
to protect the arginine side chain, however earlier in the project, during the dipeptide 
synthesis problems were encountered removing these groups in chapter 2. An alternate 
protecting strategy is to use ω-nitro group to protect the side chain. Boc-Arg(NO2)-
OH was used instead of Fmoc-Arg-OH. This meant that δ-lactam ring formation was 
prevented, however the coupling was still unsuccessful. Tests to remove the NO2 
protecting group using hydrogenation were also unsuccessful after 24 hours, and with 
the only other deprotection method for this group being HF, the use of ω-nitro group 
arginine was discontinued.96 
We hypothesised that a more reactive activated carboxylic acid derivative was needed 
to successfully couple an arginine residue to the aniline, and so thionyl chloride was 
used (Scheme 10) to generate the acid chloride of Fmoc-Arg-OH, and then added to 
the aniline with DIPEA. This coupling was successful, and 32 was identified using 
HR-MS. 32 was isolated using RP-HPLC (Synergi™ 4 µm Polar-RP 80 Å). The use 
of thionyl chloride was a concern because of epimerisation, however Carpino et al. 
showed that amino acids protected with Fmoc did not undergo epimerisation due to 
the neighbouring atoms of the Fmoc group.146 The reactivity of the acid chloride 
caused the formation of many side reactions, and this lead to a difficult purification by 
RP-HPLC and a low yield (<2%). 
 
 
Scheme 10: The synthesis of arginine acid chloride using thionyl chloride following by the 
coupling to 31 in basic conditions. 
 
It was found that the removal of the methyl ester could not be carried out without 
removing the Fmoc group. Without the α-amino group protected the synthesis could 
125 
 
not be continued. Non-basic conditions were used in a further attempt remove the 
methyl group (NaI and SiCl4), however this was unsuccessful.
147  
Protecting the arginine with a Boc group would not be suitable due to the strongly 
acidic coupling conditions. 
Ghosez’s reagent is used to form acid chlorides in neutral conditions (Figure 88).148 
This would allow the use of acid labile protecting groups. Boc-Arg-OH was treated 
with Ghosez’s reagent. NMR was used to assess whether the acid chloride had formed, 
however after 7 hours it had not. The intermediates and by product also could not be 
seen, indicating that Ghosez’s reagent was not sufficiently reactive or compatible to 
form an acid chloride of Boc-Arg-OH. 
 
 
Figure 88: Reaction of Ghosez’s reagent with carboxylic acids.148 
 
As both Fmoc and Boc amine protection were unsuitable, the next option was to try 
Cbz protection. When reacted with thionyl chloride, Cbz-Arg-OH formed a tar-like 
residue which would not dissolve in DMF, and therefore was not suitable for the 
coupling reaction with the aniline. 
It is possible that the arginine side chain was affecting the coupling. Once coupled it 
made the purification of the compound more difficult (using RP-HPLC) and during 
this purification, yield was lost. In order to get around this, if a protected ornithine 
derivative could be coupled to the aniline, then the guanidinium group could be added 
as the final step. This would allow silica column chromatography to be used for the 
purification prior to the installation of the guanidinium group. A possible method of 
installing the guanidinium group is shown in Figure 89, using o-isomethylurea at 
pH10.149 It is possible to carry out this reaction using S-methylisothiourea, but this 





Figure 89: Guanidination of ornithine using o-isomethylurea at pH 10.149 
 
In order to carry out this reaction, L-ornithine must be suitably protected (Scheme 11) 
using a method described by Rzeszotarskat et al.151 The side chain was protected with 
Boc and the amine was protected with Cbz. In order to selectively protect the ornithine 
side chain with a Boc group, L-ornithine was chelated to copper, combining with 
Cu(OAc)2, which left the side chain free. This was followed by the addition of Boc2O 
to install the Boc group on the side chain. To remove the copper from the ornithine, 
the chelating agent, 8-quinolinol was used. The α-amine was now free to react with 
benzyl chloroformate to give Cbz-Orn(Boc)-OH. 
The presence of an acid labile Boc group meant that the thionyl chloride coupling 
method would not be suitable since it generates SO2 and HCl. The coupling reagent 
HATU was used again, but was unsuccessful. 
 
 
Scheme 11: Synthesis of Cbz-Orn(Boc)-OH from L-ornithine using copper acetate and Boc2O 
following be Cbz-Cl.151  
 
Having exhausted the possible protecting and deprotecting strategies available, 
including a variety of conditions to remove the methyl ester (Na2CO3, LiOH and 
NaOH) this synthesis route was discontinued. 
In order to synthesise peptidomimetic 1 a new route was designed. As the coupling 
step would likely be the lowest yielding it was decided to make this the last step. The 
first step could be changed to the coupling of the octyl chain. This would remove the 
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need to deprotect the acid later in the synthesis, and so the overall number of steps in 
the synthesis was decreased. The new synthesis route is shown in Scheme 12. 
 
 
Scheme 12: The revised synthetic route for peptidomimetic peptidomimetic 1. Yields are not 
given for the last two steps as the first was carried out in situ and only some of the second was 
purified. 
 
To install the octyl chain, the benzoic acid was activated with DCC in the presence of 
DMAP and then 1-octylamine was added to afford 34. This step was followed by the 
alkylation of the 3’hydroxyl group (35) and reduction of the nitro group (36), as 
previously carried out. Fmoc-Arg-OH was coupled to the aniline using thionyl 
chloride, and then deprotected using 20% piperidine in DCM. RP-HPLC (Synergi™ 4 





4.3 Dipeptide peptidomimetic: Peptidomimetic 2  
Scheme 13shows the initial synthetic route that was proposed for the synthesis of 
peptidomimetic 2. 
 
Scheme 13: The synthetic route proposed for the synthesis of peptidomimetic 2 
 
The starting compound, 2-hydroxy-4-nitrobenzoic acid, was protected as its methyl ester 
38, before the alkylation (39) and reduction of the nitro group (40) were carried out as 
described in section 4.2. To incorporate the octyl chain onto the aniline nitrogen 
NaCNBH3 and 1-octanal were initially used with acetic acid at pH 4 to give 41. The 
yield of this reaction was low (<20%), and was not sufficient to carry out the following 
steps. Optimisation of the reductive amination was attempted. Using the same 
reactants as before, the amine and the aldehyde were refluxed (to form the imine) prior 
to the addition of NaCNBH4.
152 The only product which now formed had two octyl 
chains attached to the aniline. Acidic and basic conditions were used to try and form 
and then isolate the imine, but this was not successful. Next, NaBH4 was used, also 
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yielding mainly the doubly alkylated product.153 An alkylation using 1-bromooctane 
and K2CO3 was carried out as previously described, but again the doubly alkylated 
product was formed (summarised in Scheme 14). The initial reaction conditions were 
therefore used, and the synthesis continued. 
 
 
Scheme 14: The reaction conditions used to optimise the reductive amination step and the 
incorrect double octyl chain product formed. 
 
As with the synthesis of peptidomimetic 1, the methyl ester was difficult to remove 
under basic conditions, and at higher pH some degradation of the compound was seen. 
After purification of 42, the yield was 36%, giving little material for the next reaction. 
In order to couple L-arginine to the benzoic acid, the carboxylic acid of the L-arginine 
must be protected. The initial strategy for this was to couple Fmoc-Arg-OH to MBHA 
rink amide resin, and then remove the Fmoc group using piperidine. Coupling to this 
resin would leave the product amidated at the C terminus, which is preferable to a free 
acid. This is because the product will be cationic rather than zwitterionic, like the 
parent peptides. The benzoic acid 42 was then coupled to the resin bound arginine 
using HBTU (Scheme 15). TFA was used to cleave the product from the resin and 
HRMS and LC-MS were used to confirm presence of the desired product. In order to 
purify the product RP-HPLC was used, however the coupling was low yielding, and 
the product could not be isolated. It is possible that the coupling conditions could be 
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Scheme 15: The coupling of Fmoc-Arg-OH to MBHA rink amide resin followed by the 
deprotection of the Fmoc group and coupling of using HBTU. 
 
The low yield of several steps in this synthetic route meant obtaining enough of the 
final compound to allow complete analysis and the subsequent biological testing was 





4.4 Dipeptide peptidomimetic: Peptidomimetic 3 
At this point, we decided to change the final compound (Figure 90). Since alkylating 
the aniline nitrogen had been surprisingly difficult, we decided to attach the octyl chain 
through a carbon-carbon bond instead of a carbon-nitrogen bond as before, using a 
palladium-catalysed coupling to form the C-C bond. 
 
Figure 90: New design, peptidomimetic 3 
 
The starting material used was 4-bromo-2-hydroxybenzoic acid, to which a methyl 
ester was introduced by the same method as before to give 43. A Sonogashira cross 





Scheme 16: The esterification of the benzoic acid of 4-bromo-2-hydroxybenzoic acid followed by 
the Songashira coupling at the aryl bromide. 
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This method introduces a carbon-carbon bond which is catalysed by palladium and co-
catalysed by copper. The new bond is formed between a terminal alkyne and an aryl 
(or vinyl) halide.154 The catalytic cycle of this reaction is shown in  Figure 91.  
 
 
Figure 91: Sonogashira catalytic cycle. 
 
Tetrakis(triphenylphosphine)palladium(0) was the catalyst used in this instance. The 
reaction proceeded with a high yield (89%).  
Following this, the alkylation to incorporate the indole group was attempted as 
previously described, but was unsuccessful. However, carrying out the alkylation 
reaction in anhydrous acetone gave the desired product, 45, in 52% yield. This is a less 
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Scheme 17: Alkylation between the hydroxyl group of 44 and 3-(2-bromoethyl)indole, using 
K2CO3 and acetone. 
 
The methyl ester could now be removed in base to give 46 with a yield of 98%, which 
was an improvement on the previous deprotection of this kind (section 4.3).  
An alternative method to couple the arginine residue to the benzoic acid was also 
carried out to improve the yield seen when using the MBHA resin. An arginine residue 
which was acid protected (Arg-OtBu) was purchased, and coupled using HATU to 46. 
Then the t-butyl ester was removed with HCl in dioxane, before being purified by RP-
HPLC to give 47. (Scheme 18). The alkyne was reduced with hydrogen and Pd/C. The 






Scheme 18: This scheme shows the coupling of NH2-Arg-O
tBu to 46 followed by the deprotection 
of the arginine acid using HCl. Finally the reduction of the alkyne using Pd/C. No yields are 
given as no purification was carried out between each of thesis steps. The final HPLC 





4.5 Biological testing of set one peptidomimetics 
Following purification the two peptidomimetics were tested using the same methods 
as the series of dipeptides.   
 
4.5.1 Microtitre broth dilution antimicrobial testing 
The antimicrobial testing was carried out using a microtitre broth dilution technique 
described in section 3.1. The results are shown in Table 16. 
 
 





4.6 Tripeptide peptidomimetic: Peptidomimetic 4 
The dipeptides synthesised in chapter 2 showed no inhibition of MraY, but they only 
contain the first two residues of the RWxxW motif. Rodolis synthesised a series of 
pentapeptides containing the entire motif and saw inhibition of MraY.48 It is possible 
that that entire motif is necessary for a compound to successfully inhibit MraY. A 
second aromatic residue could be incorporated into one of the peptidomimetics in order 
to try to mimic the full motif. 
The most obvious way to introduce the remainder of the RWxxW motif is to install 
and aromatic group at the top of the octyl amide of peptidomimetic 1 (37) (Figure 92). 
 
 
Figure 92: The proposed site for installing a second aromatic group (here shown as “R” in blue) 
to peptidomimetic 4 
 





Scheme 19: The proposed synthetic route for the tripeptide peptidomimetic 4  
  
Octylamine was coupled to the 3-hydroxy-4-nitrobenzoic acid, using DCC and DMAP, 
to form an octyl amide 34. The bromo-indole was protected with a Boc group using 
Boc anhydride to give 49 (88% yeild). The Boc protected indole was alkylated to the 
hydroxyl group as previously described to give 50. Benzyl bromide was alkylated onto 
the octyl amide nitrogen using sodium hydride giving 51 in 52% yield. The next step, 
reducing the nitro group, had previously been carried out using a hydrogenation 
reaction. These conditions could not be used with this compound as it led to the 
removal of the benzyl group. Iron (with NH4Cl) was successful at reducing the nitro 
group, to give 52 with a yield of 95%. As with the previous synthesis, the L-arginine 
needed to be coupled to the aniline. This had previously been very challenging. The 
coupling was carried out using SOCl2 and DIPEA as before, but the desired product 
was not seen by LRMS. RP-HPLC was carried out on the crude material and the peaks 
collected separately and MS repeated, but still no product was observed.  
At this point it was decided that the synthesis of this compound would be discontinued. 






4.7 Optimisation of the benzamide backbone and synthetic route 
In order to be able to synthesise a library of peptidomimetics it was necessary to 
develop a new route which allowed the easy installation of different functional groups 
on a benzamide backbone. Three changes were introduced: 
1. Changing arginine to lysine. Throughout the project the arginine residues and 
its associated protecting groups have posed problems with couplings, 
purification, protection and deprotection reactions. This in many cases led to 
insufficient yields or unsuccessful reactions. Lysine-containing dipeptides 
were shown to have antimicrobial activity, and the introduction of L-Lys-
OMe in the synthetic route seemed more straightforward in terms of 
protection and purification.  
2. Acylation of the aniline nitrogen. Since the reductive amination of the aniline 
nitrogen had been very problematic, we decided to acylate the nitrogen 
instead. 
3. Replacement of the indole group by a phenyl group. This change was made 
as it would limit the number of possible side reactions. This would allow the 
optimisation of the full route before the indole group could be reintroduced. 





Scheme 20: The synthetic route proposed to achieve peptidomimetics 5 and 7 
 
Scheme 20 shows routes to a di- and tri- peptidomimetic which both contain a lysine 
residue and benzyl groups. The initial synthesis was carried out with benzyl groups 
instead of indole groups so that the reactions could initially be tested without hindrance 
from the indole nitrogen. Once a successful route had been established, the indole 
groups could be installed. 
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The initial steps are similar to those of the previous dipeptides (Scheme 21). 
 
 
Scheme 21: The synthesis of the methyl ester 38. Alkylation of 38 with benzyl bromide was 
followed by the reduction of the nitro group with Fe to give 54. 
 
Heptanoyl chloride was added to the aniline and TEA in DCM dropwise at 0 °C, 
forming the amide 55 in 60 % yield. In the case of the tripeptide a further alkylation 
of this amide was carried out, using benzyl bromide and sodium hydride in THF, to 
give 56 in 97% yield. (Scheme 22). 
 
 
Scheme 22: Acylation and subsequent alkylation of the aniline 54 
 
The methyl ester was deprotected using NaOH and THF/water to give 57, and the 
Lys(Boc)-OMe was successfully coupled to the benzoic acid using EDC to give 58. 
(Scheme 23). The Boc side chain was then deprotected using HCl (98% yield) which 
gave the final peptidomimetic 7 (59). This was repeated on 55 to give peptidomimetic 
5 (62). 
The carboxylic acid of the lysine residue was protected as a methyl ester and this was 
not removed. Previously when an amino acid residue was coupled to the benzoic acid 
(peptidomimetic 3), its acid protecting group (tBu) was removed giving a zwitterionic 
final compound. The aim was to mimic the cationic antimicrobial peptides, and so 
zwitterionic character is probably not desirable. It is possible that this characteristic 
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caused a reduction in antimicrobial activity, so in this case the methyl ester was left, 
so that the final compound was cationic, at pH 7. 
 
 
Scheme 23: The final steps of the di and tri peptidomimetic syntheses. 
 
All of the steps were successful, with yields of >60% and the synthetic intermediates 
could easily be purified using silica column chromatography and did not require HPLC 
purification at any stage. The success of this route meant that different functionality 
could be introduced onto this backbone. 
The next step was replacing the benzyl groups with indole groups to give a compound 
that contained the RWxxW motif. The di- peptidomimetic was synthesised by the same 
route as shown in Scheme 20 but using 3-(2-bromoethyl)indole compound instead of 
benzyl bromide to give peptidomimetic 6 (66) shown in Scheme 24. 
The tripeptidomimetic required extra synthetic steps. To prevent possible side 
reactions the bromoindole was protected with a Boc group. Alkyation using NaH was 
unsuccessful. The amide starting material was broken down when treated with sodium 
hydride (shown by TLC and MS). It was unclear why this happened. The base was 
changed to potassium tert-butoxide, which is weaker than sodium hydride, but still 
strong enough to deprotonate the amide. The reaction was tested first using benzyl 
bromide to give 70. This was successful with a yield of 90%. The remaining steps of 
the synthesis were carried out on this compound to give peptidomimetic 8 (73) shown 
in Scheme 24. The alkylation using potassium t-butoxide was repeated with the bromo-
indole but only gave 74 with a yield of 5%. The reaction was repeated this time 
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refluxing for 4 hours which increased the yield to 12%. The reaction was run on a large 
enough scale so that the remaining steps of the synthesis could be carried out to give 









From the new synthetic route, 5 peptidomimetics were successfully synthesised, and 
are shown in Figure 93. These compounds will be tested using the assays described. It 
is hoped that the compounds which contain the full RWxxW motif will inhibit MraY. 
 
 
Figure 93: The five peptidomimetics synthesised using the optimised route. 
 
The optimised route was a successful method to introduce the desired functionality 
onto the benzamide backbone. Whilst L-lysine was used in this instance, an L-arginine 
residue could be introduced, but would require the final purification to be carried out 
using RP-HPLC. It is also possible that L-ornithine could be used and then the 
guanidinium sidechain of L-arginine introduced as the last step. (The method for this 





4.8 Biological testing of set two peptidomimetics 
4.8.1 Microtitre broth dilution antimicrobial testing 
The antimicrobial testing of these compounds was carried out as previously described. 
The results of which are shown in Table 17.  
 
 
Table 17: The antimicrobial results for peptidomimetics 5-9 
 
The results show that there is a notable improvement in the antimicrobial activity of 
these peptidomimetics against E. coli when compared to set one (section 4.5), and 
some activity against P. fluorescens was observed. Peptidomimetic 7 (59) has the best 
activity across the three species tested. Peptidomimetic 8 (73) and 9 (77) had the best 
activity against E. coli. 
The MIC50 values are not representative of the effect on the bacteria that was caused 
by the peptidomimetics. Figure 94 shows the raw data obtained from the antimicrobial 
testing of peptidomimetic 8 (73). When the concentration of peptidomimetic 8 (73) 
increases to ≈ 63 μg/mL The OD595 of the bacterial cultures begin to increase. This is 
seen across all three species that were tested and for all of the peptidomimetics 
(peptidomimetic 5-9). This is an effect which was not seen when testing the previous 
peptidomimetics or the dipeptides. One possible explanation for the cause of this is 
that when the compounds reach a certain concentration the bacteria are able to break 
down the compound, and utilise the components for growth. At higher concentrations 
hydrolysis of the ester may occur and this could lead to a reduction in activity. It is 
also possible that the compounds form micelles at higher concentrations, leading to 




Figure 94: The graph showing the results of the antimicrobial testing of peptidomimetic 8 against 
B.subtilis (BS), E.coli (EC) and P. fluorescens 
 
4.8.2 MIC and MBC testing against ESKAPE pathogens  
Peptidomimetic 5-9 were submitted to the Warwick university antimicrobial screening 
facility and the MIC and MBC values against the ESKAPE pathogens were determined 
by John Moat and Julie Todd. This data is shown in Table 18. 
 
 





These peptidomimetics did not show an improvement in activity across the ESKAPE 
pathogens when compared with the data obtained for the dipeptides in section 3.1.4. 
The peptidomimetics only showed activity against S. aureus and E. faecium, with the 
MIC and MBC implying bactericidal charateristics. 
 
4.8.3 Fluorescence inhibition assay 
The fluorescence inhibition assay was carried out as described in section 3.2 on 
peptidomimetic 9 (77). No inhibition of MraY was seen when tested at 100 μg/mL. 
Peptidomimetic 9 is the compound which is the most similar in structure to the 
RWxxW motif but still no inhibition of MraY is observed. Shown in Figure 95.  
 
 
Figure 95: The continuous fluorescence assay run on Peptidomimetic 9 at 100 μg/mL. 





4.8.4 Radiochemical inhibition assay results  
The 5 benzamide peptidomimetics were tested using the radiochemical inhibition 




Figure 96: A bar chart showing the % activity of MraY with no inhibitors and when treated with 
200 μM peptidomimetic 5 (62), peptidomimetic 6 (66), peptidomimetic 7 (59), peptidomimetic 8 
(73) and peptidomimetic 9 (77) with the controls which use no inhibitor (100% activity) and 
tunicamycin (100 μg/mL) 
 
The cause of the large error bar on the tunicamycin data point is discussed in section 
3.3. 
As with the tested dipeptides MraY showed >100% activity when treated with some 
of the peptidomimetics. Based on this data there is no apparent inhibition of MraY by 
these compounds. Further assays need to be carried out as discussed in section 3.3. 
 
4.8.5 AlamarBlue ™ Assay 
The AlamarBlue ™ Assay was carried out on peptidomimetics 5-9 using the same 






Figure 97: The fluorescence results of the alamarBlue™ assay carried out on peptidomimetics 5-
9. The pink box shows the fluorescence readings which fall in a similar area to bacteriostatic 
agents and the blue box shows the regions which bactericidal compounds are expected to fall in. 
[NB= no bacteria, NI= no inhibitor, Amp= amipicillin, Poly= Polymyxin B]. All compounds were 





Table 19: A table showing the colours of the alamarBlue™ dye after 2 hours in the different 
conditions used in the assay.  
 
With the exception of peptidomimetic 9, all of the peptidomimetics fell within the 
bactericidal range which was determined based on the results of the controls run in this 
assay. It is possible that this is due to the peptidomimetics making pores in the 
membrane. These results are not comparable to RWoct, and therefore it is unlikely that 





The second set of peptidomimetics had more promising antimicrobial activity against 
all three strains tested against, with peptidomimetic 7 having the best activity of this 
set. The increase of OD595 at higher concentrations of compounds is not a favourable 
property for drug molecules. 
The inhibition fluorescence assay was run with peptidomimetic 9 (77) which was most 
closely related to the RWxxW motif. No inhibition was seen. No inhibition of MraY 
was seen by the 5 benzamide peptidomimetics when tested using the radiochemical 
inhibition assay. 
The resazurin dye assay indicated that the peptidomimetics may be toxic. The potential 
adverse effects exhibited on the membrane by these compounds may affect any results 
seen in assays containing membranes and therefore the results would not be reliable. 
It is not possible to have control samples which would allow the determination 
between membrane disruption and MraY inhibition. 
Further alterations to the structures could be made. Swapping the lysine residue for an 
arginine may help the peptidomimetics interact similarly to RWoct (6). RWoct (6) had 
shown the most favourable antimicrobial activity overall (section 3.1). This would 
require more time and a more difficult purification which would extend beyond the 
timeframe of this project. RW-Noct (22) which contained the amide linker did not 
show as favourable results in section 3.1 as RWoct (6). This is due to the amide bond 
which replaced the ester linker. The benzamide backbone uses amide linkers, which 
could potentially be changed to ester linkers, however ester linkers are not favourable 
in the design of drug molecules. Alterations to the chain length may also lead to an 
improvement of activity, but it is likely that this would only enhance the surfactant 




CHAPTER 5: Additional Arg-Trp peptidomimetics and 
molecular modelling 
Additional peptidomimetic structures on which Arg and Trp sidechains could be 
positioned were also explored. This chapter focuses on a cyclic structure which will 
replace the peptide backbone with the aim of maintaining or improving the MIC50 of 




5.1 cyclic backbone designs  
Two cyclic structures which have been designed based on the results obtained from 
the dipeptide series and the peptidomimetics synthesised in the previous chapter are 




Figure 98: The structures of two peptidomimetics which incorporate a cyclic backbone 
replacement 
 
Peptidomimetic 13 is based on a Houghten model and peptidomimetic 14 is based on 
a triazinedione model proposed by Congiu.86,155 
The triazinedione structure had previously been used by Ralbovsky et al. (2009) and 
Congiu et al. (2014) in the design and synthesis of prokineticin receptor 
antagonists.155,156 Congiu refined the synthetic route which Ralbovsky had previously 
proposed. Whilst the prokineticin interaction was not of interest for the design of 
antimicrobial peptidomimetics, the triazinedione backbone provided a structure onto 
which functionality could be installed. The central ring is more constrained than the 
parent peptide backbone reducing the overall flexibility of the molecule. By testing 
peptidomimetics with more constrained backbones a better picture of the interaction 
can be built up. 
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The Houghten model is one of a series of backbones designed by the group for the 
conversion of dipeptides into peptidomimetics.86 This series of peptidomimetic 





5.2 Design and synthesis of triazinedione peptidomimetic backbone- 
Peptidomimetic 11 
Using the general synthetic route described by Congiu different reagents could be 
employed to allow the installation of an octyl chain, an aromatic group and cationic 
lysine and/or arginine mimic onto the triazinedione backbone.155 The route is shown 
in Scheme 25. 
 
 
Scheme 25: The synthetic route to PM 10, 11 and 12. The final compounds are shown in blue. 
 
Three peptidomimetics could be synthesised using the same route. Peptidomimetic 10 
has a free amine which is linked to the ring by two carbons whereas peptidomimetic 
12 has a three carbon linker (more closely mimicking lysine). This will aid the 
determination of how flexible the cationic moiety needs to be. Peptidomimetic 11 
contains a guanidinium group to mimic the arginine moiety.  
The first step involves the formation of octyl urea 78 from 1-octylamine and potassium 
cyanate under acidic conditions (80% yield). 78 is precipitated from the solution and 
was isolated using suction filtration. Octyl urea was then coupled with ethyl 
isothiocyante to give the N-ethoxycarbonylthiourea 79 which was precipitated from 
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diethyl ether (66% yield). The thiourea was cyclised and alkylated in situ using MeI 
to give 80 (38% yield).The resulting intermediate was purified using silica gel 
chromatography. A second alkylation was then carried out using benzyl bromide in 
the presence of NaH to give 81 (33% yield). Ethylenediamine was then used to 
displace the thiomethyl group to give peptidomimetic 10 (82) (87% yield). The 
solvents from this reaction were removed in vacuo in a fumehood due to the liberation 
of methanethiol. 
To give the peptidomimetic 12 (84), N-Boc-1,3-propanediamine was used in place of 
ethylenediamine. The Boc protection was necessary as 1,3-diaminopropane is very 
toxic. The Boc group was removed in the 100 °C reaction conditions used, so no 
deprotection step was necessary. Both peptidomimetic 10 (82) and peptidomimetic 12 
(84) were purified using silica gel chromatography, where the silica had been 
deactivated using TEA. 
Peptidomimetic 11 (83) was formed when 82 was reacted with 1H-Pyrazole-1-
carboxamidine hydrochloride in the presence of DIPEA. The desired product 






5.3 Biological testing of triazinedione peptidomimetics 
 
5.3.1 Microtitre broth dilution antimicrobial testing 
The antimicrobial testing of these compounds was carried out as previously described. 
The results of which are shown in Table 20.  
 
 
Table 20: The results of the antimicrobial testing carried out on the series of dipeptides. The three 
organisms tested against were E. coli, B. subtilis and P. fluorescens.  
 
All three compounds showed promising antimicrobial activity but, PM 11 (83) shows 
the best activity across the three bacteria, which might be attributed to the guanidinium 
group.  
  
5.3.2 MIC and MBC testing against ESKAPE pathogens  
PM10-PM12 were submitted to the Warwick university antimicrobial screening 
facility and the MIC and MBC values against the ESKAPE pathogens were determined 





Table 21: The MIC and MBC values in μg/mL of PM10-PM12 against the ESKAPE pathogens 
 
Of all the groups of compounds synthesised in this project PM10-PM12 have the best 
overall data when tested against the ESKAPE pathogens with MIC values of less than 
64 μg/mL against all of the pathogens. There are no clear trends with the differing 
cationic functionality. As with the other groups of compounds, these peptidomimetics 
appear to also be bactericidal. 
 
5.3.3 Radiochemical inhibition assay results peptidomimetics 2 
The 3 heterocyclic peptidomimetics were tested using the radiochemical inhibition 






Figure 99: A bar chart showing the % activity of MraY with no inhibitors and when treated with 
200 μM PM10 (62), PM11 (83), and PM 12 (84) with the controls which use no inhibitor (100% 
activity) and tunicamycin (100 μg/mL) 
 
The cause of the large error bar on the tunicamycin data point is discussed in section 
3.3. 
Based on this data there is no apparent inhibition of MraY by these compounds. 





5.3.4 AlamarBlue ™ Assay 
The alamarBlue ™ Assay was carried out on peptidomimetics 10-12 using the same 




Figure 100: A graph to show the fluorescence readings from the AlamarBlue™ assay. [NB= no 
bacteria, NI= no inhibitor, Poly= polymyxin, Amp= ampicillin]. The pink box shows the 
fluorescence readings considered to be bacteriostatic agents and the blue box the bactericidal 




Table 22: A table showing the colours of the alamarBlue™ dye after 2 hours in the different 
conditions used in the assay. All compounds were tested at 250 μg/mL. 
 
Both peptidomimetics with the free amine (10 and 12) show results which are more 
similar to polymyxin. Peptidomimetic 11 which had the best antimicrobial activity 
appears to be bacteriostatic in the alamarBlue assay. From the biological assay results 





5.5 Peptidomimetic 13 
The synthesis route design had a number of steps which would need a lot of 
optimisation to allow the full route to be carried out. For these reasons the synthesis of 






From the molecular modelling peptidomimetic 11 was chosen to be synthesised and 
tested. The simple synthesis route designed by Congiu et al. was easily executed and 
three new peptidomimetics were synthesised.155 
The antimicrobial testing showed that the guanidinium had the best activity and this 
compound also gave the most favourable results based on the alamarblue assay. 
Based on this data and the data gained in the previous chapters the guanidinium group 
is preferable over the free amine of lysine (or lysine mimics). This is most apparent in 
this chapter and that could be due to the simplified and constrained nature of the new 
peptidomimetics.  
It would be interesting to introduce an indole in place of the benzyl group. This would 
allow further determination of the important functionality. 
The MraY inhibition of the heterocyclic peptidomimetics was tested using this 




CHAPTER 6: CONCLUSIONS AND FUTURE WORK 
The synthesis route for the Arg-Trp dipeptide series was optimised during this project 
along with the purification methods. The series of dipeptides was tested using several 
biological tests to determine the antimicrobial activity and the inhibition of MraY. 
From the MIC50 calculations there was only one clear trend which showed that 
increasing the alkyl chain length improved the activity. Both the arginine and lysine 
residues showed promising activity when coupled with tryptophan and so these were 
the residues that would be carried forward to the peptidomimetic design. The dipeptide 
series were also tested in a continuous fluorescence assay to determine if the 
compounds were able to inhibit MraY. None of the peptides showed inhibition of 
MraY in this assay. Both RWoct (6) and KWoct (16) were tested using the 
radiochemical inhibition assay also. This confirmed the results of the fluorescence 
based assay. Previous work proclaimed that when MraY was overexpressed the MIC50 
for RWoct (6) increased, implying that MraY was infact the target. These results could 
not be replicated and following the optimisation of this assay no conclusive data could 
be obtained. This indicates that the dipeptides exhibit their antimicrobial effects via 
different mechanisms, and this theory is corroborated by the alamarBlue assay which 
was carried out. This indicated that most of the dipeptides were acting in a bactericidal 
manner, which is not consistent with the proposed MraY inhibition. When considering 
that the increase in alkyl chain length increased the antimicrobial activity, it may 
indicate that the dipeptides are acting similarly to detergents. 
The next step was to use this data to design a series of peptidomimetics. The first series 
were based on a benzamide backbone described in chapter 1. Following the synthesis 
of dipeptide mimetics and synthesis route optimisation a second tryptophan side chain 
was installed so the peptidomimetics included the entire RWxxW motif. It was hoped 
that the addition of this third residue would confer the inhibition of MraY. The 
tripeptide mimetic did not show inhibition of MraY. The mimetics did however have 
antimicrobial activity, which was improved upon in the second round of mimetics.  
The mechanism of action could be similar to the dipeptide but it is impossible to say 
based on the biological data that was obtained. The MraY inhibition of the final five 
benzamide peptidomimetics were tested using the radiochemical inhibition assay, 
however none showed inhibition. 
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The cyclic backbone of the second round of mimetics was chosen based on 
computation modelling analysis. The diazepine backbone was furnished with the same 
groups as the benzamide backbone. These compounds showed antimicrobial activity 
which was comparable to the parent dipeptides but no inhibition of MraY. 
A summary of the antimicrobial data and the radiochemical inhibition data is shown 
in Table 23 and Figure 101 respectively.  
 
 





Figure 101: The summary of the antimicrobial data obtained for the compounds synthesised in 
this project. 
 
Despite having series of dipeptides and peptidomimetics which have antimicrobial 
activity, we were unable to obtain data which allows us to draw conclusions of how 
they exhibit these effects. Based on the data obtained in this project there is no 
evidence to suggest that there is an interaction between MraY and any of the 
compounds tested. The data shows the MBC and MIC are the same and this coupled 
with the alamarBlue data indicated that many of the compounds are acting in a 
bactericidal manner and could indicate that the peptides and mimetics are toxic. Based 
on the structures of the compounds it would not be unrealistic to think that they could 
lead to pore formation in the membrane. 
The future work could take two routes. The first would be to go back to the 
pentapeptides which show inhibition of the enzyme and make changes and 
peptidomimetics based on these.48 It would also be advisable to confirm there is 
actually an interaction occurring at this site, by carrying out more conclusive biological 
tests on Epep and MraY (such as a pull down assay). The second would be to pursue 
the antimicrobial activity and develop the peptidomimetics. However it may be wise 
to first test for toxicity against mammalian cell lines. More testing could be carried out 




CHAPTER 7: EXPERIMENTAL 
All chemicals used during this research project were purchased from Merck, Sigma 
Aldrich, Fluorochem and Fisher scientific. 
The biological reagent C55-P was purchased from Larodan Fine Chemicals. The 
substrate UDP-MurNAc pentapeptide was purchased from UK Bacterial Cell Wall 
Assembly Network (BaCWAN) and fluorescently tagged by summer student Namrita 
Modgill. Water used during these experimental procedures was deionized and 
autoclaved when necessary.  
Deuterated methanol, acetone and DMSO used for recording NMR spectra were 
purchased from Sigma Aldrich. HPLC grade solvents were purchased from Fischer 
Scientific. Anhydrous solvents which were used were obtained from Sigma Aldrich. 
Solvents were evaporated using a Buchi Rotavapor R-114 equipped with a Buchi 
Vacuum pump V-700 and a Buchi Heating bath B-480. 
Flash column chromatography was conducted on silica gel (40-63μm, 60Å) purchased 
from Sigma Aldrich. 
Thin Layer Chromatograpy (TLC) was performed on aluminum backed plates 
precoated with Merck TLC Silica Gel 60 F254 and were visualized under UV radiation, 
permanganate, ninhydrin or vanillin. 
Semi-preparative HPLC purification was conducted on an Agilent Technologies series 
1200 Preparative HPLC instrument equipped with a Synergi™ (4 µm Polar-RP 80 Å) 
column and analytical HPLC was carried out using the same machine but equipped 
with a Kinetex (5u EVO C18 100A) column. 
Low resolution ESI mass spectra were recorded using a Bruker Esquire 2000 
electrospray ionization spectrometer. High resolution mass spectra were recorded on 
a Bruker Micro TOF spectrometer equipped with an electrospray ionization source (by 
Lijiang Song). 
1H-NMR spectra were recorded at 300, 400 or 600 MHz using Bruker DPX300, 
DPX400 or AV III-600 spectrometers, respectively. Chemical shifts (δH) are quoted in 
ppm with reference to the residual solvent peak. The data in parenthesis follow the 
order (i) multiplicity: s, singlet; d, doublet, t, triplet; q, quartet; m, multiplet (ii) number 
168 
 
of equivalent protons (iii) coupling constant (J) in Hz (iv) assignment. HMBC, 
HMQC, COSY and NOESY were used in selected cases to aid in assignments. 
Fluorescence data and bacterial growth data were recorded using a HIDEX Sense 
Microplate Reader 425-301. 
The optical purity of the compounds could not be tested due to lack of instrumentation  
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7.1 Synthesis of the amino acid precursors and dipeptides  




L-Tryptophan (2.04 g, 0.01 mol, 1 eq) was added to 1-octanol (10 mL, 8.24 g, 0.06 
mol, 6.3 eq) and was refluxed at 80°C. H2SO4 conc. (1 mL) was added to the reaction 
mixture and stirred for 1 hour. The reaction mixture was taken up in EtOAc (25 mL) 
and then washed with sat. Na2CO3 (3x25 mL). The organic layer was separated and 
dried under MgSO4 and then concentrated. To remove the excess 1-octanol from the 
tryptophan octyl ester, purification by silica column chromatography was carried out 
using deactivated silica and eluted with 1:9/MeOH:EtOAc. The resulting product was 
an off white solid.  The procedure was modified from literature reference87; (1.35 g, 
4.2 mmol, 43%). Rf = 0.54 (1:9/MeOH:EtOAc) 
1H-NMR: (400 MHz, MeOD) δH: 
0.90 (t, 3H, J=6.5 Hz, H-1), 1.18-1.32 (m, 10H, H-2, H-3, H-4, H5, H-6), 1.51 (m, 2H, 
H-7), 3.14 (qd, J= 6.0 Hz, 3.5 Hz, 2H, H-10), 3.76 (t, 1H, J=6.5 Hz, H-9), 3.99 (t, 2H, 
J=6.5 Hz, H-8), 7.00 (t, 1H, J=7.5, H-13), 7.08 (s, 1H, H-11), 7.09 (t, 1H, J=7.5 Hz, 
H-14) , 7.31 (d, 1H, J=8.0, H-12), 7.52 (d, 1H, J=8.0, H-15). 13C-NMR (125 MHz, 
MeOD): 13.39 (CH3), 22.30 (CH2), 25.63 (CH2), 27.44 (CHCH2), 28.48 (CH2), 29.08 
(CH2), 31.60 (CH2), 32.23 (CH2), 54.32 (COCH), 64.20 (CH2), 110.06 (NHCCH), 
111.35 (CH2C), 118.48 (CCHCH), 120.94 (NHCCHCH), 121.37 (CCH), 123.86 
(CCHNH), 127.24 (CC), 136.74 (NHC), 172.84 (OCHO). LRMS m/z (ESI): 317.3 
[M+H]+. HRMS m/z (ESI): calculated for C19H29N2O2
+ [M+H]+: Exact Mass: 





Hexyl L-tryptophanate; L-Trp-hex157 (2) 
 
 
L-Tryptophan (4.12 g, 0.02 mol, 1eq) was added to 1-hexanol (20 mL, 16.3 g, 0.16 
mol, 8 eq) and was refluxed at 80°C. H2SO4 conc. (1 mL) was added to the reaction 
mixture and stirred for 45 minutes. The reaction mixture was taken up in EtOAc (25 
mL) and then washed with sat. Na2CO3 (3x25 mL). The organic layer was separated 
and dried under MgSO4 and then concentrated. To remove the excess 1-hexanol from 
the tryptophan hexyl ester, purification by silica column chromatography was carried 
out using deactivated silica and eluted with 1:9/MeOH:EtOAc. The resulting product 
was an off white solid; (2.69g, 9.3x10-3mol, 47%). Rf = 0.54 (1:9/MeOH:EtOAc) 
1H-
NMR: (400 MHz, MeOD) δH: 0.88 (t, 3H, J=7.0 Hz, H-1), 1.12-1.33 (m, 8H, H-2, H-
3, H-4), 1.47 (m, 2H, J=6.5 Hz, H-5), 3.14 ((qd, J= 6.0 Hz, 3.5 Hz, 2H, H-8), 3.76 (t, 
1H, J=6.0 Hz, H-7), 3.99 (t, 2H, J=6.5 Hz, H-6), 7.00 (t, 1H, J=7.13, H-11), 7.08 (s, 
1H, J=6.0 Hz, H-9), 7.09 (t, 1H, J=7.0 Hz, H-12) , 7.33 (d, 1H, J=8.0 Hz, H-10), 7.52 
(d, 1H, J=8.0 Hz, H-13). 13C-NMR (125 MHz, MeOD): 13.01 (CH3), 22.30 (CH2), 
25.63 (CH2), 27.09 (CHCH2), 28.48 (CH2), 29.08 (CH2), 53.72 (COCH), 64.88 
(OCH2), 109.32 (CH2C), 112.02 (NHCCH), 118.02 (CCHCH), 120.18 (NHCCHCH), 
121.68 (CCH), 123.18 (CCHNH), 127.14 (CC), 136.74 (NHCCH), 175.07 (OCHO). 
LRMS m/z (ESI): 289.2 [M+H]+. HRMS m/z (ESI): calculated for C17H25N2O2
+ 










L-Tryptophan (4.12 g, 0.02 mol, 1eq) was added to 1-decanol (20 mL, 16.59 g, 0.10 
mol, 5eq) and was refluxed at 80°C. H2SO4 conc. (1 mL) was added to the reaction 
mixture and stirred for 1 hour. The reaction mixture was taken up in EtOAc (25 mL) 
and then washed with sat. Na2CO3 (3x25 mL). The organic layer was separated and 
dried under MgSO4 and then concentrated. To remove the excess 1-decanol from the 
tryptophan decyl ester, purification by silica column chromatography was carried out 
using deactivated silica and eluted with 1:9/MeOH:EtOAc. The resulting product was 
an off white solid; (4.36g, 0.13 mol, 63%). Rf = 0.57 (1:9/MeOH:EtOAc). 
1H-NMR: 
(400 MHz, MeOD) δH: 0.9 (t, 3H, J=7.0 Hz, H-1), 1.12-1.39 (m, 8H, H-2, H-3, H-4, 
H-5, H-6, H-7, H-8), 1.48 (m, 2H, J=7.0 Hz, H-9), 3.14 ((qd, J= 6.0 Hz, 3.5 Hz, 2H, 
H-12), 3.76 (t, 1H, J=6.5, H-11), 4.00 (t, 2H, J=6.5 Hz, H-10), 7.00 (t, 1H, J=7.0 Hz, 
H-15), 7.08 (s, 1H, H-13), 7.09 (t, 1H, J=7.0 Hz, H-16) , 7.33 (d, 1H, J=8.0 Hz, H-14), 
7.52 (d, 1H, J=8.0 Hz, H-17). 13C-NMR (125 MHz, MeOD): 13.27 (CH3), 22.45 
(CH2), 25.62 (CH2), 30.38 (CH2), 25.43 (CH2), 27.35 (CH2), 29.44 (CH2), 28.21 (CH2), 
31.77 (CH2), 65.50 (OCH2), 174.93 (OCHO), 53.29 (COCH), 28.09 (CHCH2), 109.29 
(CH2C), 123.39 (CCHNH), 136.70 (NHCCH), 111.07 (NHCCH), 120.15 
(NHCCHCH), 121.85 (CCH), 118.45 (CCHCH). 127.43 (CC). LRMS m/z (ESI): 
367.3 [M+Na]+. HRMS m/z (ESI): calculated for C21H32N2NaO2
+ [M+Na]+: Exact 









L-phenylalanine (1.00 g, 6.1 mmol) was added to 1-octanol (10mL, 8.24 g, 0.06 mol) 
and was refluxed at 80°C. H2SO4 conc. (0.5 mL) was added to the reaction mixture 
and stirred for 45 minutes. The reaction mixture was taken up in EtOAc (25 mL) and 
then washed with Na2CO3 sat. (3x25 mL). The organic layer was separated and dried 
under MgSO4 and then concentrated. To remove the excess 1-octanol from the 
tryptophan octyl ester purification by silica column chromatography was carried out 
using deactivated silica, eluting with EtOAc. The resulting product was an off white 
solid. The procedure was modified from literature reference48; (0.44 g, 2.7 mmol, 
45%). Rf = 0.41 (EtOAc) 
1H-NMR: (400 MHz, MeOD) δH: 0.90 (t, 3H, J=6.5 Hz, H-
1), 1.21-1.40 (m, 10H, H-2, H-3, H-4, H5, H-6), 1.45-1.59 (m, 2H, H-7), 2.89-3.04 (m, 
2H, H-10), 3.70 (t, 1H, J=6.5 Hz, H-9), 4.05 (t, 2H, J=6.5 Hz, H-8), 7.16-7.32 (m, 5H, 
H-11, H-12, H-13). 13C-NMR (125 MHz, MeOD): 14.49 (CH3), 23.76 (CH2), 27.00 
(CH2), 29.66 (CH2), 30.34 (CH2), 30.63 (CH2), 33.06 (CH2), 41.97 (CHCH2), 56.78 
(CH2), 66.11 (COCH), 127.90 (CHCHCH), 129.58 (CCH), 130.38 (CCHCH), 138.35 
(CH2C), 175.91 (OCHO). LRMS m/z (ESI): 278.3 [M+H]
+. HRMS m/z (ESI): 
calculated for C17H28NO2









L-Tyrosine (1.00 g, 5.5 mmol) was added to 1-octanol (10mL, 8.24 g, 0.06 mol) and 
was refluxed at 80°C. H2SO4 conc. (0.5 mL) was added to the reaction mixture and 
stirred for 45 minutes. The reaction mixture was taken up in EtOAc (25 mL) and then 
washed with Na2CO3 sat. (3x25 mL). The organic layer was separated and dried under 
MgSO4 and then concentrated. To remove the excess 1-octanol from the tryptophan 
octyl ester purification by silica column chromatography was carried out using 
deactivated silica, eluting with 1:9/MeOH:EtOAc. The resulting product was an off 
white solid. The procedure was modified from literature reference48; (0.64 g, 2.1 
mmol, 38%). Rf = 0.67 (1:9/MeOH:EtOAc) 
1H-NMR: (400 MHz, MeOD) δH: 0.90 (t, 
3H, J=6.8 Hz, H-1), 1.25-1.38 (m, 10H, H-2, H-3, H-4, H5, H-6), 1.53 (m, 2H, J=6.5 
Hz, H-7), 2.87 (m, 2H, H-10), 3.63 (t, 1H, J=6.5 Hz, H-9), 4.05 (t, 2H, J=6.5 Hz, H-
8), 6.72 (d, 2H, J=7.0 Hz, H-11) , 6.99 (d, 2H, J=7.0 Hz, H-12). 13C-NMR (125 MHz, 
MeOD): 13.13 (CH3), 22.29 (CH2), 25.50 (CH2), 28.38 (CH2), 29.13 (CH2), 32.01 
(CH2), 32.50 (CH2), 39.58 (CHCH2), 48.27 (CH2), 55.15 (COCH), 127.78 (CH2C), 
130.17 (CCH), 144.44 (CCHCH), 156.19 (COH), 174.48 (OCHO). LRMS m/z (ESI): 
294.3 [M+H]+. HRMS m/z (ESI): calculated for C17H28NO3
+ [M+H]+: Exact Mass: 










Boc-Arg-OH (0.69 g, 2.5 mmol, 1 eq), HATU (0.95 g, 2.5 mmol, 1 eq), 1 (0.79 g, 2.5 
mmol, 1 eq) and DIPEA (0.32 g, 0.45 mL, 2.5 mmol, 1 eq) were stirred in anhydrous 
DCM (15 mL) and stirred for 18 hours. The solvent was removed in vacuo. The 
resulting oil (50 mg) was added to Amberlyst 15 resin (1.5 g) in DCM (10 mL) and 
stirred overnight. The DCM was removed by suction filtration. The resin was then 
successively washed with hexane, THF and methanol. The resin was then stirred with 
3M ammonia in methanol for 30 minutes. The solvent was then evaporated in vacuo 
and the product was dried under high vacuum to produce a brown oil. The procedure 
was modified from a literature reference48,158 1H-NMR: (400 MHz, MeOD) δH: 0.90 
(t, 3H, J=7.0 Hz, H-1), 1.15-1.40 (m, 10H, H-2, H-3, H-4, H5, H-6), 1-44-1.50 (m, 2H, 
H-7), 1. 67-1.73 (m, 2H, H-18), 1.77-1.83 (m, 2H, H-17), 3.14 (dd, J=8.5, 2.5 Hz, 2H, 
H-19), 3.20-3.27 (m, 2H, H-10), 3.70-3.77 (m, 1H, H-16), 3.92-3.98 (m, 1H, H-9), 
4.02 (t, 2H, J=6.5 Hz, H-8), 7.01 (t, 1H, J= 6.0 Hz, H-13), 7.09 (t, 1H, J=7.5 Hz, H-
14), 7.17 (s, 1H, H-11), 7.35 (d, 1H, J=8.0 Hz, H-15), 8.34 (d, 1H, J=8.0 Hz, H-12). 
13C-NMR (125 MHz, MeOD): 13.04 (CH3), 22.30 (CH2), 22.35 (CH2), 22.65 (CH2), 
23.66 (CH2CH2), 25.48 (CHCH2), 28.09 (CH2), 28.88 (CH2), 28.89 (CHCH2), 31.56 
(CH2), 44.32 (CH2NH), 52.33 (COCH), 53.85 (NHCOCH), 65.72 (CH2), 172.13 
(OCHO), 108.98 (CH2C), 111.06 (NHCCH), 117.60 (CHCHC), 118.49 (CHCHC), 
123.16 (NHCCHCH), 123.23 (CCHNH), 127.13 (CHC), 136.73 (NHC), 157.27 
(NHCNH), 168.59 (NHCO). LRMS m/z (ESI): 473.2 [M+H]+. HRMS m/z (ESI): 
calculated for C21H32N2O3








Boc-Arg-OH (0.69 g, 2.5 mmol, 1 eq), HATU (0.95 g, 2.5 mmol, 1 eq), 2 (0.72 g, 2.5 
mmol, 1 eq) and DIPEA (0.32 g, 0.45 mL, 2.5 mmol, 1 eq) were stirred in anhydrous 
DCM (15 mL) and stirred for 18 hours. The solvent was removed in vacuo. The 
resulting oil (50 mg) was added to Amberlyst 15 resin (1.5 g) in DCM (10 mL) and 
stirred overnight. The DCM was removed by suction filtration. The resin was then 
successively washed with hexane, THF and methanol. The resin was then stirred with 
3M ammonia in methanol for 30 minutes. The solvent was then evaporated and the 
product was dried under high vacuum to produce a brown oil; 1H-NMR: (400 MHz, 
MeOD) δH: 0.89 (t, 3H, J=7.0 Hz, H-1), 1.16-1.32 (m, 8H, H-2, H-3, H-4), 1.37-1.42 
(m, 2H, H-5), 1.68-1.70 (m, 2H, H-16), 1.79-1.91 (m, 2H, H-15), 2.92-3.08 (m, 2H, 
H-17), 3.17 (dd, J=8.5, 2.5 Hz, 2H, H-8), 3.91 (t, 1H, J=6.5 Hz, H-7), 4.02 (t, 2H, J=6.5 
Hz, H-6), 4.10 (t, 1H, J=7.0 Hz, H-14), 7.01 (t, 1H, J=7.5 Hz, H-11), 7.08 (s, 1H, H-
9), 7.09 (t, 1H, J=7.5 Hz, H-12), 8.15 (d, 1H, J=8.0 Hz, H-10), 8.49 (d, 1H, J=8.0 Hz, 
H-13). 13C-NMR (125 MHz, MeOD): 13.04 (CH3), 22.30 (CH2), 22.65 (CH2), 23.66 
(CH2CH2), 25.48 (CHCH2), 28.88 (CH2), 28.89 (CHCH2), 31.56 (CH2), 44.32 
(CH2NH), 52.33 (COCH), 53.85 (NHCOCH), 65.72 (OCH2), 108.98 (CH2C), 111.06 
(NHCCH), 118.49 (CHCHC), 123.16 (NHCCHCH), 123.23 (CCHNH), 136.73 
(NHC), 172.13 (OCHO), 117.60 (CHCHC), 127.13 (CHC), 157.27 (NHCNH), 168.59 
(NHCO). LRMS m/z (ESI): 445.2 [M+H]+. HRMS m/z (ESI): calculated for 
C23H37N6O3








Boc-Arg-OH (0.69 g, 2.5 mmol, 1 eq), HATU (0.95 g, 2.5 mmol, 1 eq), 3 (0.86 g, 2.5 
mmol, 1 eq) and DIPEA (0.32 g, 0.45 mL, 2.5 mmol, 1 eq) were stirred in anhydrous 
DCM (15 mL) and stirred for 18 hours. The solvent was removed in vacuo. The 
resulting oil (50 mg) was added to Amberlyst 15 resin (1.5 g) in DCM (10 mL) and 
stirred overnight. The DCM was removed by suction filtration. The resin was then 
successively washed with hexane, THF and methanol. The resin was then stirred with 
3M ammonia in methanol for 30 minutes. The solvent was then evaporated in vacuo 
and the product was dried under high vacuum to produce a brown oil. The procedure 
was modified from literature reference48,158; 1H-NMR: (400 MHz, MeOD) δH: 0.89 (t, 
3H, J=7.0 Hz, H-1), 1.15-1.35 (m, 12H, H-2, H-3, H-4, H-5, H-6, H-7, H-8), 1.43-1.52 
(m, 2H, H-9), 1.60-1. 72 (m, 2H, H-20), 1.78-1.91 (m, 2H, H-19), 3.20 (dd, J=8.5, 2.5 
Hz, 2H, H-12), 3.54 (t, 2H, J=6.5 Hz, H-21), 4.00 (t, 1H, J=7.0 Hz, H-11), 4.09 (t, 2H, 
J=6.5 Hz, H-10), 4.27 (t, 1H, J=7.5 Hz, H-18), 7.11 (t, 1H, J=7.5 Hz, H-15), 7.31 (t, 
1H, J=7.5 Hz, H-16), 7.33 (s, 1H, H-13), 8.17 (d, 1H, J=8.5 Hz, H-17), 8.49 (d, 1H, 
J=8.0 Hz, H-14). 13C-NMR (125 MHz, MeOD): 14.41 (CH3), 22.35 (CH2), 23.61 
(CH2CH2), 26.21 (CH2), 27.42 (CHCH2), 27.49 (CH2), 27.55 (CHCH2), 28.24 (CH2), 
28.35 (CH2), 28.88 (CH2), 28.91 (CH2), 30.80 (CH2), 42.11 (CH2NH), 53.68 (COCH), 
54.51 (NHCOCH), 63.22 (CH2), 109.18 (CH2C), 110.62 (NHCCH), 117.22 
(CHCHC), 118.50 (CHCHC), 122.22 (CCHNH), 123.43 (NHCCHCH), 127.67 
(CHC), 136.60 (NHC), 156.55  (NHCNH), 170.10 (NHCO), 172.90 (OCHO). LRMS 
m/z (ESI): 501.2 [M+H]+. HRMS m/z (ESI): calculated for C27H45N6O3
+ [M+H]+: 
Exact Mass: 501.3548 found 501.3550. 
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Fmoc-Arg-OH (0.99 g, 2.5 mmol, 1 eq), HBTU (0.10 g, 2.75 mmol, 1.1 eq), 4 (0.76 
g, 2.75 mmol, 1.1 eq) and DIPEA (0.1.92 g, 2.60 mL, 2.5 mmol, 6 eq) were stirred in 
anhydrous DCM under N2 gas for 18 hours. The solvent was removed in vacuo. The 
dipeptide was deprotected with 20% piperidine in THF (10 mL). Once the deprotection 
was complete the solution was concentrated under high vacuum to remove the 
piperidine and then precipitated from Et2O. The sample was then purified by RP-
HPLC using Synergi™ 4 µm Polar-RP 80 Å and an elution gradient of H2O + 0.1% 
TFA /MeCN + 0.1% TFA (80:20 to 0:100) over 30 minutes with a flow rate of 2 
mL/min. The fractions were pooled and lyophilized. 1H-NMR: (400 MHz, MeOD) 
δH: 0.91 (t, 3H, J=6.5 Hz, H-1), 1.23-1.35 (m, 10H, H-2, H-3, H-4, H5, H-6) 1.42-1.49 
(m, 2H, H-7), 1.66- 1.78 (m, 2H, H-16), 1.84- 1.96 (m, 2H, H-15), 3.00-3.09 (m, 2h, 
H-16), 3.22 (t, 2H, J=7.0 Hz, H-8), 3.89 (t, 1H, J=6.0 Hz H-9), 4.07 (t, 2H, J=6.5 Hz, 
H-10), 4.72 (t, 1H, J=7.5 Hz H-14), 7.21-7.36 (m, 5H, H-11, H-12, H-13). 13C-NMR 
(125 MHz, MeOD): 12.97 (CH3), 21.97 (CH2), 23.66 (CH2), 25.54 (CH2CH2), 28.16 
(CHCH2), 28.49 (CH2), 28.89 (CH2), 31.36 (CH2), 32.82 (CH2), 36.81 (CHCH2), 40.46 
(CH2CH2CH2), 52.48 (COCH), 54.26 (COCH), 65.35 (OCH2), 126.73 (CCHCHCH), 
128.27 (CH2C), 128.72 (CCHCH), 136.54 (CH2C) 156.21 (NHCNH), 171.59 (OCO), 
174.20 (NHCO). LRMS m/z (ESI): 434.4 [M+H]+. HRMS m/z (ESI): calculated for 
C23H40N5O3









Fmoc-Arg-OH (0.99 g, 2.5 mmol, 1 eq), HBTU (0.96 g, 2.5 mmol, 1 eq), 5 (0.74 g, 
2.5 mmol, 1 eq) and DIPEA (0.32 g, 0.45 mL, 2.5 mmol, 1 eq) were stirred in 
anhydrous DCM under N2 gas for 18 hours. The dipeptide was deprotected with 20% 
piperidine in DCM (10 mL). Once the deprotection was complete the solution was 
concentrated under high vacuum to remove the piperidine and precipitated from Et2O. 
The sample was then purified by RP-HPLC using Synergi™ 4 µm Polar-RP 80 Å and 
an elution gradient of H2O + 0.1% TFA /MeCN + 0.1% TFA (100:0 to 0:100) over 30 
minutes with a flow rate of 2 mL/min. The fractions were pooled and lyophilized. 1H-
NMR: (400 MHz, MeOD) δH: 0.91 (t, 3H, J=7.0 Hz, H-1), 1.20-1.35 (m, 10H, H-2, 
H-3, H-4, H5, H-6) 1.53-1.62 (m, 2H, H-7), 1.65- 1.75 (m, 2H, H-15), 1.76- 1.82 (m, 
2H, H-14), 1.89- 1.95 (m, 2h, H-16), 2.87 (m, 2H, H-10), 3.22 (t, 2H, J=7.0 Hz, H-8), 
3.90-3.94 (m, 1H, H-9), 4.60-4.64 (m, 1H, H-13), 6.71 (d, 2H, J=8.0 Hz, H-11), 7.04 
(d, 2H, J=8.0 Hz, H-12). 13C-NMR (125 MHz, MeOD): 13.31 (CH3), 21.80 (CH2), 
23.53 (CH2), 25.37 (CH2), 28.37 (CH2), 28.44 (CH2), 28.81 (CH2), 31.54 (CHCH2), 
35.92 (CH2CH2), 40.20 (CHCH2), 44.38 (CH2CH2CH2), 52.43 (COCH), 54.52 
(COCH), 65.17 (OCH2), 115.00 (CCHCH), 126.96 (CH2C), 129.82 (CCH), 156.26 
(COH), 160.81 (NHCNH), 168.38 (OCO), 171.78 (NHCO). LRMS m/z (ESI): 450.4 
[M+H]+. HRMS m/z (ESI): calculated for C23H40N5O4
+ [M+H]+: Exact Mass: 









Boc-Arg-OH (1 g, 2.5 mmol, 1 eq), HATU (0.95 g, 2.5 mmol, 1 eq), 1 (0.69 g, 2.5 
mmol, 1 eq) were stirred in minimum DCM. DIPEA (0.32 g, 0.45 mL, 2.5 mmol, 1 
eq) was added to the reaction mixture which was then stirred over 3 days. The reaction 
was monitored with LC-MS. The reaction mixture was concentrated to dryness. The 
dipeptide was precipitated from Et2O. The sample was then purified by RP-HPLC 
using Synergi™ 4 µm Polar-RP 80 Å and an elution gradient of H2O + 0.1% TFA 
/MeCN + 0.1% TFA (100:0 to 0:100) over 30 minutes with a flow rate of 2 mL/min. 
The fractions were pooled and lyophilized; 1H-NMR: (400 MHz, MeOD) δH: 0.90 (t, 
3H, J=7.0 Hz, H-1), 1.21-1.34 (m, 12H, H-2, H-3, H-4, H5, H-6), 1.39 (s, 9H, H-20), 
1.44-1.51 (m, 2H, H-7), 1.64-1.70 (m, 2H, H-18), 1.71-1.80 (m, 2H, H-17), 3.13-3.19 
(m, 2H, H-19), 3.20 (dd, J=8.5, 2.5 Hz, 2H, H-10), 3.93-4.00 (t, 2H, H-16), 4.10 (t, 
1H, J=6.5 Hz, H-8), 4.32 (t, 1H, J=6.5 Hz, H-9), 7.04 (t, 1H, J=7.5 Hz, H-13), 7.29 (s, 
1H, H-11), 7.30 (t, 1H, J=7.5 Hz, H-14), 7.68 (dd, 2H, J=8.0 Hz, H-12, H-15). 13C-
NMR (125 MHz, MeOD): 12.24 (CH3), 21.52 (CH2), 22.62 (CH2CH2), 23.45 (CH2), 
24.60 (CH2), 27.89 (CHCH2), 28.19 (3CH3), 28.24 (CH2), 29.80 (CHCH2), 29.82 
(CH2), 30.24 (CH2), 44.32 (CH2NH), 52.50 (NHCOCH), 54.30 (COCH), 64.21 (CH2), 
80.21 (CH3C), 109.29 (CH2C), 110.61 (NHCCH), 118.02 (CHCHC), 119.92 
(CHCHC), 122.16 (NHCCHCH), 122.49 (CCHNH), 128.13 (CHC), 136.73 (NHC), 
157.27 (NHCNH), 156.33 (NHCOOC), 169.10 (NHCO), 170.23 (OCHO). LRMS 
LRMS m/z (ESI): 573.3 [M+H]+. HRMS m/z (ESI): calculated for C30H49N6O5
+ 








Boc-Arg-OH (1 g, 2.5 mmol, 1 eq), HATU (0.95 g, 2.5 mmol, 1 eq), 1 (0.79 g, 2.5 
mmol, 1 eq) and DIPEA (0.32 g, 0.45 mL, 2.5 mmol, 1 eq) were stirred in anhydrous 
DCM under N2 gas for 18 hours. The solvent was removed and the resulting oil was 
stirred in 4N HCl in dioxane (4 mL) for 4 hours. The solvent was removed and the 
resulting oil containing H2N-RW-Oct was added to acetic anhydride (4 mL, 4.32 g, 
0.042 mol) and DIPEA (4 mL, 2.98 g, 0.023 mol) in DCM (12 mL) and stirred for 30 
minutes. The solvent was then evaporated. The sample was then purified by RP-HPLC 
using Synergi™ 4 µm Polar-RP 80 Å and an elution gradient of H2O + 0.1% TFA 
/MeCN + 0.1% TFA (100:0 to 0:100) over 30 minutes with a flow rate of 2 mL/min. 
The fractions were pooled and lyophilized; 1H-NMR: (400 MHz, MeOD) δH: 0.90 (t, 
3H, J=7.0 Hz, H-1), 1.18-1.38 (m, 10H, H-2, H-3, H-4, H5, H-6), 1-41-1.48 (m, 2H, 
H-7), 1. 60-1.69 (m, 2H, H-18), 1.72-1.80 (m, 2H, H-17), 1.94 (s, 3H, H-20), 3.14 (dd, 
J=8.5, 2.5 Hz, 2H, H-19), 3.21-3.27 (m, 2H, H-10), 3.69-3.75 (m, 1H, H-16), 3.93-
3.98 (m, 1H, H-9), 4.00 (t, 2H, J=6.5 Hz, H-8), 7.03 (t, 1H, J= 6.0 Hz, H-13), 7.09 (t, 
1H, J=7.5 Hz, H-14), 7.15 (s, 1H, H-11), 7.38 (d, 1H, J=8.0 Hz, H-15), 8.34 (d, 1H, 
J=8.0 Hz, H-12). 13C-NMR (125 MHz, MeOD): 13.09 (CH3), 22.47 (CH2), 23.09 
(COCH3),23.42 (CH2), 23.63 (CH2CH2), 24.85 (CH2), 28.92 (CHCH2), 29.10 (CH2), 
29.71 (CH2), 29.80 (CHCH2), 30.90 (CH2), 46.28 (CH2NH), 52.50 (NHCOCH), 54.28 
(COCH), 64.22 (OCH2), 110.27 (CH2C), 111.42 (NHCCH), 119.12 (CHCHC), 119.59 
(CHCHC), 121.29 (CCHNH), 121.97 (NHCCHCH), 128.13 (CHC), 136.32 (NHC), 
157.27 (NHCNH), 169.89 (NHCOCH3), 170.10 (NHCO), 172.99 (OCHO). LRMS 
m/z (ESI): 515.2 [M+H]+. HRMS m/z (ESI): calculated for C27H43N6O4
+ [M+H]+: 
Exact Mass: 515.3340 found 515.3344. 
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Boc-His(Trt)-OH (0.62 g, 1.25 mmol, 1 eq), HBTU (0.48 g, 1.25 mmol, 1 eq), 1 (0.40 
g, 1.25 mmol, 1 eq)and  DIPEA (0.16 g, 0.23 mL, 1.25 mmol, 1 eq) were stirred in 
anhydrous DCM (15 mL) under N2 gas for 18 hours. The solvent was removed in 
vacuo. The resulting oil was purified using silica column chromatography, using 
deactivated silica, and the product was eluted with 2:8/EtOAc:petroleum ether. The 
solvent was removed and the resulting oil was stirred in 4N HCl in dioxane (4 mL) for 
4 hours. The solvent was removed in vacuo. to give an orange oil; (8 mg, 0.02 mmol, 
2%). 1H-NMR: (400 MHz, MeOD) δH: 0.89 (t, 3H, J=5.81, H-1), 1.20-1.35 (m, 10H, 
H-2, H-3, H-4, H5, H-6) 1.50 (m, 2H, H-7), 2.38 (m, 2H, H-17), 3.12 dd, J=8.5, 3.0 
Hz, 2H, H-10),  3.53 (t, 2H, J=6.5 Hz, H-8), 3.91 (t, 1H, J=7.0 Hz, H-9), 4.29 (t, 1H, 
J=7.0 Hz, H-16), 7.08 (t, 1H, J=7.5 Hz, H-13), 7.09 (s, 1H, H-11), 7.12 (d, 2H, J= 2.0 
Hz, H-18), 7.25 (t, 1H, J=7.5 Hz, H-14), 7.41 (d, 1H, J=8.0, H-12), 7.65 (d, 1H, J=8.0 
Hz, H-15). 8.95 (d, 1H, J= 4.0, H19). 13C-NMR (125 MHz, MeOD): 10.14 (CH3), 
20.25 (CH2), 23.45 (CH2), 23.90 (CH2), 26.82 (CH2), 28.19 (CH2), 29.67 (CHCH2), 
30.61 (CH2), 33.41 (CHCH2), 51.33 (COCH), 53.82 (NHCOCH), 65.88 (OCH2), 
108.83 (CH2C), 111.06 (NHCCH), 117.34 (NHCHC), 118.11 (CHCHC), 118.49 
(CHCHC), 122.44 (CCHNH), 123.16 (NHCCHCH), 127.13 (CHC), 127.89 
(NCHNH), 131.45 (CH2CN), 135.55 (NHC), 168.38 (OCHO), 171.88 (NHCO). 
LRMS m/z (ESI): 454.1 [M+H]+. HRMS m/z (ESI): calculated for C25H36N5O3
+ 








L-Lysine (2 g, 0.01 mol, eq) was dissolved in DCM (10 mL) and 1N NaOH (10 mL) 
was added and the reaction was stirred rapidly. To this Boc2O (4.4 g, mmol, 2 eq) was 
added and the reaction was stirred for 18 hours. DCM (20 mL) and water (20 mL) 
were added and the pH was adjusted to 4 using dilute HCl. The water layer was 
removed and the the organic layer was washed a further two times with water. The 
organic layer was dried over MgSO4. The solvent was removed in vacuo. Adapted 
from literature reference159; (2.7 g, 7.9 mmol, %).  1H-NMR: (400 MHz, MeOD) δH: 
1.20-1.35 (m, 12H, H-4), 1.45 (s, 9H, H-1), 1.48 (s, 9H, H-7), 1.51-1.58 (m, 2H, H-3 
1.65-1.78 (m, 2H, H-5), 1.83-1.99 (m, 2H, H-2), 4.44 (m, 1H, H-6). 13C-NMR (125 
MHz, MeOD): 22.31(NHCH2CH2CH2), 26.53 (CH2CH2CH), 27.51, 27.69 (3CH3), 
29.00 (NHCH2CH2), 30.50 (NHCH2), 54.89 (NHCH), 79.51, 79.59 (CH3C), 157.02, 





Octyl N2,N6-bis(tert-butoxycarbonyl)-L-lysyl-L-tryptophanate (15) 
 
 
14 (1.0 g, 2.9 mmol, 1 eq), HBTU (1.2 g, 3.2 mmol, 1.1 eq), 1 (1 g, 3.2 mmol, 1.1 eq) 
and DIPEA (0.94 mL, 0.74 g, 5.8 mmol, 2 eq) were stirred in anhydrous DCM (10 
mL) under N2 gas for 18 hours. DCM (40 mL) was added and then washed three times 
with water (50 mL). The organic layer was dried over MgSO4 and the solvent removed 
in vacuo. The resulting residue was applied to a silica column and the product was 
eluted with EtOAc; Rf = 0.68 (EtOAc). (0.79 g, 1.22 mmol, 42 %). 
1H-NMR: (400 
MHz, MeOD) δH: 0.90 (t, 3H, J=7.0 Hz, H-1), 1.17-1.36 (m, 12H, H-2, H-3, H-4, H5, 
H-6, H-18), 1.41 (s, 9H, H-22), 1.44 (s, 9H, H-21), 1.45-1.56 (m, 2H, J=7.04Hz, H-7), 
1.67-1.76 (m, 2H, H-19), 1.86-195 (m, 2H, H-17), 2.94 (t, 2H, J= 7.5 Hz, H-20), 3.18 
(dd, J=8.5, 2.5 Hz, 2H, H-10), 3.91 (t, 1H, J=6.5 Hz, H-16), 4.03 (t, 2H, J=6.5 Hz, H-
8), 4.77 (t, 1H, J=7.0 Hz, H-9), 7.06 (dt, 2H, J= 7.5, 40 .5 Hz, H-13, H-14) 7.15 (s, 1H, 
J=4.2 Hz, H-11), 7.34 (d, 1H, J=8.0 Hz, H-12), 7.53 (d, 1H, J=8.0 Hz, H-15). 13C-
NMR (125 MHz, MeOD): 13.30 (CH3), 21.20 (CH2), 22.30 (CHCH2), 26.54 (CH2), 
27.10, 27.16 (3CH3). 27.32 (CH2), 28.29 (CH2), 28.89 (CH2CH2), 29.13 (CHCH2), 
29.50 (CH2), 30.72 (CH2), 31.56 (CHCH2), 38.91 (CH2NHCO), 52.50 (COCH), 53.82 
(NHCOCHNH), 65.40 (CH2), 79.72, 79.79 (CH3C), 109.63 (CH2C), 112.00 
(NHCCH), 117.61 (CHCHC), 118.50 (CHCHCH), 121.66 (NHCCHCH), 122.98 
(CCHNH), 127.14 (CC), 136.74 (NHC), 157.22, 157.54 (NHCOOC), 169.24 
(OCHO), 172.20 (NHCO). LRMS m/z (ESI): 415.2 [M+Na]+. HRMS m/z (ESI): 
calculated for C35H56N4NaO7








Compound 15 (0.1 g, 0.23 mmol) was stirred in 4N HCl in dioxane (1 mL) for 4 hours. 
The solvent was removed in vacuo; (0.094 g, 0.21 mmol, 94%). 1H-NMR: (400 MHz, 
MeOD) δH: 0.90 (t, 3H, J=7.0 Hz, H-1), 1.17-1.36 (m, 12H, H-2, H-3, H-4, H5, H-6, 
H-18), 1.40-1.56 (m, 2H, J=7.04Hz, H-7), 1.67-1.76 (m, 2H, H-19), 1.86-195 (m, 2H, 
H-17), 2.94 (t, 2H, J= 7.5 Hz, H-20), 3.22 (dd, J=8.5, 2.5 Hz, 2H, H-10), 3.91 (t, 1H, 
J=6.5 Hz, H-16), 4.03 (t, 2H, J=6.5 Hz, H-8), 4.77 (t, 1H, J=7.0 Hz, H-9), 7.06 (dt, 2H, 
J= 7.5, 13.5 Hz, H-13, H-14) 7.15 (s, 1H, J=4.2 Hz, H-11), 7.34 (d, 1H, J=8.0 Hz, H-
12), 7.53 (d, 1H, J=8.0 Hz, H-15). 13C-NMR (125 MHz, MeOD): 13.03 (CH3), 21.10 
(CH2), 22.30 (CHCH2), 26.75 (CH2), 27.12 (CH2), 28.09 (CH2), 28.89 (CH2CH2), 
29.13 (CHCH2), 29.44 (CH2), 30.72 (CH2), 31.56 (CHCH2), 38.91 (CH2NH2), 52.50 
(COCH), 53.82 (NHCOCH), 65.25 (CH2), 109.03 (CH2C), 111.06 (NHCCH), 117.61 
(CHCHC), 118.50 (CHCHCH), 121.18 (NHCCHCH), 123.17 (CCHNH), 127.14 
(CC), 136.74 (NHC), 172.20 (NHCO), 168.72 (OCHO). LRMS m/z (ESI): 415.2 
[M+Na]+. HRMS m/z (ESI): calculated for C25H40N4NaO3











2-Chloropyrimidine (1.3 g, 1.1 mmol, 1.1 eq), Boc-Orn-OH (0.23 g, 1 mol, 1 eq) and 
K2CO3 (0.15 g, 1.1 mol, 1.1 eq) were added to MeOH (10mL) and stirred at 40°C 
under reflux for 3 days. The solvent was removed in vacuo and the resulting brown oil 
was purified using silica column chromatography. The silica was deactivated and the 
column and then the product eluted with 20:55:25/MeOH:EtOAc:Acetone. The 
fractions were pooled and concentrated and dried under high vacuum. The procedure 
was modified from literature reference102; (0.27 g, 0.87 mmol, 87%). 1H-NMR: (400 
MHz, MeOD) δH: 1.42 (s, 9H, H-8), 1.66 (m, 2H, H-2), 1.86 (m, 2H, H-3), 3.63 (t, 1H, 
J=6.0 Hz, H-4), 3.98 (m, 1H, J=6.0 Hz, H-1), 6.55 (t, 1H, J=5.0 Hz, H-6), 8.23 (d, 2H, 
J=5.0 Hz, H-5, H-7). 13C-NMR (125 MHz, MeOD): 10.20 (CH3), 23.45 (CHCH2), 
27.41 (COCH), 30.32 (CHCH2CH2), 46.30 (CH2NH), 58.64 (OCCH3), 109.59 
(NCHCH), 156.27 (COOH), 157.82 (NCHCH), 162.17 (NHC), 162.17 (NHCO). 
LRMS m/z (ESI): 310.9 [M+H]+. HRMS m/z (ESI): calculated for C14H22N4NaO4
+ 










Compound 17 (0.27 g, 0.87 mmol, 1eq), HATU (0.33g, 0.87 mmol, 1eq), 1 (0.28g, 
0.87 mmol, 1eq) and DIPEA (0.11g, 0.14 mL, 0.87 mmol, 1eq) were stirred in 
anhydrous DCM (10 mL) under N2 gas for 18 hours. The solvent was removed and the 
resulting oil was stirred in 4N HCl in dioxane (4 mL) for 4 hours. The sample was then 
purified by RP-HPLC using Synergi™ 4 µm Polar-RP 80 Å and an elution gradient of 
H2O + 0.1% TFA /MeCN + 0.1% TFA (100:0 to 0:100) over 30 minutes with a flow 
rate of 2 mL/min. The fractions were pooled and lyophilized; 1H-NMR: (400 MHz, 
MeOD) δH: 0.89 (t, 3H, J=5.7 Hz, H-1), 1.17-1.36 (m, 10H, H-2, H-3, H-4, H5, H-6), 
1.47 (t, 2H, J=7.0 Hz, H-7), 1.74 (m, 2H, H-18), 1.93 (m, 2H, H-17), 3.18 (dd, J= 8.5, 
2.5 Hz, 2H, H-10), 3.28 (t, 2H, J=6.5 Hz, H-19), 3.88 (t, 1H, J=5.9 Hz, H-9), 4.01 (t, 
2H, J=6.6 Hz, H-8), 4.77 (t, 1H, J=7.1 Hz, H-16), 6.70 (t, 1H, J=4.8 Hz, H-21), 7.01 
(t, 1H, J=7.9 Hz, H-13), 7.09 (t, 1H, J=7.4 Hz, H-14), 7.12 (s, 1H, J=4.2 Hz, H-11), 
7.34 (d, 1H, J=8.6 Hz, H-12), 7.53 (d, 1H, J=8.1 Hz, H-15), 8.34 (d, 2H, J=4.8 Hz, H-
22, H-20). 13C-NMR (125 MHz, MeOD): 12.96 (CH3), 22.26 (CH2), 24.18 (CH2), 
25.51 (CH2), 27.24 (CH2), 28.90 (CH2CH2), 28.21 (CH2), 28.80 (CH2), 31.52 
(CHCH2), 31.36 (CHCH2), 31.66 (NHCOCH), 40.02 (CH2NH), 53.74 (COCH), 65.15 
(OCH2), 108.72 (CH2C), 110.07 (NHCCH), 111.06 (NCHCH2), 117.75 (CCH), 118.07 
(CCHCH), 121.38 (NHCCHCH), 123.11 (CCHNH), 127.11 (CC), 136.85 (NHC), 
162.06 (NHCN), 158.05 (NCHCH2), 168.86 (NHCO), 171.71 (OCO). LRMS m/z 
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(ESI): 509.1 [M+H]+. HRMS m/z (ESI): calculated for C28H41N6O3
+ [M+H]+: Exact 









L-tryptophan (2 g, 9 mmol, 1 eq), Boc2O (3.9 g, 18 mmol, 2 eq) and NaOH (0.7 g, 18 
mmol, 2 eq) were added to 1:1 water:THF (40 mL) and stirred for 36 hours. The THF 
was then removed in vacuo and citric acid was added till pH 4 was reached. 19 was 
extracted in EtOAc (3x 50 mL). The organic layers were pooled and dried with 
MgSO4. (2.22 g, 7.3 mmol, 81%). Rf= 0.64 (EtOAc). 
1H-NMR: (400 MHz, 
CD3COCD3) δH: 1.39 (s, 9H, H-1), 3.17-3.29 (m, 1H, H-3a), 3.31-3.40(m, 1H, H-3b), 
3.99-4.10 (m, 1H, H-2), 7.07 (dt, J=7.0, 13.5 Hz, 2H, H-6, H-7), 7.24 (s, 1H, H-4), 
7.39 (d, J=8.0 Hz, 1H, H-8), 7.64 (d, J=8.0 Hz, 1H, H-5). 13C-NMR (125 MHz, 
CD3COCD3): 27.40 (CHCH2), 27.68 (3CH3), 59.66 (NHCH), 77.70 (CH3CH), 110.44 
(CH2C), 111.25 (CCH), 118.35 (CHC), 118.65 (CHCHCH), 121.28 (CCHCH), 123.49 
(CCHNH), 127.97 (CHC), 136.66 (NHC), 155.35 (OCO), 173.72 (CHCOOH). LRMS 









Compound 19 (2.22 g, 7.3 mmol, 1 eq), DCC (2.19 g, 9.9 mmol, 1.1 eq), HOBt (1.37 
g, 9.9 mmol, 1.1 eq) and DMAP (0.11 g, 0.9 mmol, 0.1 eq) were stirred in anhydrous 
DCM under N2 gas for 30 minutes. 1-Octylamine (1.5 mL, 1.16 g, 9 mmol, 1 eq) was 
then added and stirred for 18 hours. The solvent was removed in vacuo and EtOAc 
was added to precipitate the by product. The solvent was removed in vacuo and the 
product was purified by silica chromatography eluting with EtOAc. (2.05 g, 4.9 mmol, 
67%). Rf= 0.91 (1:1 Petroleum ether:EtOAc). 
1H-NMR: (400 MHz, MeOD) δH: 0.89 
(t, J= 6.6 Hz, 3H, H-16) 1.10-1.41 (m, 21H, H-1, H-10, H-11, H-12, H-13, H-14, H-
15), 2.91-3.25 (m, 3H, H-3, H-9), 4.32-4.37 (m, 1H, H-2), 6.97-7.11 (m, 3H, H-4, H-
6, H-7), 7.32 (d, J=7.8 Hz, 1H, H-8), 7.58 (d, J=7.7 Hz, 1H, H-5). 13C-NMR (125 
MHz, MeOD): 13.07 (CH3), 22.33 (CH2), 25.16 (CH2), 26.46 (NHCHCH2CO), 27.28 
(3CH3), 28.95 (CH2), 28.99 (CH2), 31.61 (CH2), 33.38 (CH2), 39.05 (NHCH2), 55.74 
(NHCH), 79.20 (CH3CH), 109.63 (CH2C), 110.87 (CCH), 118.26 (CHC), 118.37 
(CHCHCH), 121.04 (CCHCH), 123.14 (CCHNH), 127.40 (CHC), 136.66 (NHC), 









Compound 20 was stirred in HCl (4 M)/dioxane (4 mL) and stirred for 3 hours under 
N2. The solvent was removed in vacuo and water was added (50 mL). The pH was 
adjusted to 10 with Na2CO3 and then extracted with ethyl acetate (3 x 50 mL). The 
organic layers were combined and dried with MgSO4. The solvent was removed under 
reduced pressure. (1.48 g, 4.7 mmol, 96%). Rf= 0.49 (1:9 EtOAc:MeOH). 
1H-NMR: 
(400 MHz, MeOD) δH: 0.89 (t, J= 6.5 Hz, 3H, H-15) 1.12-1.49 (m, 12H, H-9, H-10, 
H-11, H-12, H-13, H-14,), 2.89-2.96 (m, 2H, H-8), 3.16 (dd, J=8.5, 2.5 Hz, 2H, H-2), 
4.13-4.18 (m, 1H, H-1), 6.99-7.10 (m, 3H, H-3, H-5, H-6), 7.40 (d, J=8.0 Hz, 1H, H-
7), 7.59 (d, J=8.0 Hz, 1H, H-4). 13C-NMR (125 MHz, MeOD): 13.55 (CH3), 24.87 
(CH2), 25.63 (CH2), 26.88 (NHCHCH2CO), 29.21 (CH2), 29.41 (CH2), 29.77 (CH2), 
30.54 (CH2), 38.49 (NHCH2), 65.50 (NH2CH), 111.19 (CCH), 111.52 (CH2C), 118.43 
(CHC), 118.80 (CHCHCH), 121.03 (CCHCH), 123.59 (CCHNH), 127.98 (CHC), 










Compound 21 (0.25 g, 0.8 mmol, 1 eq), Fmoc-Arg-OH (0.35 g, 0.9 mmol, 1.1 eq), 
HATU (0.45 g 1.1 mmol, 1.4 eq) and DIPEA (0.7 mL, 3.2 mmol, 4 eq) were stirred in 
THF (6 mL) under N2 for 18 hours. The solvent was removed in vacuo. The resulting 
oil was stirred in 20% piperidine in DCM (10 mL) for 3 hours. The solvent was 
removed in vacuo. The sample was then purified by RP-HPLC using Synergi™ 4 µm 
Polar-RP 80 Å and an elution gradient of H2O + 0.1% TFA /MeCN + 0.1% TFA (70:30 
to 0:100) over 30 minutes with a flow rate of 2 mL/min. The fractions were pooled 
and lyophilized. 1H-NMR: (400MHz, MeOD) δH: 0.90 (t, 3H, J=6.6 Hz, H-1), 1.06-
1.40 (m, 12H, H-2, H-3, H-4, H-5, H-6, H-7), 1.53-1.65 (m, 2H, H-12), 1.84-1.93 (m, 
2H, H-11), 2.81-3.23 (m, 6H, H-8, H-13, H-14) 3.85 (dt, 1H, J= 15.5, 21.7 Hz, H-9), 
4.69 (dt, 1H, J= 14.0, 20.1 Hz, H-10), 7.01 (t, 1H, J=7.6 Hz, H-17), 7.09 (t, 1H, J=7.6 
Hz, H-18), 7.13 (s, 1H, H-15), 8.15 (d, 1H, J=8.2 Hz, H-16), 8.49 (d, 1H, J=8.0 Hz, H-
19). 13C-NMR (125 MHz, MeOD): 13.03(CH3), 22.31 (CH2), 23.36 (CHCH2), 26.50 
(CH2CH2), 27.93 (CH2), 28.25 (CH2), 28.91 (CH2), 28.96 (CHCH2), 28.97 (CH2), 
31.06 (CH2), 39.18 (CH2),  40.44 (CH2NH),54.72 (COCH), 82.46 (NHCOCH), 109.4 
(CH2C), 110.98 (NHCCH), 117.89 (CCH), 118.54 (CCHCH), 121.20 (NHCCHCH), 
123.44 (CCHNH), 127.24 (CC), 136.69 (NHC), 157.35 (NHCNH), 168.22 (NHCO), 
172.12 (NHCO). LRMS m/z (ESI) 472.4 [M+H]+. LRMS m/z (ESI): 472.34 [M+H]+. 
HRMS m/z (ESI): calculated for C25H42N7O2









Compound 21 (0.09 g, 0.28 mmol, 1 eq), Fmoc-Lys(Boc)-OH (0.13 g, 0.28 mmol, 1 
eq) and HATU (0.14g, 0.39 mmol, 1.4 eq) and DIPEA (0.19 mL, 0.15 g, 1.12 mmol, 
4 eq) were dissolved in anhydrous DCM (20 mL). The resulting solution was stirred 
for 18 hours. The reaction mixture was washed with Na2CO3 (3x20 mL) and citric acid 
(3x20 mL) and then dried with MgSO4. The solvent was removed in vacuo and the 
product was purified by silica chromatography eluting with EtOAc. (0.12 g, 0.15 
mmol, 53%). Rf= 0.45 (2:3 petroleum ether:EtOAc). 
1H-NMR: (400 MHz, MeOD) 
δH: : 0.87 (t, 3H, J=7.0 Hz, H-1), 1.05-1.31 (m, 14H, H-2, H-3, H-4, H-5, H-6, H-7, H-
17), 1.36-1.41 (m, 2H, H-18) 1.43 (s, 9H, H-20), 1.50-1.65 (m, 2H, H-16), 3.04 (dd, 
J=8.5, 2.5 Hz, 2H,, H-10), 3.06 (t, J= 7.0 Hz, 1H, H-8), 3.13-3.19 (m, 1H, H-19), 4.19 
(t, J= 7.0 Hz, 1H, H-27), 4.26 (t, J=7.0 Hz, 1H, H-26), 4.34 (d, J=7.0 Hz, 2H, H-21), 
4.59 (t, J=7.0 Hz, 1H, H-9), 7.00 (t J=7.5 Hz, 1H, H-14), 7.05 (t, J=7.5 Hz, 1H, H-13), 
7.08 (s, 1H, H-11), 7.28 (d, J=8.0 Hz, 1H, H-12), 7.32 (t, J=7.5 Hz, 2H, H-23), 7.40 ( 
t, J=7.5 Hz, 2H, H-24), 7.56 (d, J=8.0 Hz, 1H, H-15), 7.65 (d, J= 7.5 Hz, 2H, H-22), 
7.87 (d, J=7.5 Hz, 2H, H-25). 13C-NMR: (125 MHz, MeOD): 13.05(CH3), 22.30 
(CH2), 22.55 (CH2CH2), 26.45 (CHCH2), 27.23 (CHCH2), 27.41 (OCCH3), 28.61 
(CHCHCH2), 28.90 (CH2), 28.95 (CH2), 29.35 (CH2), 30.94 (CH2), 31.59 (CH2), 39.18 
(CH2),  39.60 (CH2NH), 46.99 (CH2CC), 54.17 (NHCOCH), 55.71 (COCH), 66.70 
(NHCOOCH2), 78.48 (OCCH3), 109.42 (CH2C), 110.88 (NHCCH), 118.02 (CCH), 
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118.48 (CCHCH), 119.57 (CHCHCHCH), 121.07 (NHCCHCH), 123.15 (CCHNH), 
124.86 (CHCHCHCH), 127.44 (CC), 136.61 (NHC), 143.92 (CH2CC), 155.15 
(NHCOO), 157.42 (NHCOOCH2), 172.08 (NHCO), 173.22 (NHCO). 126.80 
(CHCHCHCH), 127.44 (CHCHCHCH). LRMS m/z (ESI) 788.5 [M+H]+. HRMS m/z 
calculated for C45H60N5NaO6










23 (0.12 g, 0.15 mmol) was dissolved in 20% piperidine in DCM (10 mL) and stirred 
for 1h. DCM (40 mL) was then added to the reaction mixture which was then washed 
with NaHCO3
 (3 x 50 mL). The solution was dried with MgSO4 and the solvent 
removed in vacuo. The resulting yellow oil was stirred in HCl (4 M)/dioxane (4 mL) 
and stirred for 3 hours under N2. The solvent was removed in vacuo. The sample was 
then purified by RP-HPLC using Synergi™ 4 µm Polar-RP 80 Å and an elution 
gradient of H2O + 0.1% TFA /MeCN + 0.1% TFA (70:30 to 0:100) over 30 minutes 
with a flow rate of 2 mL/min. The fractions were pooled and lyophilized. 1H-NMR: 
(400 MHz, MeOD) δH: : 0.90 (t, 3H, J=6.5 Hz, H-1), 1.03-1.13 (m, 2H, H-17), 1.15-
1.33 (m, 10H, H-2, H-3, H-4, H-5, H-6), 1.40-1.54 (m, 2H, H-7) 1.64-1.74 (s, 2H, H-
19), 1.83-1.90 (m, 2H, H-16), 2.95 (t, J=6.5 Hz, 2H, H-10), 3.16 (dd, J=8.5, 2.5 Hz, 
2H, H-10), 4.19 (t, J= 7.0 Hz, 1H, H-20) 4.62 (t, J=7.0 Hz, 1H, H-9), 7.01 (t J=7.5 Hz, 
1H, H-14), 7.05-7.13 (m, 2H, H-11, H-13), 7.34 (d, J=8.0 Hz, 1H, H-12), 7.75 (d, J=8.0 
Hz, 1H, H-15). 13C-NMR : (125 MHz, MeOD): 13.54 (CH3), 21.03 (CH2CH2), 22.31 
(CH2), 26.46 (CH2), 26.62 (CHCH2), 27.87 (CHCHCH2), 28.60 (CH2), 28.91 (CH2), 
28.96 (CH2), 30.62 (CH2), 31.60 (CHCH2), 38.81 (CH2), 39.29 (CH2NH2), 52.15 
(NHCOCH),54.79 (COCH), 109.13 (CH2C), 110.97 (NHCCH), 117.90 (CCH), 
118.48 (CCHCH), 121.12 (NHCCHCH), 123.27 (CCHNH), 127.26 (CC), 136.68 
(NHC), 168.35 (NHCO), 172.04 (NHCO). LRMS m/z (ESI) 444.5 [M+H]+. HRMS 
m/z calculated for C25H42N5O2
+ [M+H]+: 444.3333 found 444.3335. 
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 Boc- Gly-OH (2.0 g, 11.0 mmol, 1 eq), EDC.HCl (2.2 g, 12.1 mmol, 1.1 eq) and HOBt 
(1.6 g, 12.1 mmol, 1.1 eq) were stirred in anhydrous DCM (10 mL) under N2 gas for 
30 minutes. 1-Octylamine (1.8 mL, 1.4 g, 11.0 mmol, 1 eq) was then added and stirred 
for 18 hours. DCM (40 mL) was added and then was washed three times with water 
(50 mL). The organic layer was dried over MgSO4 and the solvent was removed in 
vacuo. The product was purified by silica chromatography eluting with EtOAc. (2.1 g, 
7.4 mmol, 67%). Rf= 0.91 (1:1 Petroleum ether:EtOAc). 
1H-NMR: (400 MHz, 
MeOD) δH: 0.89 (t, J= 6.6 Hz, 3H, H-1) 1.10-1.41 (m, 12H, H-2, H-3, H-4, H-5, H-6, 
H-7), 1.42 (s, 9H, H-10), 2.91-3.02 (t, 2H, J= 7.0 Hz, H-8), 3.82 (s, 2H, H-9). 13C-
NMR (125 MHz, MeOD): 28.40 (3CH3), 80.01 (CH3CH), 156.92 (OCO), 45.54 
(NHCH2), 162.82 (CH2CONH), 39.05 (NHCH2), 31.61 (CH2), 25.16 (CH2), 28.95 
(CH2), 28.99 (CH2), 33.38 (CH2), 22.33 (CH2), 13.07 (CH3). LRMS m/z (ESI): 287.3. 








25 (0.80 g, 2.7 mmol) was stirred in 4N HCl in dioxane (3 mL) for 4 hours. The solvent 
was removed in vacuo. (0.50 g, 2.7 mmol, 98%). Rf = 0.33 (1:9 MeOH:EtOAc). 
1H-
NMR: (400 MHz, MeOD) δH: 0.90 (t, J= 6.6 Hz, 3H, H-1) 1.13-1.39 (m, 12H, H-2, 
H-3, H-4, H-5, H-6, H-7), 2.90-3.00 (t, 2H, J= 7.0 Hz, H-8), 3.84 (s, 2H, H-9). 13C-
NMR (125 MHz, MeOD): 12.71 (CH3), 22.33 (CH2), 25.16 (CH2), 28.95 (CH2), 28.99 
(CH2), 31.61 (CH2), 33.38 (CH2), 38.52 (NHCH2), 42.14 (NH2CH2), 169.21 









14 (1.0 g, 2.9 mmol, 1 eq), HBTU (1.2 g, 3.2 mmol, 1.1 eq), 26 (0.59 g, 3.2 mmol, 1.1 
eq) and DIPEA (0.94 mL, 0.74 g, 5.8 mmol, 2 eq) were stirred in anhydrous DCM (10 
mL) under N2 gas for 18 hours. DCM (40 mL) was added and then washed three times 
with water (50 mL). The organic layer was dried over MgSO4 and the solvent removed 
in vacuo. The resulting residue was applied to a silica column and the product was 
eluted with EtOAc.  Rf = 0.76 (EtOAc). (0.67 g, 1.31 mmol, 39 %). 
1H-NMR: (400 
MHz, MeOD) δH: 0.89 (t, J= 6.6 Hz, 3H, H-1) 1.13-1.39 (m, 12H, H-2, H-3, H-4, H-
5, H-6, H-12), 1.45 (s, 9H, H-16), 1.48 (s, 9H, H-15), 1.50-1.59 (m, 2H, H-7), 1.65-
1.78 (m, 2H, H-13), 1.83-1.99 (m, 2H, H-11), 2.89-3.02 (t, 2H, J= 7.0 Hz, H-8), 3.20 
(m, 2H, H-14), 3.82 (s, 2H, H-9) 4.44 (m, 1H, H-10). 13C-NMR (125 MHz, MeOD): 
12.71 (CH3), 22.31 (NHCH2CH2CH2), 22.71 (CH2), 25.26 (CH2), 26.53 (CH2CH2CH), 
27.36, 27.41 (3CH3), 28.95 (CH2), 29.00 (NHCH2CH2) 29.24 (CH2), 30.50 (NHCH2), 
31.59 (CH2), 33.36 (CH2), 37.47 (NHCH2), 42.13 (CONHCH2), 55.49 (NHCH), 79.40, 
79.42 (CH3C), 157.01, 157.25 (COCONH), 170.04 (CH2CONH), 174.59 (CHCO). 
LRMS m/z (ESI): 537.4 [M+Na]+. HRMS m/z (ESI): calculated for C26H50N4NaO6
+ 









 27 (0.67 g, 1.31 mmol) was stirred in 4N HCl in dioxane (3 mL) for 4 hours. The 
solvent was removed in vacuo. (0.39 g, 1.25 mmol, 95%). Rf = 0.22 (1:9 
MeOH:EtOAc). 1H-NMR: (400 MHz, MeOD) δH: 0.89 (t, J= 6.6 Hz, 3H, H-1) 1.13-
1.39 (m, 12H, H-2, H-3, H-4, H-5, H-6, H-12), 1.42-1.55 (m, 2H, H-7), 1.63-1.74 (m, 
2H, H-13), 1.80-1.89 (m, 2H, H-11), 2.72 (m, 2H, H-14), 2.89-3.03 (t, 2H, J= 7.0 Hz, 
H-8), 3.79 (s, 2H, H-9) 4.45 (m, 1H, H-10). 13C-NMR (125 MHz, MeOD): 13.21 
(CH3), 22.71 (CH2), 22.86 (NHCH2CH2CH2), 25.26 (CH2), 26.24 (CH2CH2CH), 28.95 
(CH2), 29.24 (CH2), 29.40 (NHCH2CH2) 31.92 (CH2), 33.36 (CH2), 35.62 (NHCH2), 
42.52 (NH2CH2), 43.35 (CONHCH2), 53.09 (NH2CH), 170.02 (CH2CONH), 172.33 
(CHCO). LRMS m/z (ESI): 315.4 [M+Na]+. HRMS m/z (ESI): calculated for 
C16H35N4O2




7.2 Peptidomimetic 1 




2-Hydroxy-4-nitrobenzoic acid (1.7 g, 9.28 mmol) was dissolved in MeOH (15 mL) 
and cooled to 0 °C. SOCl2 (1 mL, 1.65 g, 1.5 eq) was added dropwise to the reaction 
mixture. The reaction mixture was refluxed for 18 hours. MeOH was removed under 
high vacuum and the resulting solid was dissolved in EtOAc (75 mL) and washed 3 
times with water (75 mL). The organic layer was dried with MgSO4 and removed under 
high vacuum. (1.43 g, 7.26 mmol, 78%). Rf = 0.60 (3:7/EtOAc:petroleum ether). 
1H-
NMR: (400 MHz, MeOD) δH: 3.94 (s, 1H, H-1), 7.59 (d, 1H, J=8.7 Hz, H-3), 7.73 (s, 
1H, H-4), 8.10 (d, 1H, J=8.7 Hz, H-3). 13C-NMR (125 MHz, MeOD): 51.84 (CH3O), 
119.73 (COHCH), 120.43 (CCHCH), 125.13 (CCHCH), 136.55 (CNO2), 137.84 









Compound 29 (1.43 g, 7.26 mmol, 1 eq), 3-(2-bromoethyl)indole (1.78 g, 8 mmol, 1.1 
eq), Cs2CO3 (4.73 g, 14.5 mmol, 2 eq) were stirred in DMF (6 mL) at 70 °C for 20 
hours. The reaction mixture was taken up in EtOAc (75 mL) and washed 3 times with 
Na2CO3 sat. (75 mL). The organic layer was dried with MgSO4 and dried under high 
vacuum. Silica column chromatography was carried out and the product was eluted 
with 2:8/EtOAc:petroleum ether. (0.51 g, 1.5 mmol, 20%). Rf = 0.41 
(3:7/EtOAc:petroleum ether). 1H-NMR: (400 MHz, MeOD) δH: 3.19 (t, 2H, J=6.5 Hz, 
H-6), 3.86 (s, 3H, H-1), 4.33 (t, 2H, J=6.5 Hz, H-5), 6.99 (t, 1H J=7.5 Hz, H-10), 7.06 
(t, 1H, J=7.5 Hz, H-9), 7.12 (s, 1H, H-7), 7.30 (d, 1H, J=8.0 Hz, H-11), 7.55 (d, 2H, 
J=8.0 Hz, H-8, H-2), 7.66 (s, 1H, H-4), 7.71 (d, J=8.0 Hz, 1H, H-3). 13C-NMR (125 
MHz, MeOD): 24.57 (CH2CH2), 51.80 (CH3O), 70.01 (COCH2), 110.19 (CH2C), 
110.84 (NHCCH), 115.10 (COHCH2), 118.38 (CHCHCH), 117.74 (CHCHC), 120.94 
(CCHCH), 122.91 (CCHCH), 124.20 (CCH), 124.51 (CCHCH), 127.24 (CHC), 









Compound 30 (0.51 g, 1.5 mmol, 1 eq), and Pd/C (0.13 g, 0.8 eq), were stirred in 
MeOH (10 mL) overnight under H2 and then filtered. Solvent was removed under high 
vacuum. (0.43 g, 1.38 mmol, 92%). Rf = 0.23 (1:1/EtOAc:petroleum ether). 
1H-NMR: 
(400 MHz, MeOD) δH: 3.27 (t, 2H, J=6.8 Hz, H-6), 3.81 (s, 3H, H-1), 4.28 (t, 2H, 
J=6.8 Hz, H-5), 6.66 (d, 1H, J=8.1 Hz, H-3), 7.02 (t, 1H, J=7.4 Hz, H-10), 7.10 (t, 1H, 
J=7.5 Hz, H-9), 7.16 (s, 1H, H-7), 7.34 (d, 1H, J=8.0 Hz, H-11), 7.42-7.46 (m, 2H, H-
2, H-4) 7.61 (d, 1H, J=7.8 Hz, H-11). 13C-NMR (125 MHz, MeOD): 24.90 (CH2CH2), 
50.69 (CH3O), 68.93 (COCH2), 110.89 (NHCCH), 111.03   (CH2C), 111.95 (COCH), 
112.55 (CCHCH), 117.57 (COCCH), 117.80 (CHCHC), 118.30 (CHCHCH),120.93 
(CCHCH), 122.34 (CCHCH), 123.95 (CCH), 127.84 (CHC), 129.91 (NHC), 143.10 










Fmoc-Arg-OH (0.54 g, 1.38 mmol, 1eq) was dissolved in THF (5 mL) and cooled to 
0°C. SOCl2 (0.3 mL, 0.49 g, 4.14 mmol, 3 eq) was added dropwise and the reaction 
was then refluxed for 2 hours. The reaction mixture was concentrated and the SOCl2 
was removed under high vacuum. The resulting brown oil was dissolved in THF (5 
mL) and to this 31 (0.43 g, 1.38 mmol, 1 eq) and TEA (0.5 mL) was added and the 
reaction mixture was stirred for 18 hours. The reaction mixture was concentrated under 
high vacuum. The sample was then purified by RP-HPLC using Synergi™ 4 µm Polar-
RP 80 Å and an elution gradient of H2O + 0.1% TFA /MeCN + 0.1% TFA (100:0 to 
0:100) over 30 minutes with a flow rate of 2 mL/min. The fractions containing the 
desired compound were pooled and lyophilized.  LRMS m/z (ESI): 689.4 [M+H]+. 
HRMS m/z (ESI): calculated for C39H40N6O6 [M+Na]
+: 689.3009 found 689.3080.  






(S)-2-(((Benzyloxy)carbonyl)amino)-5-((tert-butoxycarbonyl)amino) pentanoic acid 




Reaction mixture 1: Orn•HCl (2 g, 15 mmol, 2eq) was stirred in 2M NaOH (20 mL), 
to this a solution of Cu(CH3COO)2•H2O (1g, 7.5 mmol, 1eq) in water (10 mL) was 
added. This was followed by the addition of Boc2 (3.1 g, 9.75 mmol, 1.3 eq) dissolved 
in acetone (40 mL) After stirring for 24 hours an further volume of acetone (20 mL) 
was added and stirred for 20 hours. The resulting blue precipitate was collected by 
filtration, washed with acetone: water (2:1) and water, and then resuspended in acetone 
(20 mL). To this 10% (w/v) Na2CO3 (30mL) and 8-Hydroxyquinoline (1g, 6.75 mmol, 
0.9 eq) was added and stirred for 1.5 hours.  
Reaction mixture 2: In a separate flask a solution of N-hydroxysuccinimide (0.8 g, 6.75 
mmol, 0.9 eq) in water (10 mL) was stirred at -10˚C. To this Na2CO3 (0.35 g, 6.75 
mmol 0.9 eq) was added followed by the addition of benzyl chloroformate (1.15 g, 
6.75 mmol, 0.9 eq) in acetone (10 mL) and stirred at -10˚C for 0.5 hours.  
Reaction mixture 1 was added to reaction mixture 2 and stirred at room temperature 
for 1.5 hours. The copper quinolinate precipitate (green) was filtered off and washed 
with water. The filtrate and washings were combined and the acetone was removed in 
vacuo. The resulting aqueous solution was washed with diethyl ether (3x 80 mL) and 
then acidified to pH 3 using HCl. This was then washed with ethyl acetate (3 x 80 mL). 
The combined organic layers were dried using MgSO4 and concentrated in vacuo. The 
resulting green oil was purified using silica chromatography, eluting the product with 
ethyl acetate.(adapted from literature reference165). (0.51 g, 10 mmol, 60%). Rf = 0.20 
(1:4 MeOH:EtOAc). 1H-NMR: (400 MHz, MeOD) δH: 1.42 (s, 9H, H-1), 1.50-1.70 
(m, 2H, H-4), 1.79-1.91 (m, 2H, H-3) 3.05 (t, 2H, J=6.5 Hz, H-2), 4.09-4.19 (m, 1H, 
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H-5), 5.09 (s, 2H, H-6), 7.25-7.38 (m, 5H, H-7, H-8, H-9). 13C-NMR (125 MHz, 
MeOD): 26.07 (NHCH2CH2), 27.38 (3CH3), 28.66 (CH2CH2CH2), 39.44 (NHCH2), 
53.42 (CHNH), 66.21 (OCH2), 78.62 (C), 127.39 (CHCHCH), 127.58 (CCH), 128.06 
(CCHCH), 136.76 (CH2C), 156.82 (CO), 157.26 (CHCO), 174.06 (NHCO). LRMS 








3-hydroxy-4-nitrobenzoic acid (1.00 g, 5.5 mmol, 1 eq), DCC (1.23 g, 6.1 mmol, 1.1 
eq) and DMAP (0.07 g, 0.6 mmol, 0.1 eq) were dissolved in anhydrous THF and stirred 
under N2 for 30 minutes. 1-Octylamine (0.71 g, 0.92 mL, 5.5 mmol, 1 eq) was then 
added and stirred for 18h. The solvent was removed in vacuo and the resulting oil was 
dissolved in EtOAc (50 mL) and washed with NaHCO3 (3 x 50 mL). The organic layer 
was dried with MgSO4. The white precipitate (DCC by-product) was removed by 
filtration. The solvent was removed in vacuo. Silica column chromatography was 
carried out and the product was eluted with 1:1/EtOAc:petroleum ether. (0.81 g, 4.1 
mmol, 75%). Rf = 0.54 (3:7/EtOAc:petroleum ether). 
1H-NMR: (400 MHz, 
CD3COCD3) δH: 0.87 (t, 3H, J=5.5 Hz, H-1), 1.21-1.38 (m, 10H, H-2, H-3, H-4, H-5, 
H-6), 1.61 (q, 2H, J=6.0 Hz, H-7), 3.40 (q, 2H J=6.5, 6.5Hz, H-8), 7.51 (d, 1H, J=9.0 
Hz, H-9), 7.62 (s, 1H, H-10), 8.17 (d, 1H, J=9 Hz, H-11). 13C-NMR (125 MHz, 
CD3COCD3): 13.44 (CH3), 26.81 (CH2), 28.36 (CH2), 29.10 (CH2), 29.29 (CH2), 29.52 
(CH2), 31.67 (CH2), 39.80 (CH2NH), 118.57 (CHCHNO2), 118.62 (CHCHNO2), 









Compound 34 (1.00 g, 5.5 mmol, 1 eq), 3-(2-Bromoethyl)indole (1.30 g, 6.0 mmol, 
1.2 eq) and K2CO3 (1.25 g, 9.0 mmol, 1.5 eq) were stirred in anhydrous DMF (10 mL) 
and stirred under N2 for 18 h. EtOAc (50 mL) and washed with NaHCO3 (3 x 50 mL). 
The organic layer was dried with MgSO4. The solvent was removed in vacuo. Silica 
column chromatography was carried out and the product was eluted with 
1:19/EtOAc:petroleum ether.  (0.8 g 2.0 mmol, 36%). Rf = 0.48 (2:3/EtOAc:petroleum 
ether). 1H-NMR: (400 MHz, CD3COCD3) δH: 0.88 (t, 3H, J=6.0 Hz, H-1), 1.22-1.38 
(m, 10H, H-2, H-3, H-4, H-5, H-6), 1.55-1.61 (m, 2H, H-7), 3.29 (t, 2H J=6.5 Hz, H-
13), 3.39 (dd, 2H, J= 6.0, 12.5 Hz, H-8), 4.44 (t, 2H, J= 7.0 Hz, H-12), 7.09 (dt, 2H, 
J= 7.0, 14.5 Hz, H-16, H-17), 7.30 (s, 1H, H-14), 7.42 (d, 1H, J= 8.0 Hz, H-10), 7.63 
(dd, 2H, J= 8.0, 25.5 Hz, H-15, H-18), 7.79 (s, 1H, H-11), 7.51 (d, 1H, J=9.0 Hz, H-
9). 13C-NMR (125 MHz, CD3COCD3): 13.54 (CH3), 24.83 (CH2), 26.86 (CH2), 29.12 
(CH2), 29.22 (CH2), 29.41 (CH2), 31.70 (CH2), 32.50 (COCH2CH2), 39.92 (CH2NH), 
70.04 (COCH2), 110.55 (CH2C), 111.35 (NHCCHCH), 113.51 (COCH), 118.32 
(CHCHCH), 118.78 (CHCHCHCH), 119.04 (CCHCH), 121.30 (NHCCHCH), 123.40 
(CCHNH), 124.86 (CCHCH), 127.59 (CCH), 136.68 (NHCCH), 140.05 (COC), 









 Compound 35 (1.1 g, 2.5 mmol, 1 eq), and Pd/C (0.26 g, 2.0 mmol, 0.8 eq), were 
stirred in MeOH (10 mL) overnight under H2 and then filtered. Solvent was removed 
under high vacuum. (0.94 g, 2.3 mmol, 92%). Rf = 0.20 (9:1/EtOAc:MeOH). 
1H-
NMR: (400 MHz, CD3COCD3) δH: 0.89 (t, 3H, J=6.0 Hz, H-1), 1.15-1.31 (m, 10H, 
H-2, H-3, H-4, H-5, H-6), 1.52-1.59 (m, 2H, H-7), 3.30 (t, 2H J=6.5 Hz, H-13), 3.41 
(dd, 2H, J= 6.0, 12.5 Hz, H-8), 4.44 (t, 2H, J= 7.0 Hz, H-12), 6.97 (s, 1H, H-11), 7.10 
(dt, 2H, J= 7.0, 14.5 Hz, H-16, H-17), 7.30 (s, 1H, H-14), 7.42 (d, 1H, J= 8.0 Hz, H-
10), 7.63 (dd, 2H, J= 8.0, 25.5 Hz, H-15, H-18), 7.51 (d, 1H, J=9.0 Hz, H-9).  13C-
NMR (125 MHz, CD3COCD3): 13.05 (CH3), 24.51 (CH2), 26.85 (CH2), 29.08 (CH2), 
29.21 (CH2), 29.40 (CH2), 31.71 (CH2), 32.55 (COCH2CH2), 40.01 (CH2NH), 69.14 
(COCH2), 110.05 (CH2C), 111.58 (NHCCHCH), 113.51 (COCH), 117.61 (CCHCH), 
118.32 (CHCHCH), 118.58 (CHCHCHCH), 119.42 (CCHCH), 121.88 (NHCCHCH), 
123.45 (CCHNH), 127.90 (CCH), 136.00 (NHCCH), 139.32 (CNH2), 140.05 (COC), 
144.44 (COCH2), 165.02 (CO). LRMS m/z (ESI): 430.4 [M+Na]
+. HRMS m/z (ESI): 
calculated for C25H34N3NaO2










Fmoc-Arg-OH (0.15 g, 0.3 mmol, 1 eq) was dissolved in THF under N2 and cooled to 
0˚C. SOCl2 (80 µL, 0.13 g, 1.11 mmol, 3 eq) was added dropwise then the reaction 
was heated to reflux for 2 hours. The solvent was then removed in vacuo. The resulting 
residue was dissolved in THF and 36 (0.2 g, 0.37 mmol, 1 eq) and TEA (0.25 mL, 0.18 
g, 1.85 mmol, 5 eq) were added. The reaction mixture was stirred under N2 overnight. 
The solvent was removed in vacuo. Piperidine (20%) in DCM (The resulting oil was 
purified by RP-HPLC using Synergi™ 4 µm Polar-RP 80 Å and an elution gradient of 
H2O/MeCN (50:50 to 0:100) over 30 minutes with a flow rate of 2 mL/min. 
1H-NMR: 
(400 MHz, CD3COCD3) δH: 0.89 (t, 3H, J=6.0 Hz, H-1), 1.15-1.42 (m, 12H, H-2, H-
3, H-4, H-5, H-6, H-7), 1.55-1.67 (m, 2H, H-21), 1.77-1.89 (m, 2H, H-20), 3.14 (t, 2H 
J=6.5 Hz, H-13), 3.34 (t, 2H, J= 6.0, 12.5 Hz, H-22), 3.37 (t, 2H, J= 6.0 Hz, H-8), 3.73 
(t, 3H, J=6.5 Hz, H-19), 4.45 (t, 2H, J= 7.0 Hz, H-12), 7.11 (dt, 2H, J= 7.5, 3.5 Hz, H-
16, H-17), 7.20 (s, 1H, H-11), 7.41 (dd, 2H, J= 8.0, 4.0 Hz, H-15, H-18), 7.57 (s, 1H, 
H-14), 7.64 (d, 1H, J= 8.0 Hz, H-10), 8.15 (d, 1H, J=9.0 Hz, H-9). 13C-NMR: (125 
MHz, CD3COCD3): 13.01 (CH3), 22.35 (CH2CH2CH2NH), 22.37 (CH2), 26.01 (CH2), 
26.71 (CH2CH2CH2NH),29.02 (CH2), 29.08 (CH2), 29.35 (CH2), 31.58 (CH2), 31.99 
(COCH2CH2), 47.50 (CH2NH), 48.24 (CH2CH2CH2NH), 54.52 (COCH), 69.05 
(COCH2), 110.68 (CH2C), 111.18 (NHCCHCH), 113.47 (COCH), 117.70 (CCHCH), 
117.83 (CHCHCH), 118.57 (CHCHCHCH), 119.49 (CCHCH), 121.19 (NHCCHCH), 
122.54 (CCHNH), 127.72 (CCH), 129.32 (CNH), 131.36 (COC), 131.58 (NHCCH), 
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148.77 (COCH2), 163.99 (CO), 167.71 (NHCO). LRMS m/z (ESI): 564.3 [M+Na]
+. 
HRMS m/z (ESI): calculated for C31H46N7O3




7.3 Peptidomimetic 2 




2-Hydroxy-4-nitrobenzoic acid (1.25 g, 6.8 mmol) was dissolved in MeOH (15 mL) 
and H2SO4 conc. (0.5 mL) was added. The reaction mixture was refluxed for 18 hours. 
MeOH was removed under high vacuum and the resulting solid was dissolved in 
EtOAc (75 mL) and washed 3 times with Na2CO3 sat. (75 mL) and the organic layer 
was dried with MgSO4. (0.65 g, 3.3 mmol, 49%). Rf = 0.63 (3:7/EtOAc:petroleum 
ether). 1H-NMR: (400 MHz, MeOD) δH: 3.35 (s, 1H, H-1), 7.73 (d, 1H, J=8.7 Hz, H-
3), 7.77 (s, 1H, H-4), 8.09 (d, 1H, J=8.7 Hz, H-2). 13C-NMR (125 MHz, MeOD): 51.71 
(CH3O), 111.94 (COHCH), 112.92 (CNO2CH), 117.52 (COC) 131.08 (CHCH), 









Compound 39 (0.65 g, 3.3 mmol, 1 eq), 3-(2-bromoethyl)indole (0.81 g, 3.6 mmol, 1.1 
eq), Cs2CO3 (2.15 g, 6.6 mmol, 2 eq) were stirred in DMF (6 mL) at 60°C for 18 hours. 
The reaction mixture was taken up in EtOAc (75 mL) and washed 3 times with Na2CO3 
sat. (75 mL). The organic layer was dried with MgSO4 and dried under high vacuum. 
Silica column chromatography was carried out and the product was eluted with 
2:8/EtOAc:petroleum ether. (Adapted from literature reference167). (0.51 g, 1.5 mmol, 
45%). Rf = 0.43 (3:7/EtOAc:petroleum ether). 
1H-NMR: (400 MHz, MeOD) δH: 3.19 
(t, 2H, J=6.5 Hz, H-6), 3.82 (s, 3H, H-1), 4.27 (t, 2H, J=6.5 Hz, H-5), 6.98 (t, 1H J=7.4 
Hz, H-10), 7.06 (t, 1H, J=7.4 Hz, H-9), 7.15 (s, 1H, H-7), 7.30 (d, 1H, J=8.0 Hz, H-
11), 7.54 (d, 1H, J=7.8 Hz, H-8), 7.65-7.70 (m, 2H, H-3, H-2), 7.72 (s, 1H, H-4). 13C-
NMR (125 MHz, MeOD): 24.50  (CH2CH2), 51.57 (CH3O), 69.79 (COCH2), 107.59 
(NHCCH), 110.57 (CH2C), 110.83 (CNO2CH), 112.86 (CCH), 114.30 (CCHCH), 
117.84 (CHCHC), 118.32 (CHCHCH), 120.92 (CCHCH), 126.25 (COCCH), 127.38 
(CHC), 131.19 (CCHCH), 136.52 (NHC), 150.50 (CHCNO2), 158.20 (COCH2), 








Compound 40 (0.51 g, 1.5 mmol, 1 eq), and Pd/C (0.13 g, 0.8 eq), were stirred in 
MeOH (10 mL) overnight under H2 and then filtered through Celite. Solvent was 
removed under high vacuum. (Adapted from literature reference168). (0.23 g, 0.74 
mmol, 50%). Rf = 0.24 (1:1/EtOAc:petroleum ether). 
1H-NMR: (400 MHz, 
(CD3)2CO) δH: 3.24 (t, 2H, J=7.0 Hz, H-6), 3.74 (s, 3H, H-1), 4.38 (t, 2H, J=7.0 Hz, 
H-5), 6.24-6.28 (m, 1H, H-3), 6.37 (s, 1H, H-4), 7.02 (t, 1H, J=7.4 Hz, H-10), 7.09 (t, 
1H, J=7.4 Hz, H-9), 7.32-7.42 (m, 2H, H-7, H-2), 7.59-7.67 (m, 2H, H-8, H-11). 13C-
NMR (125 MHz, (CD3)2CO): 25.01 (CH2CH2), 50.22 (CH3O), 68.87 (COCH2), 98.10 
(CNH2CH), 105.75 (CCHCH), 107.62 (CH2C), 111.27 (NHCCH), 111.34 (COCCH), 
118.35 (CHCHC), 118.55 (CHCHCH), 121.09 (CCHCH), 123.48 (CCH), 127.72 









 Compound 40 (0.23 g, 0.74 mmol, 1 eq), was dissolved in MeOH (3 mL) and AcOH 
(40 μL, 1eq). Octanal (0.12 mL, 0.10g, 0.74 mmol, 1 eq) and NaCNBH3 (0.09g, 1.48 
mmol, 2 eq) were added and stirred for 24 hrs under N2. EtOAc (50 mL) was added 
and washed 3x with Na2CO3 (50 mL). The organic layer was dried with MgSO4 and 
concentrated under high vacuum. Silica column chromatography was carried out and 
the product was eluted with EtOAc. (Adapted from literature reference152). (0.08 g, 
0.19 mmol, 26%). Rf = 0.85 (1:1/EtOAc:petroleum ether). 
1H-NMR: (400 MHz, 
(CD3)2CO) δH: 0.86, (t, 3H, J= 6.3 Hz, H-19), 1.19-1.43 (m, 10H, H-,14, H-15, H-16, 
H-17, H-18), 1.55-1.65 (m, 2H, H-13), 3.13 (t, 2H, J=7.0 Hz, H-6), 3.25 (t, 2H, J= 7.0 
Hz, H-12), 3.74 (s, 3H, H-1), 4.22 (t, 2H, J=7.0 Hz, H-5), 6.22 (d, 1H, J= 8.0 Hz, H-
2), 6.27 (s, 1H, H-7), 7.06 (dt, 2H, J=, 7.3 10.0 Hz, H-9, H-10), 7.36-7.41 (m, 2H, H-
3, H-4), 7.65 (dd, 2H, J= 8.0, 3.0 Hz, H-8, H-11). 13C-NMR (125 MHz, (CD3)2CO): 
16.15 (CH3), 25.09 (CH2CH2), 27.74 (CH2CH2CH2CH3), 29.59 (NHCH2CH2CH2), 
30.22 (CH2CH3),31.80 (CH2CH2CH3), 31.90 (CH2CH2CH2CH2), 34.31 (NHCH2CH2), 
45.48 (NHCH2), 52.85 (CH3O), 71.63 (COCH2), 98.94(CNH2CH), 106.64 (CCHCH), 
109.75 (COCCH), 113.86 (NHCCH), 114.08 (CH2C), 121.02 (CHCHC), 121.23 
(CHCHCH), 123.77 (CCHCH), 126.01 (CCH), 130.41 (CHC), 136.18 (CCHCH), 
139.15 (NHC), 156.65 (CHCNHCH2), 163.95 (COCH2), 168.54 (OCO), LRMS m/z 
(ESI): 445.4 [M+Na]+. HRMS m/z (ESI): calculated for C26H34N2NaO3
+ [M+Na]+: 
445.2462 found 445.2468.   
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Compound 41 (0.08 g, 0.19 mmol) was dissolved in MeOH (3 mL) and 6M NaOH (1 
mL) was added and refluxed overnight. The solution was acidified using HCl and the 
precipitate was collected by filtration. (0.04 g, 0.09 mmol, 50%). Rf = 0.85 (EtOAc). 
1H-NMR: (400 MHz, (CD3)2CO) δH: 0.86, (t, 3H, J= 6.2 Hz, H-19), 1.15-1.40 (m, 
10H, H-13, H-14, H-15, H-16, H-17), 1.62-1.76 (m, 2H, H-112), 3.22 (t, 2H, J=7.3 
Hz, H-11), 3.35 (t, 2H, J= 6.8 Hz, H-5), 4.50 (t, 2H, J=6.8 Hz, H-4), , 7.06 (dt, 2H, J= 
32.3, 7.3 Hz, H-8, H-9), 7.29-7.35 (m, 2H, H-2, H-3), 7.40 (d, 1H, J= 8.0 Hz, H-10) 
7.66 (d, 1H, J=8.9 Hz, H-7) 7.79 (s, 1H, H-6). 13C-NMR (125 MHz, (CD3)2CO): 13.45 
(CH3), 22.93 (CH2CH3), 22.93 (NHCH2CH2CH2), 26.76 (CH2CH2), 28.14 
(CH2CH2CH2CH2), 28.37 (CH2CH2CH2CH3), 29.06 (CH2CH2CH3), 29.52 
(NHCH2CH2), 44.74 (NHCH2), 69.42 (COCH2), 110.29 (COCCH), 111.37 
(CNH2CH), 111.90 (NHCCH), 114.14 (CCH), 118.29 (CCHCH), 118.73 (CHCHC), 
121.37 (CHCHCH), 123.24 (CCHCH), 127.54 (CHC), 132.21 (CCH), 133.89 
(CCHCH), 139.33 (CNH), 140.98 (NHCCH), 164.01 (COCH2), 164.51 (OCO). 
LRMS m/z (ESI): 431.4 [M+Na]+. HRMS m/z (ESI): calculated for C25H32N2NaO3
+ 




7.4 Peptidomimetic 3 




4-Bromo-2-hydroxybenzoic acid (0.5 g, 2.3 mmol) was dissolved in anhydrous MeOH 
(10 mL), stirred and cooled to 0˚C. SOCl2 (0.5 mL) was added dropwise and then the 
reaction mixture was heated to reflux for 16h. The solvent was removed in vacuo. 
(0.52 g, 2.3 mmol, 99%). Rf = 0.58 (3:7/EtOAc:petroleum ether). 
1H-NMR: (400 
MHz, MeOD) δH: 3.94 (s, 3H, H-1), 7.04 (d, 1H, J=8.5 Hz, H-3), 7.15 (s, 1H, H-4), 
7.72 (d, 1H, J=9.0 Hz, H-2). 13C-NMR (125 MHz, MeOD): 51.56 (CH3O), 120.42 









Compound 43 (1.0 g, 4.35 mmol, 1.1 eq), 1-octyne (0.60 mL, 0.44 g, 3.95 mmol, 1 
eq), Pd(PPh3)4 (0.45 g, 0.39 mmol, 0.1 eq), CuI (0.07 g, 0.39 mmol, 0.1 eq) and DIPEA 
(2.75 mL, 2.04 g, 15.8 mmol, 5 eq) were added to anhydrous THF under N2 and 
refluxed for 18 hours. The solvent was removed in vacuo and the product was 
dissolved in petroleum ether. This was filtered and applied to a silica column and the 
product was eluted with petroleum ether. (0.91 g, 3.5 mmol, 89%). Rf = 0.68 
(Petroleum ether). 1H-NMR: (400 MHz, MeOD) δH: 0.91 (t, 3H, J=6.0 Hz, H-1), 1.22-
1.39 (m, 4H, H-2, H-3), 1.40-1.48 (m, 2H, H-4), 1.50-1.64 (m, 2H, H-5), 2.40 (t, 2H, 
J= 7.0 Hz, H-6), 3.92 (s, 3H, H-10), 6.85 (d, 1H, J= 8.0 Hz, H-8), 6.89 (s, 1H, H-7), 
7.72 (d, 1H, J= 8.0 Hz, H-9). 13C-NMR (125 MHz, MeOD): 13.04 (CH3), 18.69 (CH2), 
22.25 (CH2), 28.27 (CH2), 28.32 (CH2), 31.11 (CH2), 51.51 (CCOOCH3), 79.46 
(CH2CCC), 93.53 (CH2CCC), 111.38 (COHCCH), 119.50 (CCHCOH), 122.05 









 Compound 44 (0.23 g, 0.92 mmol, 1 eq), 3-(2-bromoethyl)indole (0.25 g, 1.11 mmol, 
1.2 eq) and CsCO3 (0.58 g, 1.84 mmol, 2 eq) were refluxed in anhydrous acetone for 
18 hours. The solvent was removed in vacuo and the resulting oil was dissolved in 
EtOAc. This was washed three times with Na2CO3. The organic layer was dried over 
MgSO4 and the solvent was removed in vacuo. Silica column chromatography was 
carried out and the product was eluted with 1:4/EtOAc:petroleum ether. (0.20 g, 0.47 
mmol, 52%). Rf = 0.32 (1:4/EtOAc:petroleum ether). 
1H-NMR: (400 MHz, MeOD) 
δH: 0.89 (t, 3H, J=5.5 Hz, H-1), 0.92-1.39 (m, 8H, H-2, H-3, H-4, H-5) 2.43 (t, 2H, 
J=7.0 Hz, H-6), 3.28 (t, 2H, J=6.5 Hz, H-12), 3.84 (s, 3H, H-10), 4.33 (t, 2H, J= 5.5 
Hz, H-11), 6.99-7.08 (m, 2H, H-8, H-16) 7.09-7.15 (m, 2H, H-13, H-15), 7.35-7.43 
(m, 2H, H-7, H-17), 7.65-7.70 (m, 2H, H-9, H-14). 13C-NMR (125 MHz, MeOD): 
13.45 (CH3), 22.37 (CH2), 25.05 (CH2), 28.41 (COCH2CH2), 28.43 (CH2), 31.52 
(CH2), 31.81 (CH2), 51.21 (CCOOCH3), 69.32 (COCH2CH2), 79.93 (CC), 102.1 (C), 
111.25 (NHCCH), 113.75 (CH2C), 116.12 (CCHCO), 118.35 (CHCHCHCH), 118.62 
(CHCHCHCH), 120.28 (CCHCH), 121.17 (NHCCHCH), 123.18 (CCHNH), 127.72 
(CHC), 128.16 (CHCH), 129.02 (CCC), 131.14 (CCHCH), 142.96 (NHC), 158.13 
(CCHCO), 165.99 (CCOOCH3). LRMS m/z (ESI): 426.3 [M+Na]
+. HRMS m/z (ESI): 
calculated for C25H34N3NaO3








 Compound 45 (0.20 g, 0.47 mmol, 1 eq), was stirred in THF (1 mL), MeOH (1 mL), 
water (1 mL) and 6M NaOH (0.25 mL) at 60˚C for 2 hours. The solvent was removed 
in vacuo and water (40 mL) was added. This was then acidified to pH 3 and washed 
with EtOAc (3 x 40 mL). The organic fractions were combined and dried over MgSO4. 
(0.17 g, 0.44 mmol, 95%). Rf = 0.49 (EtOAc). 
1H-NMR: (400 MHz, (CD3)2CO) δH: 
0.90 (t, 3H, J=5.5 Hz, H-1), 1.09-1.66 (m, 8H, H-2, H-3, H-4, H-5) 2.44 (t, 2H, J=7.0 
Hz, H-6), 3.37 (t, 2H, J=6.5 Hz, H-10), 4.53 (t, 2H, J= 5.5 Hz, H-11), 7.08 (dt, J=7.0, 
15.5 Hz, 2H, H-14, H-15), 7.22 (s, 1H, H-12), 7.35 (s, 1H, H-7), 7.42 (d, J=8.0 Hz, 
1H, H-8), 7.62 (d, J= 8.0 Hz, 1H, H-16), 7.87 (d, J=8.0 Hz, 1H, H-13), 7.94 (d, J=8.0 
Hz, 1H, H-9). 13C-NMR (125 MHz, (CD3)2CO): 14.35 (CH3), 19.80 (CH2), 23.22 
(CH2), 25.92 (COCH2CH2), 29.28 (CH2), 29.32 (CH2), 32.07 (CH2), 32.41 (CH2), 
70.06 (COCH2CH2), 80.66 (CC), 94.56 (C), 111.39 (CH2C), 111.99 (NHCCH), 116.88 
(CCHCO), 119.08 (CCHCH), 119.21 (CHCHCHCH), 119.64 (CHCHCHCH),122.24 
(CHCH), 122.27 (NHCCHCH), 122.42 (CCHNH), 128.52 (CHC), 130.93 (CCC), 
133.24 (CCHCH), 137.73 (NHC), 158.72 (CCHCO), 165.81 (CCOOCH3). LRMS m/z 
(ESI): 388.4 [M-H]-. HRMS m/z (ESI): calculated for C25H26N3O3
- [M-H]-: Exact 








Compound 46 (0.25 g, 0.64 mmol, 1 eq), Arg-OtBu (0.16 g, 0.70 mmol, 1.1 eq), HATU 
(0.31 g, 0.83 mmol, 1.3 eq) and DIPEA (0.22 mL, 0.16 g, 1.28 mmol, 2 eq) were 
dissolved in DCM and stirred under N2 for 18 hours. The solvent was removed in 
vacuo. To the resulting oil HCl (4M in dioxane) (5 mL) was added under N2 and stirred 
for 4 hours. The solvent was removed in vacuo to give an orange oil. Product not 
isolated but identified by MS. LRMS m/z (ESI): 546.4 [M+H]+. HRMS m/z (ESI): 
calculated for C31H41N5O4








The crude reaction mixture of 47 (0.1 g) was added to Pd/C (0.03 g, 0.28 mmol) and 
dissolved in MeOH (2 mL) under H2 and stirred for 18 hours. The sample was then 
purified by RP-HPLC using Synergi™ 4 µm Polar-RP 80 Å and an elution gradient of 
H2O/MeCN (80:20 to 0:100) over 45 minutes with a flow rate of 2 mL/min. The 
fractions containing the product were pooled and lyophilized. 1H-NMR: (400MHz, 
(CD3)2CO) δH: 0.87 (t, 3H, J=5.5 Hz, H-1), 1.35-1.47 (m, 10H, H-2, H-3, H-4, H-5, 
H-6) 1.48 (t, 2H, J=7.0 Hz, H-7), 1.66-1.74 (m, 2H, H-19), 1.75-1.81 (m, 2H, H-20), 
3.45-3.53 (m, 2H, H-21), 2.63 (t, J= 6.0 Hz, 2H, H-12), 2.82 (t, 2H, J=7.0 Hz, H-8), 
3.37 (t, 2H, J=6.5 Hz, H-13), 4.53 (t, 2H, J= 5.5 Hz, H-11), 4.54-4.59 (m, 1H, H-22), 
6.90 (d, J=8.0 Hz, 1H, H-10), 6.98-7.04 (m, 2H, H-9, H-15), 7.15 (t, J=7.5 Hz, 1H, H-
17), 7.15 (s, 1H, H-14), 7.35 (d, J= 8.0 Hz, 1H, H-15), 7.58 (d, J= 8.0 Hz, 1H, H-18), 
7.92 (d, J= 8.0 Hz, 1H, H-11). 13C-NMR (125 MHz, (CD3)2CO): 13.02 (CH3), 21.65 
(NHCHCH2CH2), 22.36 (NHCHCH2CH2), 24.22 (CH2), 24.52 (CH2), 28.91 
(COCH2CH2), 29.11 (CH2), 30.65 (CH2), 31.06 (CH2), 35.55 (CH2), 40.43 (CH2), 
44.30 (CH2NH), 52.27 (NHCH), 68.77 (COCH2CH2), 110.47 (CH2C), 110.96 (CH2C), 
112.67 (NHCCH), 117.84 (CCH), 118.40 (CHCHCHCH), 120.84 (CHCHCHCH), 
121.14 (CHCH), 121.84 (NHCCHCH), 122.29 (CCHNH), 123.91 (CHCOC), 127.37 
(CHC), 131.13 (COCCH), 136.94 (NHC), 149.56 (CCHCO), 157.46 (NHC), 166.05 
(CCO), 173.93 (NHCHCOOH). LRMS m/z (ESI): 550.5 [M+H]+. HRMS m/z (ESI): 
calculated for C31H44N5O4
+ [M+H]+: Exact Mass: 550.3388 found 550.3394. 
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3-(2-Bromoethyl)indole (2 g, 8.9 mmol,1 eq), Boc2O (3.88 g, 17.8 mmol, 2 eq), TEA 
( 2.40 mL, 1.80 g, 1.78 mmol, 2 eq), and DMAP (0.11 g, 0.9 mmol, 0.1 eq) were added 
to DCM (40 mL) and stirred overnight. The reaction mixture was washed 3 times with 
water (40 mL). The organic layer was dried over MgSO4 and reduced in vacuo. The 
resulting residue was applied to a silica column and the product was eluted with 20:80 
EtOAc/Petroleum ether. (2.54 g, 7.9 mmol, 88%). Rf = 0.85 (20:80 EtOAc/Petroleum 
ether). 1H-NMR: (400 MHz, (CD3)2CO) δH: 1.69 (s, 9H, H-8), 3.32 (t, 2H, J= 7.5 Hz, 
H-2), 3.79 (t, 2H, J= 7.5 Hz, H-1), 7.31 (dt, 2H, J= 7.5, 24.0 Hz, H-5, H-6), 7.63-7.67 
(m, 2H, H-3, H-7), 8.16 (d, 1H, J= 8.0 Hz, H-4). 13C-NMR (125 MHz, (CD3)2CO): 
28.25 (3CH3), 29.36 (BrCHCH2), 32.81 (BrCH2), 84.32 (OCOC), 110.99 (CH2C), 
115.99 (NHCCH), 118.91 (CHCHC), 119.80 (CHCHCHCH), 123.38 (CHCHCH), 
124.62 (NHCCHCH), 125.54 (CH2CCH), 130.98 (CCHNHC), 150.29 (CO). LRMS 
m/z (ESI): 346.2 [M+Na]+. HRMS m/z (ESI): calculated for C15H18BrNNaO2 
[M+Na]+: Exact Mass: 346.0413 found 346.0406. 










Compound 34 (1.00 g, 5.5 mmol, 1 eq), 49 (2.07 g, 6.0 mmol, 1.2 eq) and K2CO3 (1.25 
g, 9.0 mmol, 1.5 eq) were stirred in anhydrous DMF (10 mL) and stirred under N2 for 
18 h. EtOAc (50 mL) and washed with NaHCO3 (3 x 50 mL). The organic layer was 
dried with MgSO4. The solvent was removed in vacuo. Silica column chromatography 
was carried out and the product was eluted with 1:19/EtOAc:petroleum ether.  (1.07 g 
2.0 mmol, 36%). Rf = 0.80 (2:3/EtOAc:petroleum ether). 
1H-NMR: (400 MHz, 
CD3COCD3) δH: 0.90 (t, 3H, J=6.0 Hz, H-1), 1.20-1.38 (m, 10H, H-2, H-3, H-4, H-5, 
H-6), 1.52-1.59 (m, 2H, H-7), 1.65 (s, 9H, H-19), 3.30 (t, 2H J=6.5 Hz, H-13), 3.38 
(dd, 2H, J= 6.0, 12.5 Hz, H-8), 4.44 (t, 2H, J= 7.0 Hz, H-12), 7.09 (dt, 2H, J= 7.0, 14.5 
Hz, H-16, H-17), 7.30 (s, 1H, H-14), 7.42 (d, 1H, J= 8.0 Hz, H-10), 7.63 (dd, 2H, J= 
8.0, 2.5 Hz, H-15, H-18), 7.79 (s, 1H, H-11), 7.51 (d, 1H, J=9.0 Hz, H-9). 13C-NMR 
(125 MHz, CD3COCD3): 15.54 (CH3), 25.00 (CH2), 26.33 (CH2), 28.27 (3CH3), 29.42 
(CH2), 29.44 (CH2), 29.90 (CH2), 31.35 (CH2), 32.50 (COCH2CH2), 40.23 (CH2NH), 
70.04 (COCH2), 75.03 (COCO), 110.55 (CH2C), 111.35 (NHCCHCH), 113.51 
(COCH), 118.32 (CHCHCH), 118.78 (CHCHCHCH), 119.04 (CCHCH), 121.30 
(NHCCHCH), 123.40 (CCHNH), 124.86 (CCHCH), 127.59 (CCH), 136.68 






carboxylate (51)  
 
 
Compound 50 (1.07 g, 2.0 mmol, 1 eq) and NaH (60 % dispersion in mineral oil) (0.4 
g, 10 mmol, 5 eq) were stirred in THF (5 mL) at 0 °C for 10 minutes and then allowed 
to come to room temperature. Benzyl bromide (mL, g, 4.0 mmol, 2 eq) was then added 
dropwise and the reaction mixture stirred for 18 hours. The THF was removed in 
vacuo. The reaction mixture was taken up in EtOAc (75 mL) and washed 3 times with 
Na2CO3 sat. (75 mL). The organic layer was dried with MgSO4 and dried under high 
vacuum. Silica column chromatography was carried out and the product was eluted 
with 1:9/EtOAc:petroleum ether. (1.23 g, 1.96 mmol, 98%). Rf = 0.80 
(1:9/EtOAc:petroleum ether). 1H-NMR: (400 MHz, MeOD) δH: 0.89 (t, 3H, J=6.0 Hz, 
H-1), 1.22-1.37 (m, 10H, H-2, H-3, H-4, H-5, H-6), 1.51-1.60 (m, 2H, H-7), 1.65 (s, 
9H, H-26), 3.32 (t, 2H J=6.5 Hz, H-13), 3.39 (dd, 2H, J= 6.0, 12.5 Hz, H-8), 4.40 (t, 
2H, J= 7.0 Hz, H-12), 5.11 (s, 2H, H-20), 7.10 (dt, 2H, J= 7.0, 14.5 Hz, H-16, H-17), 
7.30 (m, 6H, H-14, H-21, H-22, H-23), 7.42 (d, 1H, J= 8.0 Hz, H-10), 7.65 (dd, 2H, 
J= 8.0, 25.5 Hz, H-15, H-18), 7.50 (d, 1H, J=9.0 Hz, H-9), 7.81 (s, 1H, H-11). 13C-
NMR (125 MHz, MeOD): 14.90 (CH3), 24.88 (CH2), 25.90 (CH2), 27.93 (3CH3), 
29.45 (CH2), 29.89 (CH2), 29.78 (CH2), 30.50 (COCH2CH2), 32.00 (CH2), 40.29 
(CH2NH), 52.32 (NCH2C), 70.41 (COCH2), 75.01 (COCO), 110.55 (CH2C), 111.32 
(NHCCHCH), 113.50 (COCH), 118.32 (CHCHCH), 118.78 (CHCHCHCH), 119.40 
(CCHCH), 121.30 (NHCCHCH), 123.40 (CCHNH), 124.82 (CCHCH), 126.90, 
127.81, 127.92(CAr).128.22 (CCH), 136.49 (NCH2C), 136.68 (NHCCH), 140.52 








Compound 51 (1.23 g, 1.96 mmol, 1 eq), and Pd/C (0.16 g, 0.8 eq), were stirred in 
MeOH (10 mL) overnight under H2 and then filtered through Celite. Solvent was 
removed under high vacuum. (Adapted from literature reference168). (0.61 g, 1.02 
mmol, 52%). Rf = 0.33 (2:1/EtOAc:petroleum ether).
1H-NMR: (400 MHz, MeOD) 
δH: 0.90 (t, 3H, J=6.0 Hz, H-1), 1.21-1.38 (m, 10H, H-2, H-3, H-4, H-5, H-6), 1.54-
1.60 (m, 2H, H-7), 1.68 (s, 9H, H-19), 3.31 (t, 2H J=6.5 Hz, H-13), 3.41 (dd, 2H, J= 
6.0, 2.5 Hz, H-8), 4.46 (t, 2H, J= 7.0 Hz, H-12), 5.14 (s, 2H, H-20), 7.11 (dt, 2H, J= 
7.0, 10.5 Hz, H-16, H-17), 7.28 (m, 6H, H-14, H-21, H-22, H-23), 7.42 (d, 1H, J= 
8.0 Hz, H-10), 7.63 (dd, 2H, J= 8.0, 25.5 Hz, H-15, H-18), 7.51 (d, 1H, J=9.0 Hz, H-
9), 7.62 (s, 1H, H-11). 13C-NMR (125 MHz, MeOD): 15.54 (CH3), 25.00 (CH2), 
26.33 (CH2), 29.42 (CH2), 29.44 (CH2), 29.71 (3CH3), 29.90 (CH2), 31.35 (CH2), 
32.50 (COCH2CH2), 40.23 (CH2NH), 54.22 (NCH2C), 70.04 (COCH2), 75.12 
(COCO), 110.55 (CH2C), 111.20 (NHCCHCH), 113.51 (COCH), 118.34 
(CHCHCH), 119.02 (CHCHCHCH), 119.04 (CCHCH), 121.42 (NHCCHCH), 
123.82 (CCHNH), 124.86 (CCHCH), 127.61 (CCH), 127.41, 128.34, 128.67 (CAr), 
136.53 (NCH2C), 137.03 (NHCCH), 140.05 (COC), 141.47 (CNH2), 151.63 
(COCH2), 162.65 (CO), 169.00 (COCONC). LRMS m/z (ESI): 620.8 [M+Na]
+. 
HRMS m/z (ESI): calculated for C37H47N3NaO4
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Compound 38 (2.0 g, 0.01 mol, 1 eq), benzyl bromide (1.32 mL, 1.88 g, 0.011 mol, 
1.1 eq), Cs2CO3 (6.5 g, 0.02 mol, 2 eq) were stirred in DMF (6 mL) at 80 °C for 18 
hours. The reaction mixture was taken up in EtOAc (75 mL) and washed 3 times with 
Na2CO3 sat. (75 mL). The organic layer was dried with MgSO4 and dried under high 
vacuum. Silica column chromatography was carried out and the product was eluted 
with 2:8/EtOAc:petroleum ether. (Adapted from literature reference167). (2.0 g, 6.9 
mmol, 69%). Rf = 0.60 (3:7/EtOAc:petroleum ether).
 1H-NMR: (400 MHz, 
(CD3)2CO) δH: 3.90 (s, 3H, H-1), 5.42 (s, 1H, H-5), 7.33-7.59 (m, 5H, H-6, H-7, H-8), 
7.29 (d, 1H, J= 8.5 Hz, H-3), 7.91 (d, 1H, J= 8.0 Hz, H-2), 7.93 (s, 1H, H-4). 13C-
NMR (125 MHz, (CD3)2CO): 51.12 (OCH3), 70.59 (OCH2), 99.48 (CNO2CH), 104.07 
(COC), 107.01 (CCHCH), 128.04 (CCHCHCH), 129.38 (CCHCHCH), 129.90 










53 (2.0 g, 6.9 mmol, 1 eq), Fe (2 g) and NH4Cl (2 g) were stirred in 1:1 EtOH and 
water  (10 mL) for 4 hours at 100 °C and then filtered through Celite. Solvent was 
removed under high vacuum. (1.72 g, 6.6 mmol, 95%). Rf = 0.52 
(1:1/EtOAc:Petroleum ether). 1H-NMR: (400MHz, (CD3)2CO) δH: 3.80 (s, 3H, H-1), 
5.12 (s, 1H, H-5), 6.44 (s, 1H, H-4), 6.82 (d, 1H, J= 8.5 Hz, H-3), 7.23-7.61 (m, 5H, 
H-6, H-7, H-8), 7.65 (d, 1H, J= 8.0 Hz, H-2). 13C-NMR (125 MHz, (CD3)2CO): 51.32 
(OCH3), 70.44 (OCH2), 98.91 (CNHCH), 107.02 (CCHCH), 110.28 (COC), 127.63 
(CCHCHCH), 128.19 (CCHCHCH), 129.09 (CCHCHCH), 134.68 (CCH), 137.91 










Compound 54 (1.72 g, 6.6 mmol, 1 eq) and DIPEA (2.18 mL, 1.7 g, 13.2 mmol, 2 eq) 
were stirred in DCM (10 mL) at 0 °C. Heptnoyl chloride (1.1 mL, 1.1 g, 7.26 mmol, 
1.1 eq) was then added dropwise over 15 minutes. The reaction was stirred for a further 
30 minutes at 0 °C before the solvent was removed in vacuo. The resulting oil was 
purified using silica column chromatography and the product was eluted with 
1:4/EtOAc:petroleum ether. (1.63 g, 4.4 mmol, 60%). Rf = 0.62 (1:4/EtOAc:petroleum 
ether). 1H-NMR: (400 MHz, (CD3)2CO) δH: 0.85 (t, 3H, J= 6.5 Hz, H-14), 1.24-1.40 
(m, 6H, H-11, H-12, H-13), 1.61-1.74 (m, 2H, H-10), 2.39 (t, 2H, J= 7.5 Hz, H-9), 
3.80 (s, 3H, H-1), 5.15 (s, 1H, H-5), 7.12 (d, 1H, J= 7.5 Hz, H-3), 7.26-7.55 (m, 5H, 
H-6, H-7, H-8), 7.57 (d, 1H, J= 7.5 Hz, H-2), 7.77 (s, 1H, H-4). 13C-NMR (125 MHz, 
(CD3)2CO): 14.35 (CH2CH2CH2CH3), 23.21 (CH2CH2CH3), 29.62 
(CH2CH2CH2CH3), 26.04 (COCH2CH2), 32.37 (COCH2CH2CH2), 37.88 (COCH2), 
51.79 (OCH3), 70.92 (OCH2), 104.97 (CNHCH), 111.40 (CCHCH), 115.65 (COC), 
127.86 (CCHCHCH), 128.41 (CCHCHCH), 129.16 (CCHCHCH), 133.51 (CCH), 
138.10 (CH2C), 145.45 (CHCNH), 163.25 (CHCO), 166.42 (OCO), 172.67 (NHCO). 
LRMS m/z (ESI): 392.3 [M+Na]+. HRMS m/z (ESI): calculated for C22H27NNaO4
+ 








Compound 55 (0.82 g, 2.2 mmol, 1 eq) and NaH (0.10 g, 4.4 mmol, 2 eq) were stirred 
in dry THF (10 mL) at 0 °C for 0.5 hours. Benzyl bromide (0.30 mL, 0.41 g, 2.3 mmol, 
1.1 eq) was then added dropwise and the reaction stirred at room temperature for two 
hours. The solvent was removed in vacuo.  The reaction mixture was taken up in 
EtOAc (75 mL) and washed 3 times with Na2CO3 sat. (75 mL). The organic layer was 
dried with MgSO4 and dried under high vacuum. Silica column chromatography was 
carried out and the product was eluted with 1:9/EtOAc:petroleum ether. (0.96 g, 2.1 
mmol, 97%). Rf = 0.80 (1:9/EtOAc:petroleum ether). 
1H-NMR: (400 MHz, 
(CD3)2CO) δH: 0.90 (t, 3H, J= 6.5 Hz, H-14), 1.22-1.35 (m, 6H, H-11, H-12, H-13), 
1.60-1.71 (m, 2H, H-10), 2.37 (t, 2H, J= 7.5 Hz, H-9), 3.79 (s, 3H, H-1), 5.15 (s, 1H, 
H-5), 5.17 (s, 2H, H-15), 7.05-7.78 (m, 13H, H-3, H-2, H-4, H-6, H-7, H-8, H-16, H-
17, H-18). 13C-NMR (125 MHz, (CD3)2CO): 13.15 (CH2CH2CH2CH3), 22.09 
(CH2CH2CH3), 25.13 (COCH2CH2), 29.36 (CH2CH2CH2CH3), 31.15 
(COCH2CH2CH2), 38.82 (COCH2), 52.00 (OCH3), 52.51 (NCH2), 70.92 (OCH2), 
105.27 (CNHCH), 110.87 (CCHCH), 115.24 (COC), 126.67 (CCH), 126.82 
(CCHCHCH), 127.27(CHCHCH), 127.57 (CCHCHCH), 128.19 (CHCHCH), 128.21 
(CCHCHCH), 134.08 (CCH), 136.90 (CH2C), 138.10 (CH2C), 145.50 (CHCNH), 
163.25 (CHCO), 166.15 (OCO), 173.44 (NCO). LRMS m/z (ESI): 482.3 [M+Na]+. 
HRMS m/z (ESI): calculated for C29H33NNaO4
+ [M+Na]+: Exact Mass: 482.2302 
found 482.2304.  
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Compound 56 (0.96 g, 2.1 mmol) was dissolved in EtOH (5 mL), water (4 mL) and 
6M NaOH (1 mL) was added and refluxed for 5 hours. After removing EtOH in vacuo 
the solution was acidified to pH 4 using HCl and the precipitate was collected by 
filtration. (0.82 g, 1.8 mmol, 81%). Rf = 0.70 (4:1/EtOAc:petroleum ether). 
1H-NMR: 
(400 MHz, MeOD) δH: 0.90 (t, 3H, J= 6.5 Hz, H-13), 1.20-1.34 (m, 6H, H-10, H-11, 
H-12), 1.62-1.68 (m, 2H, H-9), 2.39 (t, 2H, J= 7.5 Hz, H-8), 5.15 (s, 1H, H-4), 5.17 (s, 
2H, H-14), 7.02-7.80 (m, 13H, H-1, H-2, H-3, H-5, H-6, H-7, H-15, H-16, H-17,). 13C-
NMR (125 MHz, MeOD): 14.45 (CH2CH2CH2CH3), 21.99 (CH2CH2CH3), 25.13 
(COCH2CH2), 28.86 (CH2CH2CH2CH3), 32.05 (COCH2CH2CH2),38.82 (COCH2), 
52.51 (NCH2), 70.92 (OCH2), 105.27 (CNHCH), 111.07 (CCHCH), 114.46 (COC), 
133.18 (CCH), 126.82 (CCHCHCH), 126.67 (CCH), 127.27(CHCHCH), 127.57 
(CCHCHCH), 128.19 (CHCHCH), 128.21 (CCHCHCH), 136.90 (CH2C), 138.10 
(CH2C), 144.40 (CHCNH), 163.25 (CHCO), 165.35 (COOH), 173.44 (NCO). LRMS 
m/z (ESI): 444.4 [M+Na]+. HRMS m/z (ESI): calculated for C28H31NNaO4
+ [M+Na]+: 









Compound 57 (0.82 g, 1.8 mmol, 1 eq), EDC.HCl (0.42, 2.2 mmol , 1.2 eq), HOBt 
(0.29 g, 2.2 mmol, 1.2 eq)  and DIPEA (0.59 mL, 0.46 g, 3.6 mmol, 2 eq) were stirred 
in DCM (10 mL) for 15 minutes. H-Lys(Boc)-OMe hydrochloride (0.65 g, 2.2 mmol 
, 1.2 eq) was added and the reaction was stirred for 18 hours.  DCM (40 mL) was added 
and washed 3 times with Na2CO3 sat. (75 mL). The organic layer was dried with 
MgSO4 and dried under high vacuum. Silica column chromatography was carried out 
and the product was eluted with 2:4/EtOAc:petroleum ether. (0.52 g, 0.75 mmol, 41%). 
Rf = 0.70 (2:4/EtOAc:petroleum ether). 
1H-NMR: (400 MHz, MeOD) δH: 0.89 (t, 3H, 
J= 6.5 Hz, H-22), 1.20-1.40 (m, 8H, H-3, H-19, H-20, H-21), 1.42 (s, 9H, H-23), 1.51-
1.60 (m, 2H, H-18), 1.70-1.78 (m, 2H, H-4), 1.69-1.79 (m, 2H, H-2), 2.39 (t, 2H, J= 
7.5 Hz, H-17), 2.93 (m, 2H, H-5), 3.32 (s, 3H, H-1), 5.13 (s, 1H, H-9), 5.14 (s, 2H, H-
13), 6.81 (d, 1H, J= 8.0 Hz, H-7), 6.94 (s, 1H, H-8), 7.17-7.50 (m, 10H, H-10, H-11, 
H-12, H-14, H-15, H-16), 7.92 (d, 1H J=8.0 Hz, H-6). 13C-NMR (125 MHz, MeOD): 
13.00 (CH2CH2CH2CH3), 22.13 (NHCH2CH2), 22.44 (CH2CH2CH3), 25.13 
(COCH2CH2), 27.41 (3CH3), 28.53 (NHCH2CH2CH2), 28.86 (CH2CH2CH2CH3), 
30.53 (CH2CH), 32.05 (COCH2CH2CH2), 35.30 (COCH2), 39.56 (NHCH2), 51.40 
(COOCH3), 52.51 (NCH2), 52.73 (CH2CH), 71.23 (OCH2), 78.41 (COCO), 106.17 
(CNHCH), 113.56 (COC), 113.96 (CCHCH), 128.09 (CCHCHCH), 
128.37(CHCHCH), 128.47 (CCHCHCH), 128.60 (CCHCHCH), 129.10 (CCH), 
129.60 (CHCHCH), 133.16 (CCH), 136.90 (CH2C), 137.19 (CH2C), 146.13 
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(CHCNH), 158.46 (COCONH), 163.25 (CHCO), 165.35 (CONHCH), 172.51 (NCO), 
173.60 (COOCH3). LRMS m/z (ESI): 710.5 [M+Na]
+. HRMS m/z (ESI): calculated 
for C40H53N3NaO7










Compound 58 (0.52 g, 0.75 mmol) was stirred in 4N HCl in dioxane (3 mL) for 4 
hours. The solvent was removed in vacuo. (0.50 g, 0.74 mmol, 98%). Rf = 0.23 
(9:1/EtOAc:MeOH). 1H-NMR: (400 MHz, MeOD) δH: 0.85 (t, 3H, J= 6.5 Hz, H-22), 
1.14-1.34 (m, 8H, H-3, H-19, H-20, H-21), 1.48-1.59 (m, 2H, H-18), 1.70-1.78 (m, 
2H, H-4), 1.64-1.82 (m, 2H, H-2), 2.15 (t, 2H, J= 7.5 Hz, H-17), 2.94 (m, 2H, H-5), 
3.64 (s, 3H, H-1), 4.48 (m, 1H, H-23), 5.21 (s, 1H, H-9), 5.22 (s, 2H, H-13), 6.83 (d, 
1H, J= 8.0 Hz, H-7), 7.11 (s, 1H, H-8), 7.18-7.56 (m, 10H, H-10, H-11, H-12, H-14, 
H-15, H-16), 8.00 (d, 1H J=8.0 Hz, H-6). 13C-NMR (125 MHz, MeOD): 14.33 
(CH2CH2CH2CH3), 22.13 (NH2CH2CH2), 22.44 (CH2CH2CH3), 25.13 (COCH2CH2), 
28.53 (NH2CH2CH2CH2), 28.86 (CH2CH2CH2CH3), 30.53 (CH2CH), 32.05 
(COCH2CH2CH2), 35.30 (COCH2), 39.56 (NHCH2), 52.45 (COOCH3), 52.51 (NCH2), 
53.28 (CH2CH), 72.26 (OCH2), 106.17 (CNHCH), 113.56 (COC), 114.62 (CCHCH), 
128.05 (CCHCHCH), 129.21 (CCH), 129.25 (CHCHCH), 129.28 (CCHCHCH), 
129.80 (CCHCHCH), 129.86 (CHCHCH), 133.16 (CCH), 136.63 (CH2C), 137.37 
(CH2C), 147.13 (CHCNH), 163.23 (CONHCH), 163.24 (CHCO), 172.51 (NCO), 
173.05 (COOCH3). LRMS m/z (ESI): 588.5 [M+H]
+. HRMS m/z (ESI): calculated for 
C35H46N3O5









Compounds 55 (0.80 g, 2.2 mmol) was dissolved in EtOH (5 mL), water (4 mL) and 
6M NaOH (1 mL) was added and refluxed for 5 hours. After removing EtOH in vacuo 
the solution was acidified to pH 4 using HCl and the precipitate was collected by 
filtration. (0.78 g, 2.2 mmol, 96%). Rf = 0.54 (EtOAc).
 1H-NMR: (400 MHz, MeOD) 
δH: 0.90 (t, 3H, J= 6.5 Hz, H-13), 1.26-1.44 (m, 6H, H-10, H-11, H-12), 1.62-1.74 (m, 
2H, H-9), 2.38 (t, 2H, J= 7.5, H-8), 5.22 (s, 1H, H-4), 7.10 (d, 1H, J= 8.5 Hz, H-2), 
7.26-7.54 (m, 5H, H-5, H-6, H-7), 7.71 (d, 1H, J= 7.5 Hz, H-1), 7.80 (s, 1H, H-3). 13C-
NMR (125 MHz, (CD3)2CO): 14.49 (CH2CH2CH2CH3), 23.53 (CH2CH2CH3), 26.07 
(COCH2CH2), 30.01 (CH2CH2CH2CH3), 32.73 (COCH2CH2CH2), 38.16 (COCH2), 
71.82 (OCH2), 112.21 (CCHCH), 115.51 (COC), 128.51 (CCHCHCH), 129.02 
(CCHCHCH), 129.56 (CCHCHCH), 133.99 (CCH), 138.10 (CH2C), 145.66 
(CHCNH), 145.84 (CNHCH), 163.25 (CHCO), 163.75 (COOH), 172.60 (NHCO). 
LRMS m/z (ESI): 354.1 [M-H]-. HRMS m/z (ESI): calculated for C21H24NO4
-[M-H]-










Compound 60 (0.40 g, 0.67 mmol, 1 eq), EDC.HCl (0.15 g, 0.80 mmol , 1.2 eq), HOBt 
(0.1 g, 0.80 mmol, 1.2 eq)  and DIPEA (0.22 mL, 0.17 g, 1.3 mmol, 2 eq) were stirred 
in DCM (10 mL) for 15 minutes. H-Lys(Boc)-OMe hydrochloride (0.23 g, 0.80 mmol 
, 1.2 eq) was added and the reaction was stirred for 18 hours.  DCM (40 mL) was added 
and washed 3 times with Na2CO3 sat. (75 mL). The organic layer was dried with 
MgSO4 and dried under high vacuum. Silica column chromatography was carried out 
and the product was eluted with 2:4/EtOAc:petroleum ether. (0.18 g, 0.30 mmol, 45%). 
Rf = 0.49 (2:4/EtOAc:petroleum ether). 
1H-NMR: (400 MHz, MeOD) δH: 0.88 (t, 3H, 
J= 6.5 Hz, H-18), 1.20-1.37 (m, 8H, H-4, H-15, H-16, H-17), 1.38 (s, 9H, H-19), 1.48-
1.54 (m, 2H, H-18), 1.62-1.82 (m, 4H, H-4, H-2), 2.41 (t, 2H, J= 7.5 Hz, H-17), 2.97 
(m, 2H, H-5), 3.63 (s, 3H, H-1), 4.44 (m, 1H, H-20) 5.25 (s, 1H, H-9), 7.15-7.57 (m, 
5H, H-10, H-11, H-12,), 7.63 (d, 1H, J= 8.0 Hz, H-7), 7.93 (s, 1H, H-8), 8.01 (d, 1H 
J=8.0 Hz, H-6). 13C-NMR (125 MHz, MeOD): 13.00 (CH2CH2CH2CH3), 23.21 
(CH2CH2CH3), 23.54 (NHCH2CH2), 24.46 (COCH2CH2), 26.06 (CH2CH2CH2CH3), 
28.68 (3CH3), 32.05 (COCH2CH2CH2), 32.37 (NHCH2CH2CH2 ), 32.51 (CH2CH), 
37.86 (NHCOCH2), 40.80 (NHCH2), 52.20 (COOCH3), 53.37 (CH2CH), 71.23 
(OCH2), 71.93 (COCO), 104.12 (CNHCH), 112.08 (COC), 113.56 (CCHCH), 129.54 
(CCHCHCH), 129.64 (CCHCHCH), 129.67 (CCHCHCH), 136.86 (CCH), 137.19 
(CH2C), 144.87 (CHCNH), 158.46 (COCONH), 158.62 (CONHCH), 163.25 (CHCO), 
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173.39 (COOCH3), 172.66 (NHCO). LRMS m/z (ESI): 620.5 [M+Na]
+. HRMS m/z 
(ESI): calculated for C33H47N3NaO7









Compound 61 (0.18 g, 0.30 mmol) was stirred in 4N HCl in dioxane (3 mL) for 4 
hours. The solvent was removed in vacuo. (0.14 g, 0.28 mmol, 93%). Rf = 0.23 
(9:1/EtOAc:MeOH). 1H-NMR: (400 MHz, MeOD) δH: 0.92 (t, 3H, J= 6.5 Hz, H-22), 
1.23-1.41 (m, 8H, H-4, H-19, H-20, H-21), 1.45-1.57 (m, 2H, H-18), 1.60-1.80 (m, 
2H, H-2), 2.41 (t, 2H, J= 7.5 Hz, H-17), 2.78 (m, 2H, H-5), 3.69 (s, 3H, H-1), 4.47 (m, 
1H, H-13), 5.26 (s, 1H, H-9), 7.15-7.48 (m, 5H, H-10, H-11, H-12,), 7.58 (d, 1H, J= 
8.0 Hz, H-7), 7.87 (s, 1H, H-8), 7.94 (d, 1H J=8.0 Hz, H-6). 13C-NMR (125 MHz, 
MeOD): 14.39 (CH2CH2CH2CH3), 23.51 (CH2CH2CH3), 23.60 (NH2CH2CH2), 26.72 
(COCH2CH2), 26.72 (CH2CH2CH2CH3), 30.02 (COCH2CH2CH2), 32.42 (CH2CH), 
32.74 (NH2CH2CH2CH2), 38.17 (NHCOCH2), 40.43 (NH2CH2), 52.87 (COOCH3), 
53.64 (CH2CH), 72.57 (OCH2), 105.10 (CNHCH), 112.08 (COC), 113.56 (CCHCH), 
129.54 (CCHCHCH), 129.64 (CCHCHCH), 129.67 (CCHCHCH), 137.19 (CH2C), 
137.22 (CCH), 144.87 (CHCNH), 158.62 (CONHCH), 163.75 (CHCO), 172.66 
(NHCO), 175.16 (COOCH3). LRMS m/z (ESI): 498.2 [M+H]
+. HRMS m/z (ESI): 
calculated for C28H40N3O5








Compound 40 (1.0 g, 2.8 mmol, 1 eq) and DIPEA (0.92 mL, 0.72 g, 5.6 mmol, 2 eq) 
were stirred in DCM (10 mL) at 0 °C. Heptanoyl chloride (0.46 mL, 0.45 g, 3.1 mmol, 
1.1 eq) was then added dropwise over 15 minutes. The reaction was stirred for a further 
30 minutes at 0 °C before the solvent was removed in vacuo. The resulting oil was 
purified using silica column chromatography and the product was eluted with 
1:4/EtOAc:petroleum ether. (0.80 g, 1.9 mmol, 67%). Rf = 0.39 (1:4/EtOAc:petroleum 
ether). 1H-NMR: (400 MHz, (CD3)2CO) δH: 0.85 (t, 3H, J= 6.5 Hz, H-17), 1.22-1.40 
(m, 6H, H-14, H-15, H-16), 1.59-1.72 (m, 2H, H-13), 2.37 (t, 2H, J= 7.5 Hz, H-12), 
3.27 (t, 2H, J=7.0 Hz, H-6), 3.80 (s, 3H, H-1), 4.25 (t, 2H, J=7.0 Hz, H-5), 7.06 (dt, 
2H, J= 7.0, 10.5 Hz, H-9, H-10), 7.36-7.41 (m, 2H, H-7, H-8), 7.65-7.74 (m, 3H, H-2, 
H-4, H-11). 13C-NMR (125 MHz, (CD3)2CO): 14.32 (CH2CH2CH2CH3), 25.63 
(CH2CH2CH3), 25.81 (COCH2CH2), 26.03 (CH2CH2), 29.34 (CH2CH2CH2CH3), 
32.34 (COCH2CH2CH2), 37.86 (COCH2), 51.71 (CH3O), 70.01 (COCH2), 104.44 
(CNHCH), 107.62 (CH2C), 110.92 (NHCCH), 112.13 (CCHCH), 115.58 (COCCH), 
119.28 (CHCHC), 119.51 (CHCHCH), 122.05 (CCHCH), 123.48 (CCH), 128.62 
(CHC), 133.17 (CCHCH), 137.54 (NHC), 145.35 (CHCNH), 166.66 (OCO), 160.42 
(COCH2), 172.61 (NHCO). LRMS m/z (ESI): 445.3 [M+Na]
+. HRMS m/z (ESI): 
calculated for C25H30N2NaO4








63 (0.80 g, 1.9 mmol) was dissolved in EtOH (5 mL), water (4 mL) and 6M NaOH (1 
mL) was added and refluxed for 5 hours. After removing EtOH in vacuo the solution 
was acidified to pH 4 using HCl and the precipitate was collected by filtration. (0.76 
g, 1.9 mmol, 97%). Rf = 0.49 (EtOAc). 
1H-NMR: (500 MHz, (CD3)2CO) δH: 0.85 (t, 
3H, J= 6.5 Hz, H-16), 1.22-1.40 (m, 6H, H-13, H-14, H-15), 1.59-1.72 (m, 2H, H-12), 
2.39 (t, 2H, J= 7.5 Hz, H-11), 3.39 (t, 2H, J=7.0 Hz, H-5), 4.52 (t, 2H, J=7.0 Hz, H-4), 
7.07 (dt, 2H, J= 7.0, 15.5 Hz, H-8, H-9), 7.36-7.41 (m, 2H, H-6, H-7), 7.65-7.74 (m, 
3H, H-1, H-3, H-10). 13C-NMR (125 MHz, (CD3)2CO): 164.53 (COOH), 115.58 
(COCCH), 133.34 (CCHCH), 102.98 (CCHCH), 145.19 (CHCNH), 96.98 (CNHCH), 
158.75 (COCH2), 69.57 (COCH2), 25.06 (CH2CH2), 110.31 (CH2C), 123.48 (CCH), 
137.54 (NHC), 110.92 (NHCCH), 121.39(CCHCH), 118.76 (CHCHCH), 118.28 
(CHCHC), 128.62 (CHC), 171.80 (NHCO), 36.89 (COCH2), 25.81 (COCH2CH2), 
31.44 (COCH2CH2CH2), 29.34 (CH2CH2CH2CH3), 22.29 (CH2CH2CH3), 13.41 
(CH2CH2CH2CH3). LRMS m/z (ESI): 407.2 [M-H]
-. HRMS m/z (ESI): calculated for 
C24H27N2O4










Compound 64 (0.50 g, 1.2 mmol, 1 eq), EDC.HCl (0.26 g, 1.4 mmol , 1.2 eq), HOBt 
(0.19 g, 1.4 mmol, 1.2 eq) and DIPEA (0.40 mL, 0.30 g, 2.4 mmol, 2 eq) were stirred 
in DCM (10 mL) for 15 minutes. H-Lys(Boc)-OMe hydrochloride (0.41 g, 1.4 mmol 
, 1.2 eq) was added and the reaction was stirred for 18 hours.  DCM (40 mL) was added 
and washed 3 times with Na2CO3 sat. (75 mL). The organic layer was dried with 
MgSO4 and dried under high vacuum. Silica column chromatography was carried out 
and the product was eluted with 1:4/EtOAc:petroleum ether. (0.47 g, 0.7 mmol, 58%). 
Rf = 0.51 (1:4/EtOAc:petroleum ether). 
1H-NMR: (500 MHz, (CD3)2CO) δH: 0.88 (t, 
3H, J= 6.5 Hz, H-16), 1.18-1.42 (m, 8H, H-19, H-13, H-14, H-15), 1.38 (s, 9H, H-22), 
1.43-1.54 (m, 2H, H-12), 1.62-1.74 (m, 4H, H-18, H-20), 2.41 (t, 2H, J= 7.5 Hz, H-
11), 2.55 (t, 2H, J= 7.5 Hz, H-21), 3.44 (t, 2H, J=7.0 Hz, H-5), 3.69 (s, 3H, H-1), 4.49 
(t, 2H, J=7.0 Hz, H-4), 4.59 (m, 1H, H-23), 7.08 (dt, 2H, J= 7.0, 15.5 Hz, H-8, H-9), 
7.21 (d, 1H, J=8.5 Hz, H-7), 7.33 (s, 1H, H-6), 7.41 (d, 1H J=8.0 Hz, H-2), 7.63 (d, 
1H, J= 8.0 Hz, H-10), 7.84 (s, 1H, H-3), 8.01 (d, 1H, J= 8.0 Hz, H-1). 13C-NMR (125 
MHz, (CD3)2CO): 14.32 (CH2CH2CH2CH3), 21.35 (CH2CH2CH3), 22.09 
(NHCH2CH2), 25.06 (CH2CH2), 25.29 (COCH2CH2), 26.51 (CH2CH2CH2CH3), 28.61 
(COCH2CH2CH2), 28.68 (3CH3), 30.65 (CH2CH), 31.32 (NHCH2CH2CH2), 37.84 
(COCH2), 40.87 (NHCH2), 52.32 (CH2CH), 53.31 (COOCH3), 68.76 (COCH2), 71.93 
(COCO), 103.80 (CNHCH), 110.42 (CH2C), 111.81 (CCHCH), 112.01 (NHCCH), 
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112.08 (COC), 115.19 (COCCH), 118.24 (CHCHC), 118.63 (CHCHCH), 122.13 
(CCH), 122.19 (CCHCH), 127.38 (CHC), 133.27 (CCHCH), 136.76 (NHC), 145.19 
(CHCNH), 157.96 (COCH2), 163.23 (COCONH), 164.85 (CONHCH), 172.63 
(COOCH3), 173.63 (NHCO). LRMS m/z (ESI): 673.5 [M+Na]
+. HRMS m/z (ESI): 
calculated for C36H50N4NaO7










Compound 65 (0.47 g, 0.7 mmol,) was stirred in 4N HCl in dioxane (3 mL) for 4 hours. 
The solvent was removed in vacuo. (0.38 g, 0.7 mmol, 99%). Rf = 0.23 
(9:1/EtOAc:MeOH). 1H-NMR: (500 MHz, MeOD) δH: 0.90 (t, 3H, J= 6.5 Hz, H-16), 
1.20-1.40 (m, 8H, H-19, H-13, H-14, H-15), 1.43-1.54 (m, 2H, H-18), 1.64-1.73 (m, 
4H, H-20), 2.39 (t, 2H, J= 7.5 Hz, H-11), 2.55 (t, 2H, J= 7.5 Hz, H-21), 3.38 (t, 2H, 
J=7.0 Hz, H-5), 3.69 (s, 3H, H-17), 4.48 (t, 2H, J=7.0 Hz, H-4), 4.56 (m, 1H, H-22) 
7.08 (m, 3H, H-6, H-8, H-9), 7.34 (d, 1H J=7.0 Hz, H-2), 7.57 (d, 1H, J= 8.0 Hz, H-
10), 7.78 (s, 1H, H-7), 7.94 (d, 1H, J= 8.0 Hz, H-1). 13C-NMR (125 MHz, MeOD): 
12.97 (CH2CH2CH2CH3), 22.09 (NHCH2CH2), 22.18 (CH2CH2CH3), 25.06 
(CH2CH2), 25.29 (COCH2CH2), 26.51 (CH2CH2CH2CH3), 28.61 (COCH2CH2CH2), 
30.65 (CH2CH), 31.32 (NHCH2CH2CH2), 36.75 (COCH2), 46.51 (NHCH2), 51.50 
(COOCH3), 52.22 (CH2CH), 68.57 (COCH2), 103.33 (CNHCH), 110.42 (CH2C111.01 
(NHCCH), 111.33 (CCHCH), ), 112.08 (COC), 115.19 (COCCH), 117.86 (CHCHC), 
118.45 (CHCHCH), 121.21 (CCHCH), 122.13 (CCH), 127.38 (CHC), 131.81 
(CCHCH), 136.76 (NHC), 145.19 (CHCNH), 157.96 (COCH2), 165.69 (CONHCH), 
172.40 (COOCH3), 173.80 (NHCO). LRMS m/z (ESI): 551.4 [M+H]
+. HRMS m/z 
(ESI): calculated for C36H50N4NaO7








Compound 39 (1.5 g, 7.6 mmol, 1 eq), 49 (2.8 g, 8.3 mmol, 1.1 eq), K2CO3 (2.8 g, 15.2 
mmol, 2 eq) were stirred in DMF (8 mL) at 50°C for 20 hours. The reaction mixture 
was taken up in EtOAc (75 mL) and washed 3 times with Na2CO3 sat. (75 mL). The 
organic layer was dried with MgSO4 and dried under high vacuum. The resulting 
residue was applied to a silica column and the product was eluted with 20:80 
EtOAc/Petroleum ether. (2.5 g, 5.8 mmol, 81%). Rf = 0.69 (3:7/EtOAc:petroleum 
ether).  1H-NMR: (400 MHz, (CD3)2CO) δH: 1.67 (s, 9H, H-12), 3.28 (t, 2H, J=6.5 
Hz, H-6), 3.89 (s, 3H, H-1), 4.55 (t, 2H, J=6.5 Hz, H-5), 7.29 (dt, 2H, J= 7.0, 15.5 Hz, 
H-8, H-9), 7.62-7.77 (m, 2H, H-8, H-11), 7.86-7.89 (m, 2H, H-3, H-7),  7.95 (s, 1H, 
H-4), 8.14 (d, 1H, J= 8.0 Hz, H-2). 13C-NMR (125 MHz, (CD3)2CO): 24.50  
(CH2CH2), 28.27 (3CH3), 51.57 (CH3O), 69.79 (COCH2), 75.03 (COCO), 107.59 
(NCCH), 110.57 (CH2C), 110.83 (CNO2CH), 112.86 (CCH), 114.30 (CCHCH), 
117.84 (CHCHC), 118.32 (CHCHCH), 120.92 (CCHCH), 126.25 (COCCH), 127.38 
(CHC), 131.19 (CCHCH), 136.52 (NC), 150.50 (CHCNO2), 158.20 (COCH2), 165.85 









Compound 67 (2.5 g, 5.8 mmol, mmol, 1 eq), Fe (3 g) and NH4Cl (3 g) were stirred in 
1:1 EtOH and water  (10 mL) for 4 hours at 100 °C and then filtered through Celite. 
Solvent was removed under high vacuum. (2.3 g, 5.4 mmol, 93%). Rf = 0.33 
(1:1/EtOAc:petroleum ether). 1H-NMR: (400 MHz, (CD3)2CO) δH: 1.68 (s, 9H, H-
12), 3.24 (t, 2H, J=7.0 Hz, H-6), 3.74 (s, 3H, H-1), 4.38 (t, 2H, J=7.0 Hz, H-5), 6.24-
6.28 (m, 1H, H-3), 6.37 (s, 1H, H-4), 7.02 (t, 1H, J=7.4 Hz, H-10), 7.09 (t, 1H, J=7.5 
Hz, H-9), 7.32-7.42 (m, 2H, H-7, H-2), 7.59-7.67 (m, 2H, H-8, H-11). 13C-NMR (125 
MHz, (CD3)2CO): 25.01 (CH2CH2), 28.70 (3CH3), 50.22 (CH3O), 68.87 (COCH2), 
72.32 (COCO), 98.10 (CNH2CH), 105.75 (CCHCH), 107.62 (CH2C), 111.27 
(NHCCH), 111.34 (COCCH), 118.35 (CHCHC), 118.55 (CHCHCH), 121.09 
(CCHCH), 123.48 (CCH), 127.72 (CHC), 133.70 (CCHCH), 136.40 (NHC), 154.16 
(CHCNH2), 161.19 (COCH2), 165.88 (OCO), 168.81 (COCONC). LRMS m/z (ESI): 
433.2 [M+Na]+. HRMS m/z (ESI): calculated for C23H26N2NaO5
+ [M+Na]+: Exact 










Compound 68 (2.3 g, 5.4 mmol, 1 eq) and DIPEA (1.78 mL, 1.4 g, 10.8 mmol, 2 eq) 
were stirred in DCM (10 mL) at 0 °C. Heptanoyl chloride (0.89 mL, 0.87 g, 5.9 mmol, 
1.1 eq) was then added dropwise over 15 minutes. The reaction was stirred for a further 
30 minutes at 0 °C before the solvent was removed in vacuo. The resulting oil was 
purified using silica column chromatography and the product was eluted with 
1:4/EtOAc:petroleum ether. (1.82 g, 3.3 mmol, 62%). Rf = 0.39 (1:4/EtOAc:petroleum 
ether). 1H-NMR: (400 MHz, (CD3)2CO) δH: 0.85 (t, 3H, J= 6.5 Hz, H-17), 1.21-1.39 
(m, 6H, H-14, H-15, H-16), 1.59-1.64 (m, 2H, H-13), 1.66 (s, 9H, H-18) 2.36 (t, 2H, 
J= 7.5 Hz, H-12), 3.21 (t, 2H, J=7.0 Hz, H-6), 3.79 (s, 3H, H-1), 4.29 (t, 2H, J=7.0 Hz, 
H-5), 7.21-7.36 (m, 3H, H-3, H-9, H-10), 7.65-7.77 (m, 4H, H-4, H-7, H-8, H-11). 
8.14 (d, 1H, J= 8.0 Hz, H-2). 13C-NMR (125 MHz, (CD3)2CO): 14.34 
(CH2CH2CH2CH3), 25.37 (CH2CH2CH3), 26.03 (CH2CH2), 28.31 (3CH3), 29.36 
(CH2CH2CH2CH3), 29.62 (COCH2CH2), 32.35 (COCH2CH2CH2), 37.87 (COCH2), 
51.79 (CH3O), 69.00 (COCH2), 84.07 (COCO), 104.52 (CNHCH), 111.14 (NCCH), 
115.14 (CCHCH), 115.52 (CH2C), 118.04 (CHCHC), 118.14 (COCCH), 119.96 
(CHCHCH), 123.37 (CCHCH), 125.14 (CCH), 131.53 (CHC), 133.17 (CCHCH), 
136.30 (NC), 145.38 (CHCNH), 150.38 (COCH2), 160.62 (OCO), 166.59 
(COCONC), 172.62 (NHCO). LRMS m/z (ESI): 545.2 [M+Na]+. HRMS m/z (ESI): 
calculated for C23H26N2NaO5








Compound 69 (0.70 g, 1.3 mmol, 1 eq) and potassium tert-butoxide (0.29 g, 2.6 mmol, 
2 eq) were stirred in dry THF (10 mL) for 0.5 hours. Benzyl bromide (0.17 mL, 0.24 
g, 1.4 mmol, 1.1 eq) was then added dropwise and the reaction stirred for 18 hours. 
The solvent was removed in vacuo.  The reaction mixture was taken up in EtOAc (75 
mL) and washed 3 times with water (75 mL). The organic layer was dried with MgSO4 
and dried under high vacuum. Silica column chromatography was carried out and the 
product was eluted with 1:9/EtOAc:petroleum ether. (0.5 g, 0.8 mmol, 67%) Rf = 0.34 
(1:9/EtOAc:petroleum ether). 1H-NMR: (400 MHz, (CD3)2CO) δH: 0.81 (t, 3H, J= 6.5 
Hz, H-17), 1.11-1.25 (m, 6H, H-14, H-15, H-16), 1.50-1.61 (m, 2H, H-13), 1.67 (s, 
9H, H-18) 2.16 (t, 2H, J= 7.5 Hz, H-12), 3.14 (t, 2H, J=7.0 Hz, H-6), 3.49 (s, 3H, H-
1), 4.24 (t, 2H, J=7.0 Hz, H-5), 5.31 (s, 2H, H-19), 6.73-7.75 (m, 12H, H-2, H-3, H-7, 
H-8, H-9, H-10, H-11, H-20, H-21, H-22), 8.14 (d, 1H, J= 8.0 Hz, H-2), 8.13 (d, 1H, 
J= 8.0 Hz, H-3). 13C-NMR (125 MHz, (CD3)2CO): 13.47 (CH2CH2CH2CH3), 20.46 
(CH2CH2CH3), 26.03 (CH2CH2), 28.31 (3CH3), 28.50 (CH2CH2CH2CH3), 31.44 
(COCH2CH2), 33.96 (COCH2CH2CH2), 40.93 (COCH2), 51.29 (CH3O), 51.94 
(NCOCH2), 69.24 (COCH2), 83.28 (COCO), 110.46 (Ar-C), 110.79 (Ar-CH), 113.86 
(Ar-CH), 115.04 (Ar-CH), 117.02 (Ar-C), 118.83 (Ar-CH), 119.96 (Ar-CH), 122.39 
(Ar-CH), 124.26 (Ar-CH), 128.26 (Ar-CH), 128.32 (Ar-CH), 128.45 (Ar-CH), 132.03 
(Ar-CH), 136.61 (Ar-C), 138.21 (Ar-C), 138.21 (Ar-C), 145.38 (CHCN), 150.38 
(COCH2), 160.62 (OCO), 166.59 (COCONC), 172.62 (NCO). LRMS m/z (ESI): 
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636.5 [M+Na]+. HRMS   (ESI): calculated for C37H45N2NaO6
+ [M+Na]+: Exact Mass: 








Compound 70 (0.5 g, 0.8 mmol) was dissolved in EtOH (5 mL), water (4 mL) and 6M 
NaOH (0.5 mL) was added and refluxed for 5 hours. After removing EtOH in vacuo 
the solution was acidified to pH 4 using HCl and the precipitate was collected by 
filtration. (0.42 g, 1.9 mmol, 95%). Rf = 0.58 (EtOAc). 
1H-NMR: (400 MHz, 
(CD3)2CO) δH: 0.82 (t, 3H, J= 6.5 Hz, H-16), 1.08-1.28 (m, 6H, H-13, H-14, H-15), 
1.55-1.62 (m, 2H, H-12), 2.19 (t, 2H, J= 7.5 Hz, H-11), 3.26 (t, 2H, J=7.0 Hz, H-4), 
4.36 (t, 2H, J=7.0 Hz, H-5), 5.37 (s, 2H, H-19), 6.82-7.63 (m, 12H, H-2, H-3, H-7, H-
8, H-9, H-10, H-11, H-20, H-21, H-22), 8.14 (d, 1H, J= 8.0 Hz, H-2), 7.87 (d, 1H, J= 
8.0 Hz, H-2). 13C-NMR (125 MHz, (CD3)2CO): 13.47 (CH2CH2CH2CH3), 22.36 
(CH2CH2CH3), 25.32 (CH2CH2), 26.21(CH2CH2CH2CH3), 27.38 (COCH2CH2CH2), 
31.71 (COCH2CH2), 34.06 (COCH2), 52.11 (NCOCH2), 72.06 (COCH2), 109.98 (Ar-
CH), 110.40 (Ar-C), 111.35 (Ar-CH), 115.04 (Ar-CH), 118.31 (Ar-CH), 118.72 (Ar-
C), 118.86 (Ar-CH), 121.42 (Ar-CH), 123.21 (Ar-CH), 128.07 (Ar-CH), 128.40 (Ar-
CH), 128.54 (Ar-CH), 132.94 (Ar-CH), 136.65 (Ar-C), 138.08 (Ar-C), 138.40 (Ar-C), 
147.92 (CHCN), 158.56 (COCH2), 165.02 (COOH), 171.67 (NCO). LRMS m/z (ESI): 
497.2 [M-H]-. HRMS m/z (ESI): calculated for C31H33N2O4
- [M-H]-: Exact Mass: 











Compound 71 (0.42 g, 1.9 mmol, 1 eq), EDC.HCl (0.43 g, 2.3 mmol , 1.2 eq), HOBt 
(0.31 g, 2.3 mmol, 1.2 eq) and DIPEA (0.62 mL, 0.49 g, 3.8 mmol, 2 eq) were stirred 
in DCM (10 mL) for 15 minutes. H-Lys(Boc)-OMe hydrochloride (0.68 g, 2.3 mmol 
, 1.2 eq) was added and the reaction was stirred for 18 hours. DCM (40 mL) was added 
and washed 3 times with Na2CO3 sat. (75 mL). The organic layer was dried with 
MgSO4 and dried under high vacuum. Silica column chromatography was carried out 
and the product was eluted with 3:4/EtOAc:petroleum ether. (0.21 g, 0.3 mmol, 15%). 
Rf = 0.56 (3:4/EtOAc:petroleum ether). 
1H-NMR: (400 MHz, (CD3)2CO) δH: 0.83 (t, 
3H, J= 6.5 Hz, H-16), 1.20-1.37 (m, 8H, H-24, H-13, H-14, H-15), 1.40 (s, 9H, H-27), 
1.48-1.54 (m, 2H, H-12), 1.58-1.75 (m, 4H, H-23, H-25), 2.21 (t, 2H, J= 7.5 Hz, H-
11), 2.91 (m, 2H, H-26), 3.25 (t, 2H, J=7.0 Hz, H-4), 3.70 (s, 3H, H-22), 4.33 (t, 2H, 
J=7.0 Hz, H-5), 4.44 (m, 1H, H-17), 5.37 (s, 2H, H-18), 6.82-7.55 (m, 10H, H-1, H-3, 
H-7, H-8, H-9, H-10, H-11, H-20, H-21, H-22), 7.88 (d, 1H, J= 8.0 Hz, H-2). 13C-
NMR (125 MHz, (CD3)2CO): 12.94 (CH2CH2CH2CH3), 22.09 (NHCH2CH2), 22.42 
(CH2CH2CH3), 24.42 (CH2CH2CH2CH3), 25.27 (CH2CH2), 27.38 (COCH2CH2CH2), 
27.40 (3CH3), 30.83 (CH2CH), 31.20 (NHCH2CH2CH2), 31.71 (COCH2CH2), 33.89 
(COCH2), 39.58 (NHCH2), 51.40 (NCOCH2), 52.32 (CH2CH), 52.69 (COOCH3), 
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71.93 (COCO), 72.06 (COCH2), 111.02 (Ar-C), 111.20 (Ar-CH), 113.35 (Ar-CH), 
117.84 (Ar-CH), 118.44 (Ar-CH), 120.00 (Ar-CH), 121.20 (Ar-763.5CH), 122.18 (Ar-
CH), 127.26 (Ar-CH), 127.33 (Ar-CH), 128.00 (Ar-CH), 128.20 (Ar-C), 132.13 (Ar-
CH), 136.75 (Ar-C), 137.20 (Ar-C), 138.01 (Ar-C), 146.17 (CHCN), 157.54 (COCH2), 
164.85 (CONHCH), 165.15 (COCONH), 171.67 (NCO), 172.50 (COOCH3). LRMS 
m/z (ESI): 763.5 [M+Na]+. HRMS m/z (ESI): calculated for C43H56N4NaO7
+ [M+Na]+: 





Methyl (2-(2-(1H-indol-3-yl)ethoxy)-4-(N benzylheptanamido) benzoyl)-L-lysinate; 




Compound 72 (0.21 g, 0.3 mmol,) was stirred in 4N HCl in dioxane (3 mL) for 4 hours. 
The solvent was removed in vacuo. (0.16 g, 0.23 mmol, 76%). Rf = 0.30 
(9:1/EtOAc:MeOH). 1H-NMR: (400 MHz, MeOD) δH: 0.83 (t, 3H, J= 6.5 Hz, H-16), 
1.10-1.30 (m, 8H, H-24, H-13, H-14, H-15), 1.31-1.43 (m, 2H, H-12), 1.41-1.52 (m, 
2H, H-25), ), 1.53-1.63 (m, 2H, H-23), 2.17 (t, 2H, J= 7.5 Hz, H-11), 2.74 (m, 2H, H-
26), 3.27 (t, 2H, J=7.0 Hz, H-6), 3.73 (s, 3H, H-22), 4.37 (t, 2H, J=7.0 Hz, H-5), 4.50 
(m, 1H, H-17), 5.31 (s, 2H, H-19), 6.74-7.56 (m, 12H, H-2, H-3, H-7, H-8, H-9, H-10, 
H-11, H-20, H-21, H-22), 7.92 (d, 1H, J= 8.0 Hz, H-2). 13C-NMR (125 MHz, MeOD): 
12.94 (CH2CH2CH2CH3), 22.09 (NH2CH2CH2), 22.91 (CH2CH2CH3), 24.63 
(CH2CH2), 25.25 (CH2CH2CH2CH3), 28.53 (COCH2CH2CH2), 30.80 (CH2CH), 31.88 
(COCH2CH2), 31.20 (NH2CH2CH2CH2), 33.89 (COCH2), 38.99 (NH2CH2), 51.40 
(NCOCH2), 51.54 (COOCH3), 52.25 (CH2CH), 69.06 (COCH2), 110.25 (Ar-C), 
111.04 (Ar-CH), 113.32 (Ar-CH), 117.83 (Ar-CH), 118.45 (Ar-CH), 121.23 (Ar-CH), 
122.24 (Ar-CH), 122.90 (Ar-CH), 127.26 (Ar-C), 127.33 (Ar-CH), 128.20 (Ar-CH), 
128.56 (Ar-CH), 136.71 (Ar-C), 137.20 (Ar-C), 137.40 (Ar-C), 146.30 (CHCN), 
157.53 (COCH2), 164.85 (CONHCH), 165.24 (NCO), 172.20 (COOCH3), 132.08 (Ar-
CH). LRMS m/z (ESI): 641.5 [M+H]+. HRMS m/z (ESI): calculated for C38H49N4O5
+ 








Compound 69 (0.70 g, 1.1 mmol, 1 eq) and potassium tert-butoxide (0.25 g, 2.2 mmol, 
2 eq) were stirred in dry THF (10 mL) for 0.5 hours. 49 (0.39 g, 1.2 mmol, 1.1 eq) was 
then added and the reaction stirred 18 hours. The solvent was removed in vacuo.  The 
reaction mixture was taken up in EtOAc (75 mL) and washed 3 times with water (75 
mL). The organic layer was dried with MgSO4 and dried under high vacuum. Silica 
column chromatography was carried out and the product was eluted with 
1:9/EtOAc:petroleum ether. (0.18 g, 0.2 mmol, 20%) Rf = 0.23 (1:9/EtOAc:petroleum 
ether). 1H-NMR: (400 MHz, (CD3)2CO) δH: 0.81 (t, 3H, J= 6.5 Hz, H-16), 1.08-1.27 
(m, 6H, H-13, H-14, H-15), 1.43-1.62 (m, 2H, H-12), 1.63 (s, 9H, H-26), 1.67 (s 9H, 
H-25), 2.09 (t, 2H, J= 7.5 Hz, H-11), 3.19 (t, 2H, J=7.0 Hz, H-19), 3.26 (t, 2H, J=7.0 
Hz, H-5), 3.86 (s, 3H, H-27), 4.20 (t, 2H, J=7.0 Hz, H-18), 4.30 (t, 2H, J=7.0 Hz, H-
4), 6.90-8.01 (m, 13H, H-1, H-2, H-3, H-7, H-8, H-9, H-10, H-20, H-21, H-22, H-23, 
H-24). 13C-NMR (125 MHz, (CD3)2CO): 13.44 (CH2CH2CH2CH3), 20.46 
(CH2CH2CH3), 26.03, 28.60 (CH2CH2), 27.37, 27.40 (3CH3), 28.50 
(CH2CH2CH2CH3), 31.44 (COCH2CH2), 33.96 (COCH2CH2CH2), 40.93 (COCH2), 
50.88 (CH3O), 51.33 (NCOCH2), 68.08 (CNCH2), 69.29 (COCH2), 83.18, 83.26 
(COCO), 110.06 (Ar-C), 111.23 (Ar-CH), 113.87 (Ar-CH), 114.24 (Ar-CH), 117.20 
(Ar-C), 118.23 (Ar-CH), 119.02 (Ar-CH), 122.30 (Ar-CH), 125.62 (Ar-CH), 128.05 
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(Ar-CH), 128.23 (Ar-CH), 128.66 (Ar-CH), 130.24 (Ar-C), 132.66 (Ar-CH), 135.43 
(Ar-C), 135.60 (Ar-C), 138.21 (Ar-C), 138.33 (Ar-C), 144.58 (CHCN), 149.49 
(COCH2), 160.62 (OCO), 165.68, 165.79 (COCON), 171.61 (NCO). LRMS m/z 
(ESI): 788.5 [M+Na]+. HRMS m/z (ESI): calculated for C45H55N3NaO8
+ [M+Na]+: 










Compound 74 (0.18 g, 0.2 mmol) was dissolved in EtOH (5 mL), water (4 mL) and 
6M NaOH (0.5 mL) was added and refluxed for 5 hours. After removing EtOH in 
vacuo the solution was acidified to pH 4 using HCl and the precipitate was collected 
by filtration. (0.17 g, 0.2 mmol, 95%). Rf = 0.58 (EtOAc).
 1H-NMR: (400 MHz, 
(CD3)2CO) δH: 0.85 (t, 3H, J= 6.5 Hz, H-16), 1.21-1.32 (m, 6H, H-13, H-14, H-15), 
1.32-1.50 (m, 2H, H-12), 2.12 (t, 2H, J= 7.5 Hz, H-11), 3.20 (t, 2H, J=7.0 Hz, H-19), 
3.33 (t, 2H, J=7.0 Hz, H-5), 4.22 (t, 2H, J=7.0 Hz, H-18), 4.34 (t, 2H, J=7.0 Hz, H-4), 
6.98-8.12 (m, 13H, H-1, H-2, H-3, H-7, H-8, H-9, H-10, H-20, H-21, H-22, H-23, H-
24). 13C-NMR (125 MHz, (CD3)2CO): 14.02 (CH2CH2CH2CH3), 20.46 
(CH2CH2CH3), 25.44, 26.04 (CH2CH2), 28.52 (CH2CH2CH2CH3), 32.62 
(COCH2CH2), 33.05 (COCH2CH2CH2), 40.92 (COCH2), 51.89 (NCOCH2), 68.98 
(CNCH2), 70.34 (COCH2), 110.20 (Ar-CH), 111.34 (Ar-C), 114.72 (Ar-CH), 115.22 
(Ar-C), 116.40 (Ar-CH), 118.32 (Ar-CH), 119.32 (Ar-CH), 122.32 (Ar-CH), 124.42 
(Ar-CH), 125.02 (Ar-CH), 127.98 (Ar-CH), 128.64 (Ar-CH), 129.11 (Ar-CH), 130.45 
(Ar-C), 132.36 (Ar-CH), 135.81 (Ar-C), 136.13 (Ar-C), 138.20 (Ar-C), 138.54 (Ar-
C), 144.50 (CHCN), 150.09 (COCH2), 161.22 (COOH), 172.60 (NCO).
 LRMS m/z 
(ESI): 550.2 [M-H]-. HRMS m/z (ESI): calculated for C34H33N3O4
- [M-H]-: Exact 









Compound 75 (0.17 g, 0.2 mmol, 1 eq), EDC.HCl (0.05 g, 0.24 mmol, 1.2 eq), HOBt 
(0.03 g, 0.24 mmol, 1.2 eq) and DIPEA (0.06 mL, 0.05 g, 0.4 mmol, 2 eq) were stirred 
in DCM (10 mL) for 15 minutes. H-Lys(Boc)-OMe hydrochloride (0.07 g, 0.24 mmol 
, 1.2 eq) was added and the reaction was stirred for 18 hours. DCM (40 mL) was added 
and washed 3 times with Na2CO3 sat. (75 mL). The organic layer was dried with 
MgSO4 and dried under high vacuum. Silica column chromatography was carried out 
and the product was eluted with 3:4/EtOAc:petroleum ether. (0.08 g, 0.08 mmol, 42%). 
Rf = 0.23 (3:4/EtOAc:petroleum ether). 
1H-NMR: (400 MHz, (CD3)2CO) δH: 0.85 (t, 
3H, J= 6.5 Hz, H-16), 1.18-1.38 (m, 8H, H-28, H-13, H-14, H-15), 1.42 (s, 9H, H-31), 
1.48-1.54 (m, 2H, H-12), 1.58-1.75 (m, 4H, H-27, H-29), 2.23 (t, 2H, J= 7.5 Hz, H-
11), 2.92 (m, 2H, H-30), 3.21 (t, 2H, J=7.0 Hz, H-19), 3.29 (t, 2H, J=7.0 Hz, H-5), 
3.71 (s, 3H, H-26), 4.20 (t, 2H, J=7.0 Hz, H-18), 4.31 (t, 2H, J=7.0 Hz, H-4), 4.54 (m, 
1H, H-25), 6.85-8.09 (m, 13H, H-1, H-2, H-3, H-7, H-8, H-9, H-10, H-20, H-21, H-
22, H-23, H-24). 13C-NMR (125 MHz, (CD3)2CO): 14.15 (CH2CH2CH2CH3), 20.30 
(CH2CH2CH3), 22.14 (NHCH2CH2), 26.19 28.02, (CH2CH2), 28.22 (3CH3), 28.28 
(CH2CH2CH2CH3), 30.34 (CH2CH), 32.42 (NHCH2CH2CH2), 32.62 (COCH2CH2), 
33.00 (COCH2CH2CH2), 40.92 (COCH2), 41.81 (NHCH2), 50.95 (NCOCH2), 51.22 
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(CH2CH), 52.70 (COOCH3), 69.89 (COCO), 69.98 (CNCH2), 72.40 (COCH2), 110.11 
(Ar-C), 111.34 (Ar-CH), 114.25 (Ar-CH), 114.92 (Ar-C), 116.90 (Ar-CH), 117.88 
(Ar-CH), 118.41 (Ar-CH), 120.12 (Ar-CH), 124.51 (Ar-CH), 128.02 (Ar-CH), 128.64 
(Ar-CH), 129.17 (Ar-CH), 132.70 (Ar-CH), 132.23 (Ar-C), 134.10 (Ar-C), 135.24 
(Ar-C), 137.92 (Ar-C), 138.06 (Ar-C), 145.02 (CHCN), 149.98 (COCH2), 164.44 
(CONHCH), 164.55 (COCONH), 172.40 (NCO), 173.20 (COOCH3). LRMS m/z 
(ESI): 816.6 [M+Na]+. HRMS m/z (ESI): calculated for C46H59N4NaO7
+ [M+Na]+: 










Compound 76 (0.08 g, 0.08 mmol) was stirred in 4N HCl in dioxane (1 mL) for 4 
hours. The solvent was removed in vacuo. (0.04 g, 0.05 mmol, 62%). Rf = 0.30 
(9:1/EtOAc:MeOH). 1H-NMR: (400 MHz, MeOD) δH: 0.87 (t, 3H, J= 6.5 Hz, H-16), 
1.22-1.40 (m, 8H, H-28, H-13, H-14, H-15), 1.42-1.50 (m, 2H, H-12), 1.53-1.73 (m, 
4H, H-27, H-29), 2.18 (t, 2H, J= 7.5 Hz, H-11), 2.90 (m, 2H, H-30), 3.19 (t, 2H, J=7.0 
Hz, H-19), 3.28 (t, 2H, J=7.0 Hz, H-5), 3.71 (s, 3H, H-26), 4.21 (t, 2H, J=7.0 Hz, H-
18), 4.31 (t, 2H, J=7.0 Hz, H-4), 4.59 (m, 1H, H-25), 6.86-8.05 (m, 13H, H-1, H-2, H-
3, H-7, H-8, H-9, H-10, H-20, H-21, H-22, H-23, H-24). 13C-NMR (125 MHz, 
MeOD): 14.15 (CH2CH2CH2CH3), 20.54 (CH2CH2CH3), 22.63 (NH2CH2CH2), 26.41, 
(CH2CH2), 29.12 (CH2CH2CH2CH3), 32.38 (CH2CH), 32.62 (COCH2CH2), 33.15 
(COCH2CH2CH2), 34.34 (NH2CH2CH2CH2), 40.92 (COCH2), 41.22 (NH2CH2), 50.20 
(CH2CH), 51.73 (COOCH3), 52.16 (NCOCH2) 69.23 (CNCH2), 70.56 (COCH2), 
110.00 (Ar-CH), 111.45 (Ar-C), 114.20 (Ar-C), 115.22 (Ar-CH), 117.21 (Ar-CH), 
117.77 (Ar-CH), 118.34 (Ar-CH), 121.78 (Ar-CH), 123.28 (Ar-CH),  125.23 (Ar-CH), 
127.82 (Ar-CH), 128.55 (Ar-CH), 129.18 (Ar-CH), 129.88 (Ar-C), 133.46 (Ar-CH), 
135.60 (Ar-C), 136.32 (Ar-C), 138.69 (Ar-C), 139.02 (Ar-C), 146.23 (CHCN), 150.99 
(COCH2), 165.25 (CONHCH), 171.02 (NCO), 172.40 (COOCH3). LRMS m/z (ESI): 
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694.5 [M+H]+. HRMS m/z (ESI): calculated for C41H52N5O5
+ [M+Na]+: Exact Mass: 









1-Octylamine (2.55 mL, 2.0 g, 0.015 mol, 1 eq) and HCl (0.72 mL, 1 eq) were stirred 
in hot ethanol (20 mL) for 15 minutes before KOCN (5.02g, 0.062 mol, 4 eq) in water 
(20 mL) was added. The solution was stirred for 16 hours. The ethanol was removed 
in vacuo. Water (30 mL) was added and this was washed three times with Et2O (3x 
50mL). The organic layers were combined and dried over MgSO4. (Adapted from 
literature reference155). (2.10 g, 0.012 mol, 80%). 1H-NMR: (400 MHz, (CD3)2CO) 
δH: 0.91 (t, 3H, J= 6.5 Hz, H-1), 1.24-1.44 (m, 10H, H-2, H-3, H-3, H-4, H-5, H-6),  
1.55-1.70 (m, 2H, H-7), 2.77 (t, 2H, J= 7.0 Hz, H-8). 13C-NMR (125 MHz, (CD3)2CO): 
14.46 (CH3), 23.72 (CH2), 27.99 (CH2), 30.45 (CH2), 31.23 (CH2), 31.45 (CH2), 33.00 









Compound 78 (2.10 g, 0.012 mol, 1 eq) and ethoxycarbonyl isothiocyanate (1.78 mL, 
1.96 g, 0.015 mol, 1.2 eq) were stirred in toluene (8 mL) at 60˚C for 4 hours. The 
solvent was removed in vacuo. The resulting residue was applied to a silica column 
and the product was eluted with 20:80 EtOAc/Petroleum ether. (Adapted from 
literature reference155).  (2.25 g, 7.4 mmol, 66 %). Rf = 0.25 (20:80 EtOAc/Petroleum 
ether). 1H-NMR: (400 MHz, (CD3)2CO) δH: 0.88 (t, 3H, J= 6.5 Hz, H-1), 1.10 (t, 3H, 
J= 6.5 Hz, H-10), 1.26-1.40 (m, 10H, H-2, H-3, H-3, H-4, H-5, H-6), 1.52-1.60 (m, 
2H, H-7), 3.40 (t, 2H, J= 7.0 Hz, H-8), 4.27 (q, 2H, J=7.0, 7.0 Hz, H-9). 13C-NMR 
(125 MHz, (CD3)2CO): 13.47 (COOCH2CH3), 14.76 (CH3), 22.46 (CH2), 26.72 (CH2), 
29.01 (CH2), 29.07 (CH2), 29.43 (CH2), 29.71 (CH2), 39.74 (CH2NH), 65.30 
(COOCH2), 152.60 (NHCOO), 163.30 (NCON) 179.20 (NHCSNH). LRMS m/z 
(ESI): 326.2 [M+Na]+. HRMS m/z (ESI): calculated for C13H26N3O3SNa
+ [M+Na]+: 









Compound 79 (2.25 g, 7.4 mmol, 1 eq) and NaOMe (0.41 g, 7.4 mmol, 1 eq) were 
refluxed in anhydrous methanol (30 mL) for 45 minutes. The reaction mixture was 
cooled to room temperature and MeI (1.41 mL, 3.16 g, 0.022 mol, 3 eq) were added 
and the reaction mixture was stirred for 4 hours. The solvent was removed in vacuo. 
The resulting residue was dissolved in EtOAc (50 mL) and washed three times with 
water (3 x 50mL). The organic layer was dried using MgSO4. The resulting residue 
was applied to a silica column and the product was eluted with 60:40 EtOAc/Petroleum 
ether. (Adapted from literature reference155). (0.78 g, 2.8 mmol, 38 %). Rf = 0.53 
(60:40 EtOAc/Petroleum ether). 1H-NMR: (400MHz, (CD3)2CO) δH: 0.88 (t, 3H, J= 
6.5 Hz, H-1), 1.24-1.36 (m, 10H, H-2, H-3, H-3, H-4, H-5, H-6), 1.56-1.63 (m, 2H, H-
7), 2.52 (s, 3H, H-9) 3.78 (t, 2H, J= 7.0 Hz, H-8). 13C-NMR (125 MHz, (CD3)2CO): 
12.31 (CSCH3), 13.48 (CH3), 22.40 (CH2), 26.62 (CH2), 27.28 (CH2), 29.10 (CH2), 
29.43 (CH2), 31.36 (CH2), 40.81 (CH2NCO), 168.15 (NCONCS). LRMS m/z (ESI): 
270.1 [M-H]-. HRMS m/z (ESI): calculated for C12H20N3O2S










Compound 80 (0.78 g, 2.92 mmol, 1 eq) and benzyl bromide (1.72 mL, 2.48 g, 14.5 
mmol, 5 eq) were stirred in DMF (3 mL) at 0 ˚C. To this NaH (1.16 g, 29 mmol, 10 
eq) was added in two halves. The reaction was allowed to come to room temperature 
and was stirred for 16 hours. The reaction was taken up in EtOAc (50 mL) and washed 
3 times with water and dried with MgSO4. The solvent was removed in vacuo. The 
resulting residue was applied to a silica column and the product was eluted with 50:50 
EtOAc/Petroleum ether. (Adapted from literature reference155). (0.33 g, 0.91 mmol 
mmol, 32 %). Rf = 0.75 (50:50 EtOAc/Petroleum ether). 
1H-NMR: (400 MHz, 
(CD3)2CO) δH: 0.89 (t, 3H, J= 6.5 Hz, H-1), 1.21-1.36 (m, 10H, H-2, H-3, H-3, H-4, 
H-5, H-6), 1.59-1.70 (m, 2H, H-7), 2.49 (s, 3H, H-9), 3.86 (t, 2H, J= 7.0 Hz, H-8), 5.15 
(s, 2H, H-10), 7.25-7.41 (m, 5H, H-11, H-12, H-13). 13C-NMR (125 MHz, (CD3)2CO): 
14.46 (CH3), 15.21 (CSCH3), 23.36 (CH2), 27.59 (CH2), 28.14 (CH2), 30.01 (CH2), 
30.05 (CH2), 32.58 (CH2), 43.07 (CH2NCO), 48.81 (NCH2), 128.12 (NCH2CCH), 
128.66 (CCHCHCH), 129.49 (CCHCHCH), 136.24 (NCH2CCH), 152.42 (CNCO), 
163.23 (CH2NCO), 170.45 (NCONCS). LRMS m/z (ESI): 362.3 [M+H]
+. HRMS m/z 
(ESI): calculated for C19H28N3O2S









 Compound 81 (0.33 g, 0.91 mmol, 1 eq) and ethylenediamine (0.30 mL, 0.27 g, 4.55 
mmol, 5 eq) were refluxed in toluene for 6 hours. The solvent was removed in vacuo. 
The residue was dissolved in EtOAc (50 mL) and washed twice with water (2 x 50 
mL), then dried with MgSO4. The resulting residue was applied to a silica column and 
the product was eluted with 8:2 EtOAc/MeOH.  (Adapted from literature reference155). 
(0.29 g, 0.80 mmol, 87%). 1H-NMR: (400 MHz, (CD3)2CO) δH: 0.87 (t, 3H, J= 6.0 
Hz, H-1), 1.20-1.35 (m, 10H, H-2, H-3, H-3, H-4, H-5, H-6), 1.53-1.65 (m, 2H, H-7), 
3.29 (t, 2H, J= 6.0 Hz, H-10), 3.51 (t, 2H, J= 6.0 Hz, H-9), 3.86 (t, 2H, J= 7.0 Hz, H-
8), 5.19 (s, 2H, H-11), 7.18-7.41 (m, 5H, H-12, H-13, H-14). 13C-NMR (125 MHz, 
(CD3)2CO): 14.40 (CH3), 23.33 (CH2), 27.62 (CH2), 28.61 (CH2), 30.01 (CH2), 30.14 
(CH2), 33.56 (CH2), 42.63 (CNHCH2CH2), 43.16 (CH2NCO), 45.67 (NCH2), 51.16 
(CNHCH2CH2), 127.52 (CCHCHCH), 128.32 (CCHCHCH), 129.61 (NCH2CCH), 
136.40 (NCH2CCH), 152.53 (CNCO), 154.53 (CH2NCO), 163.24 (NCONCNH). 
LRMS m/z (ESI): 374.4 [M+H]+. HRMS m/z (ESI): calculated for C8H11N2O
+ 










Compound 82 (0.29 g, 0.80 mmol, 1 eq), 1H-Pyrazole-1-carboxamidine hydrochloride 
(0.80 mmol, 1 eq) and DIPEA (0.80 mmol, 1 eq) in MeCN for 18 hours. The precipitate 
which formed was removed by filtration. (Adapted from literature reference155). (0.29 
g, 0.80 mmol, 87%). 1H-NMR: (400 MHz, MeOD) δH: 0.89 (t, 3H, J= 7.0 Hz, H-1), 
1.21-1.40 (m, 10H, H-2, H-3, H-3, H-4, H-5, H-6), 1.57-1.67 (m, 2H, H-7), 3.35 (t, 
2H, J= 7.0 Hz, H-10), 3.51 (t, 2H, J= 7.0 Hz, H-9), 3.87 (t, 2H, J= 7.0 Hz, H-8), 5.16 
(s, 2H, H-11), 7.22-7.38 (m, 5H, H-12, H-13, H-14). 13C-NMR (125 MHz, MeOD): 
13.04 (CH3), 22.31 (CH2), 27.62 (CH2), 26.44 (CH2), 27.32 (CH2), 28.96 (CH2), 31.54 
(CH2), 40.00 (CNHCH2CH2), 42.03 (CH2NCO), 43.30 (CNHCH2CH2), 44.93 (NCH2), 
125.99 (CCHCHCH), 127.53 (CCHCHCH), 128.53 (NCH2CCH), 134.53 
(NCH2CCH),151.10 (CNCO), 155.07 (CH2NCO), 155.69 (NCONCNH), 157.58 
(NHCNH). LRMS m/z (ESI): 415.2 [M+H]+. HRMS m/z (ESI): calculated for 
C9H12N2O









Compound 81 (0.33 g, 0.91 mmol, 1 eq) and N-Boc-1,3-propanediamine (0.79 g, 4.55 
mmol, 5 eq) were refluxed in toluene for 6 hours. The solvent was removed in vacuo. 
The residue was dissolved in EtOAc (50 mL) and washed twice with water (2 x 50 
mL), then dried with MgSO4. The resulting residue was applied to a silica column and 
the product was eluted with 8:2 EtOAc/MeOH.  (Adapted from literature reference155). 
(0.20 g, 0.52 mmol, 57%). 1H-NMR: (400 MHz, MeOD) δH: 0.90 (t, 3H, J= 7.0 Hz, 
H-1), 1.26-1.37 (m, 10H, H-2, H-3, H-3, H-4, H-5, H-6), 1.56-1.68 (m, 2H, H-7), 1.87 
(p, 2H, J= 7.0, 7.0 7.0, 7.0 Hz, H-10) 2.84 (t, 2H, J= 7.0 Hz, H-11), 3.48 (t, 2H, J= 7.0 
Hz, H-9), 3.89 (t, 2H, J= 7.0 Hz, H-8), 5.17 (s, 2H, H-12), 7.23-7.40 (m, 5H, H-13, H-
14, H-15). 13C-NMR (125 MHz, MeOD): 13.04 (CH3), 22.31 (CH2), 26.44 (CH2), 
27.62 (CH2), 27.32 (CH2), 28.96 (CH2), 31.54 (CH2), 40.00 (CNHCH2CH2), 42.03 
(CH2NCO), 43.30 (CNHCH2CH2), 44.93 (NCH2), 125.99 (CCHCHCH), 127.53 
(CCHCHCH), 128.53 (NCH2CCH), 134.53 (NCH2CCH), 151.10 (CNCO), 155.07 
(CH2NCO), 155.69 (NCONCNH), 157.58 (CH2NH2), LRMS m/z (ESI): 387.4 
[M+H]+. HRMS m/z (ESI): calculated for C9H13N2O





7.8 Biological methods 
 
Table 24:  table of bacteria used during the project and the uses of them 
 
7.8.1 Antibiotic stock preparation 
The antibiotics used in the inoculations and agar plates are shown in Table 25. The 
stock concentrations were filter sterilised before use. 
 
Table 25: antibiotic preparation conditions. 
 
7.8.2 LB agar plate preparation  
The LB agar media is made up as described in Table 26 and then autoclaved. The media 
is melted in the microwave and allowed to cool to ~55 °C. If antibiotics are required 
they are added at the corresponding working concentration (Table 25) before the agar 
is poured into petri dishes (~25 mL per plate). The plates are allowed to set before use. 
 
 
Table 26: LB agar composition  
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Miles and Misra CFU/mL calculation111 
P. Fluorescens, E. coli (TOP10) and B. subtilis (W23) colonies were isolated from an 
agar plate and inoculated in 5 mL of LB broth (Table 27) overnight at 37 °C. A dilution 
series of the seeded MH2 (Table 28) was performed to get 10-1, 10-2, 10-3, 10-4, 10-5, 
10-6, 10-7 and 10-8 fold dilutions. The dilution series was performed by taking 0.5 mL 
of the seeded MH2 and diluting it with 4.5 mL of MH2. Then 0.5 mL of this was taken 
and was diluted with 4.5 mL of MH2. This was repeated until the dilution series was 
complete. 
From each dilution 20 μL was pipetted onto an agar plate. An L-shaped cell spreader 
was used to assure the solution was evenly distributed across the plate. The plates were 
then inverted and incubated overnight at 37 °C or 30 °C. The colonies were counted 




Table 27: LB broth composition  
 
 





7.8.3 Antimicrobial testing - micro titre broth dilution technique87 
On a sterile 96-welled plate (which had a sterilised lid), 190 μl of the seeded broth 
(CFU/mL = 1000) was added to each well. 2.5 mg/mL solutions of dipeptide or 
peptidomimetic were serially diluted to obtain 7 different concentrations (1250, 625, 
312.5, 186, 78.2, 39, and 19.5 μg/mL). 10 μL of these diluted inhibitors were added to 
the 96-well plate to give a final volume of 200 μL and final concentrations of 125, 
62.5, 31.25, 15.63, 7.82, 3.90, 1.95 and 0.97 μg/mL. 10 μL of water, MeOH and 
DMSO were added to separate wells to serve as a growth control. Each test condition 
was tested in triplicate. 
The sterile lid was placed on the plate 96-well plate and incubated overnight at 30 or 
37°C. The optical density (OD595) was the measured using a HIDEX Sense Microplate 
Reader 425-301. The inhibitor concentration which reduced the growth by 50 % was 










UDP-MurNAc-pentapeptide was isolated from cultures of Bacillus subtillis 
W23.28,172,173 50 mL of PYP media was inoculated with B. subtillis W23 and incubated 
at 37°C overnight. 4x 10mL of this was added to 4x 500mL of PYP media in 2 L flasks 
to give 2% of the B. subtillis culture which was then grown to at OD600 = 1.2 at 37°C. 
The cultures were then chilled on ice again and cells pelleted by centrifugation at 4400 
rpm at 4°C for 30 minutes. The 4 pellets were suspended in 4x 50 mL CWSM media. 
This was then added to 4x 75 mL of prewarmed CWSM in 4x 250mL conical flasks 
and then incubated at 37°C for 45 minutes. The cultures were chilled on ice again and 
cells pelleted by centrifugation at 4400 rpm at 4°C for 30 minutes and then stored at -
20°C overnight. The thawed cells were (~8 g wet weight) were re-suspended in ice 
cold 5% (w/v) TCA (5 mL/g cells). The pellet was extracted a further two times with 
half volumes of ice cold TCA. The supernatants (80 mL) were pooled and extracted 3 
times with equal volumes of ice cold diethyl ether (3x 80 mL). The aqueous phase was 
neutralised with 3 M NaOH. The traces of ether were evaporated by rotary evaporation 
and the sample lyophilised overnight. The sample was dissolved in water and clarified 
by centrifugation. 
PYP medium (pH 7.2) and cell wall synthesis medium (CSWM) (pH 7.4) contained 
the ingredients described in Table 29 and Table 30 respectively. The PYP and CWSM 
were autoclaved without MgCl2, FeSO4, glucose, antibiotics and amino acid residues, 




Table 29: PYP media composition 
 
 
Table 30: CWSM media composition 
 
Isolation of the substrate was carried out by RP-HPLC using Synergi™ 4 µm Polar-
RP 80 Å and an elution with a gradient of 0:100 to 30:70 Acetonitrile/ 0.05M aqueous 
NH4HCO3 and monitored at 262 nm as previously carried out by Siricilla et al.
122  Each 
peak was collected and subjected to LC-MS by Lijiang Song after being desalted by 
by RP-HPLC using Synergi™ 4 µm Polar-RP 80 Å and an elution with an isocratic 
gradient of 10:90 MeCN/water. The peak containing the substrate was identified and 
collected. The fractions were pooled and lyophilised and then desalted. HRMS m/z 
(ESI): calculated for C41H66N9O28P2
+
 [M+H]






7.8.5 MraY inhibitioin assay - continuous fluorescence plate reader 
A HIDEX Sense Microplate Reader 425-301 was used to determine the inhibitory 
activity of dipeptides and peptidomimetics at an excitation wavelength of 340 nm and 
emission wavelength of 535 nm to monitor the formation of dansyl-Lipid I.  
Membranes containing overexpressed MraY were treated with a master mix 
containing dansyl-tagged UDP-MurNAc-pentapeptide and lipid carrier undecaprenyl 
phosphate (C55-P). Dansyl-tagged UDP-MurNAc-pentapeptide was provided by 
Namrita Modgill (summer student).  
The lipid carrier C55-P was purchased from Larodan Fine Chemicals in a 
chloroform/methanol (2:1) + 3 % (v/v) ammonia solution. 20 μL of the 10 mg/mL 
stock solution (total 0.2 mg) was transferred to a small vial. The solvents were removed 
from this sample using a gentle stream of N2(g). Once the solution was completely dried 
it was redissolved in 2 mL of a buffer solution. The lipid carrier buffer solution 
contained 50 mM Tris Base (pH 7.5), 2 mM β-mercaptoethanol, 1mM MgCl2, 20 % 
glycerol and 0.5 % TritonX100. The solution 100 μg/mL was sonicated until it became 
clear. 
 
Preparation of the Master Mix (MM) 
The master mix contained a mixture of buffer A, water, dansyl-UDP-MurNAc-
pentapeptide and lipid carrier C55-P Buffer A contained a final concentration of 100 
mM Tris base (pH 7.5) and 25 mM MgCl2. The master mix contained 21.0 μM Dansyl-
UDP-MurNAc-pentapeptide and 47.2 μM C55-P. 
 
Preparation of Membrane-bound MraY 
Agnes Mihalyi (PhD) overexpressed E. coli MraY in E. coli DH5α cells and stored 
them in a membrane buffer containing 50 mM Tris (pH 7.5) 2 mM β-mercaptoethanol 
and 1 mM MgCl2. The final protein concentrations of membranes containing 




Plate reader assay protocol 
To a black 96-well plate, 10 μL of overexpressed MraY membranes was added to 85 
μL of master mix and 5 μL of the inhibitor (final concentration 100 μg/mL in MeOH 
or DMSO). MeOH and DMSO were used as the negative controls. Tunicamycin at a 
final concentration of 50 μg/mL in MeOH, was used as a positive controls. 
Had inhibition at this concentration of compound been seen a serial dilution would 
have been carried out.  
Fluorescence measurements (excitation wavelength of 340 nm and emission 
wavelength of 535 nm) were taken before the addition of membranes, t =0, then at 10 
second intervals for 10 minutes. 
 
7.8.6 Radiochemical inhibition assay 
Assays were carried out as described by A. Lloyd et al. (2004).22 A solution of [14C]-
UDPMurNAc-pentapeptide (1-4 nCi) which was prepared by Agnes Mihalyi was 
added to the master mix (described below). Into an eppendorf 80 μL of master mix 
was added to 10 μL of inhibitor or DMSO. To start the reaction 10 μL containing 20-
50 μg of over expressed MraY membranes in a buffer containing 100 mM Tris (pH 
7.5), 17.5 M MgCl2, 4.0 % (v/v) glycerol, 2.3 % (v/v) DMSO, 0.1 % Triton X-100 was 
added. The total reaction volume was 100 μL. The mixture was then left for 30 minutes 
to allow the lipid product to form. The reaction was quenched with 50 % 6M 
pyridinium acetate (100 μL) and vortexed. To this 50 % butanol (200 μL) was added 
and the mixture was vortexed again. The reaction mixture was centrifuged at 13,000 x 
g for 2 minutes causing the separation of the two layers. 200 μL of butanol was added 
to 5 mL ScintiSafe scintillation liquid and quantified by liquid scintillation counting. 
The controls were as follows: 
 Scintillation fluid only, to show background radiation 
 No enzyme, to serve as an extraction control i.e how much unconverted 
substrate is in the butanol layer 
 No inhibitor, which gives 100 % enzyme activity 
 Negative control, using 100 μg/mL tunicamycin  
The typical composition of master mix: 
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 1500 μL of assay buffer (200 mM Tris pH 7, 50 mM MgCl2) 
 1000 μL of undecaprenyl phosphate stock solution (0.1 mg/mL in 50 mM 
Tris pH 7.5, 2 mM β-mercaptoethanol, 1 mM MgCl2, 20 % glycerol and 0.5 
% Triton-X100) 
 100 μL DMSO 
 60 μL [14C]-UDPMurNAc-pentapeptide (24,500 dpm/10 μL) 
 340 μL water 
 
7.8.7 Chemical competency transformation 
5 μL of plasmid DNA were added to 50 μL of E. coli TOP10 competent cells (prepared 
by James Williamson, Post Doc) and incubated in ice for 30 minutes. The samples 
were then transferred to a 42 °C  water bath and incubated for 45 seconds and then 
immediately transferred to ice for 3 minutes. 300 μL of LB was added to the sample 
and incubated at 37°C with shaking (180 rpm) for 1 hour. 100 μL of the seeded LB 
was poured to an LB agar plate. An L-shaped cell spreader was used to assure the 
mixture was evenly distributed across the plate. The agar plate was incubated 
overnight at 37 °C. 
 
7.8.8 Protection assay- IC50 of inhibitors against E. coli overexpressing MraY 
A single colony of the appropriate bacteria was isolated from the transformed plate 
and inoculated in 5mL of MH2+Amp (100 μg/mL) or MH2+Kan (50 μg/mL) 
overnight at 37 °C with shaking. This start-up culture was diluted 100-fold with MH2 
(with the appropriate antibiotic at the concentration stated) and induced with 0.5 mM 
IPTG. To a sterile 96-well microtitre plate, 190 μl of the IPTG-induced seeded broth 
was added to each well. 10 μL of dipeptide was added to the deep 96-well plate to give 
a final volume of 200 μL and final inhibitor concentrations of 500, 450, 400, 350, 300, 
250, 125, 62.5, 31.25, 15.63, 7.82, 3.90, 1.95 and 0.98 μg/mL. Each inhibitor 
concentration was tested in triplicate. 10 μL of water, MeOH and DMSO were added 
to separate wells to serve as a growth controls. MH2 was also used as a negative 
control. The sterile lid was replaced on the plate and incubated at 37 °C with shaking 
for 8 hours. The optical density (OD595) was the measured using a HIDEX Sense 
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Microplate Reader 425-301. The inhibitor concentration which reduced the growth by 
50 % was considered the IC50 of the compound. 
 
7.8.9 General procedure for restriction digests 
Plasmids were digested after isolation using a Monarch miniprep kit. Restriction 
digests of plasmids were conducted at 37 °C for 1 hour using 0.5-1 μl of Thermo Fisher 
fast digest restriction enzyme, and the buffer conditions suggested by the 
manufacturer. The digested fragments were purified by gel electrophoresis and gel 
extraction. 
 
7.8.10 General procedure for Agarose gel electrophoresis  
Agarose and TBE buffer (Table 31) 0.8% (w/v) were microwaved until the agarose 
had dissolved and then cooled slightly before Gel Red (0.003%) was added and the gel 
was set. Once set the gel was placed into the electrophoresis tank and submerged in 
TBE buffer. The samples of plasmid DNA (20 μL) were pipetted into separate wells. 
The DNA ladder which in this case was 1kb generuler (thermoscientific) was added to 
a separate well. The gel was run at 100V for 45 minutes and visualised under UV light. 












7.8.11 General procedure for ligations 
The ligations between the cut plasmids and inserts or PCR products were performed 
using a 3:1 molar ratio of insert to vector. T4 ligase (1 μL) and 10x ligase buffer (2 
μL) were mixed with vector (50 ng) and insert and made up to 20 μL with dH2O. The 
reaction was incubated for 40 minutes at room temperature and then at 4 °C overnight, 
and 5 μL used to transform E. coli TOP10 chemically competent cells or E. coli C43 
electro-competent cells. 
 
7.8.12 General procedure for PCR 
Amplification of the kanamycin cassette was carried out using Phusion polymerase 
using the manufacturer’s conditions. The primers used are shown in Table 32. Mixture: 
1 μL forward primer (kan cassette, 10 μM), 1 μL reverse primer (kan cassette, 10 μM), 
1 μL template DNA (50 ng/μL), 0.4 μL dNTPs (10 mM), 4 μL Phusion GC buffer, 0.2 
μL Phusion polymerase, 0.6 μL DMSO and dH2O to make upto 20 μL. Conditions: 
98 °C 30 s Denaturation, 98 °C 10 s Denaturation 65 °C 30 s Annealing 72 °C 30 s 
Extension (25 cycles) 72 °C 600s extension. PCR products were analysed by agarose 
gel electrophoresis in TBE buffer using a gel of 0.8 % agarose in TBE buffer with 
GelRed under UV light for detection. 
 
 
Table 32: table of primers used in PCR 
 
7.8.13 Transformation of plasmid DNA into Electrocompetent E. coli C43 
The plasmid DNA was firstly transformed into chemically competent TOP10. A single 
colony was then inoculated in 5 mL LB+Amp (100 μg/mL) and incubated overnight 
at 37 °C. The plasmids were then isolated using a Monarch miniprep kit. This plasmid 
was then transformed in to electro-competent cells. 
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Firstly the electro-competent E. coli C43 cells were made. A single colony of E. coli 
C43 was inoculated in 20 mL of LB and incubated overnight at 37 °C. The cells were 
pelleted (4000 g for 15 minutes) and the supernatant discarded. The pellet was 
resuspended in 10 mL 10% glycerol. The cells were pelleted again and then 
resuspended in 10 mL 10% glycerol. The cells were pelleted a final time and then 
resuspended in 0.5 mL 10% glycerol and then transferred aliquots of 100 μL. 
The electroporation cuvettes and electrocompetent cells were placed on ice. Once the 
cells had defrosted transfer 100 μL of the cells were transferred to a chilled 
electroporation cuvette and then 1 μL of the DNA solution was added and mixed. 
Electroporate at 1.8 kV. Immediately add 900 µL of LB to the cuvette, gently mix up 
and down then transfer into a 1.5 mL Eppendorf microcentrifuge tube. Incubate and 
shake at 37°C for 1 hour. 100 μL of the seeded LB was poured to an LB agar plate. An 
L-shaped cell spreader was used to assure the mixture was evenly distributed across 
the plate. The agar plate was incubated overnight at 37 °C. 
 
7.8.14 AlamarBlue™ Assay 
A single colony of E. coli was isolated from an agar plate and inoculated in 5mL of 
MH2 overnight at 37 °C with shaking. This start-up culture was diluted 100-fold with 
MH2 to give a volume of 10 mL. The culture was then incubated at 37 °C until 
OD(595)=0.8  was reached. 
On a sterile 96-well plate (which had a sterilised lid), 90 μl of the seeded broth was 
added to each well. 2.5 mg/mL solutions of dipeptide or peptidomimetic were serially 
diluted to obtain 7 different concentrations (1250, 625, 312.5, 186, 78.2, 39, and 19.5 
μg/mL). 10 μL of these diluted inhibitors were added to the 96-well plate to give a 
final volume of 200 μL and final concentrations of 250, 125, 62.5, 31.25, 15.63, 7.82, 
3.90, 1.95 and 0.97 μg/mL. 10 μL of water, MeOH and DMSO were added to separate 
wells to serve as a growth control. Each test condition was tested in triplicate.  
The sterile lid was placed on the plate 96-well plate and incubated for 1 hour at 37°C. 
To each well 10 μL of alamarBlue™ was added and the plate was incubated for a 
further 2-3 hours. The fluorescence was read on the HIDEX Sense Microplate Reader 
425-301 using an excitation wavelength of 530 nm and emission wavelength of 580 
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nm. The inhibitor concentration which reduced the growth by 50 % was considered 
the IC50 of the compound. 
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